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Summary 
Ewing sarcoma is a rare pediatric bone and soft tissue tumor with an aggressive behavior and a 
prevalence to metastasize. The 5-year survival rate for the localized disease is around 70% while for 
patients with metastasis it is less than 40%. Ewing sarcoma is characterized by a balanced 
translocation of the EWSR1 gene on chromosome 22 and FLI1 gene on chromosome 11 leading to 
expression of the aberrant EWS/FLI1 oncoprotein. Sequencing of Ewing sarcoma tumors revealed 
that the fusion protein is the only consistent genetic alteration despite apart from few secondary 
mutations. The EWS/FLI1 protein modulates a variety of target genes and protein-protein interactions. 
As the transcription factor is unique for Ewing sarcoma cells, it serves as an ideal therapeutic target. 
Protein turnover is mainly mediated by the ubiquitin proteasome system. An enzymatic cascade of 
three enzymes transfers a ubiquitin to a target protein. The linkage of the polyubiquitin chain 
determines if proteins are degraded by the proteasome or involved in signaling events. The chains can 
be modified or removed by deubiquitinating enzymes. EWS/FLI1 ubiquitination has barely been 
investigated even though it might be of therapeutic relevance. In this thesis, we aim to investigate the 
mechanisms of EWS/FLI1 degradation and identify regulators of the ubiquitin pathway as targets for 
therapeutic interventions. 
We first characterized EWS/FLI1 as a polyubiquitinated substrate of the proteasome system. By using 
Global Protein Stability profiling, we determined the turnover rate of EWS/FLI1 as faster compared to 
both full length proteins EWSR1 and FLI1. Mass spectrometry analysis revealed two ubiquitin 
acceptor sites within EWS/FLI1 of which only mutation of the K380 residue in the DNA-binding domain 
abolished ubiquitination and posttranslationally stabilized the protein. By comparing the transcriptional 
activation properties of wild type EWS/FLI1 and its turnover deficient mutant, we identified the majority 
of target genes as saturated. Further, one subgroup of target genes was increased by higher fusion 
protein levels whereas a second subgroup was partly dependent on continuous fusion protein 
turnover. Both subgroups were consisting of protein and RNA coding genes. We identified EWS/FLI1 
turnover as an important and critical pathway for Ewing sarcoma pathogenesis. 
We then aimed at understand how EWS/FLI1 is ubiquitinated and which E3 ligase(s) mediate stability. 
We identified the N-terminal PPxY motif as critical for E3 ligase binding. Mutation of this site 
decreased ubiquitination and stabilized the fusion protein. As only NEDD4 family members, a 
subgroup of HECT E3 ligases, are binding this motif, we screened all members for their ability to 
destabilize EWS/FLI1. Most consistently, WWP1 negatively regulated EWS/FLI1 protein levels. This 
interaction was partly abolished upon mutation of the PPxY domain. On a physiological level, WWP1 
overexpression slightly decreased Ewing sarcoma cell growth and colony formation. Hence, we 
characterized a novel E3 ligase binding motif in the fusion protein leading to deepen our 
understanding of the molecular mechanisms underlying EWS/FLI1 turnover.  
To identify potential inhibitory targets within the EWS/FLI1 turnover machinery, we screened for 
deubiquitinating enzymes capable to mediate fusion protein stability. We identified ubiquitin specific 
protease 19 as a main candidate. Depletion of USP19 directly destabilized the protein and modulated 
a subset of target genes. This effect was accompanied by an increase in EWS/FLI1 ubiquitination. On 
a cellular level, USP19 knockdown delayed tumor growth both in vitro and in vivo. Hence, we 
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demonstrate that destabilization of EWS/FLI1 can be achieved by inhibition of deubiquitinating 
enzymes which is a new and promising strategy for Ewing sarcoma therapy.  
Within these studies, we unraveled the turnover of the EWS/FLI1 fusion protein and identified the E3 
ligase WWP1 and the deubiquitinating enzyme USP19 as potential targets for novel therapeutic 
strategies. As current treatment protocols include only non specific chemotherapeutics, combinations 
with agents directly destabilizing the main driver EWS/FLI1 present a promising approach and another 
step towards targeted therapies in Ewing sarcoma.  
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Zusammenfassung 
Ewing Sarkoma ist ein seltener pädiatrischer Knochen- oder Weichegewebetumor, der ein aggressives Verhalten 
zeigt und häufig metastasiert. Die 5-Jahres Überlebensrate liegt für einen begrenzten Tumor bei ungefähr 70% 
gegenüber 40% für Patienten mit Metastasen. Ewing Sarkoma zeichnet sich durch eine ausbalancierte 
Translokation des EWSR1 Gens auf Chromosom 22 und des FLI1 Gens auf Chromosom 11 aus, das zur 
Expression des abnormalen EWS/FLI1 Onkoproteins führt. Sequenzierungen von Ewing Sarkoma Tumoren 
haben ergeben, dass das Fusionsprotein neben einigen wenigen sekundären Mutationen die einzige konsistente 
gentische Veränderung darstellt. Das EWS/FLI1 Protein reguliert eine Vielzahl an Zielgenen und Protein-Protein-
Interaktionen. Da der Transkriptionsfaktor einzigartig ist für Ewing Sarkoma Zellen, stellt es ein ideales Ziel dar. 
Der Proteinabbau ist hauptsächlich über das Ubiquitin-Proteasome-System reguliert. Eine enzymatische Kaskade 
von drei Enzymen überführt ein Ubiquitin auf das Substratprotein. Die Verbindung der Multiubiquitinketten 
bestimmt, ob das Protein über das Proteasom abgebaut wird oder sich an Signaltransduktionen beteiligt. Die 
Ketten können von Hydrolasen verändert oder entfernt werden. Die EWS/FLI1 Ubiquitinierung wurde bis jetzt 
kaum erforscht, obwohl es von potenzieller therapeutischer Relevanz ist. In dieser Dissertation beabsichtigen wir 
die Mechanismen des EWS/FLI1 Proteinabbaus zu untersuchen und mögliche Regulatoren aus der 
Ubiquitingruppe für therapeutische Ziele zu identifizieren.  
Zuerst haben wir das EWS/FLI1 Protein als multiubiquitiniertes Substrat des Proteasome Systems charakterisiert. 
Durch die Globale-Protein-Stabilitätsanalyse konnten wir eine schnellere Abbaurate von EWS/FLI1 gegenüber 
den vollständigen EWSR1 und FLI1 Proteinen zeigen. Die Massenspektrometrie Analyse ergab, dass EWS/FLI1 
an zwei Stellen Ubiquitin binden kann. Nur eine Mutation der K380 Seite in der DNS-Bindungsdomäne beseitigt 
die Ubiquitinierung und führt zu einer posttranslationalen Stabilisierung des Proteins. Ein Vergleich der 
transkriptionalen Aktivität vom Wildtypprotein und der Abbaumutante ergab, dass der Grossteil der Zielgene in 
einem gesättigten Zustand vorliegt. Weiterhin gibt es jedoch eine Untergruppe von Zielgenen, deren 
Expressionen nur bei hohem Proteinniveau erhöht ist sowie eine zweite Untergruppe, die von konstanten 
EWS/FLI1 Abbauraten abhängig ist. Beide Untergruppen bestehen aus Protein kodierenden und RNS 
kodierenden Genen. Zusammenfassend haben wir den Abbau des EWS/FLI1 Proteins als wichtigen und 
kritischen Weg in der Ewing Sarkoma Krankheitsentstehung beschrieben. 
Als nächstes haben wir versucht zu verstehen, wie das EWS/FLI1 Protein ubiquitiniert und durch welche E3 
Ligase(n) die Stabilität beeinflussen wird. Dazu haben wir das N-terminale PPxY Motiv als kritische E3 
Bindungsstelle gefunden. Eine Mutation dieser Seite verringert die Ubiquitinierung und stabilisiert das 
Fusionsprotein. Da nur die NEDD4 Proteinfamily als Untergruppe der HECT E3 Ligasen an dieses Motiv binden, 
haben wir alle Mitglieder auf ihre destabilisierende Wirkung für das EWS/FLI1 Protein überprüft. Am 
konsistentesten regulierte WWP1 die EWS/FLI1 Proteinlevel. Diese Interaktion konnte teilweise verhindert 
werden, wenn das PPxY Motiv mutiert vorlag. Physiologisch wird durch eine WWP1 Überexpression das Ewing 
Sarkoma Zellwachstum und die Koloniebildung leicht vermindert. Daher konnten wir ein neues E3 Ligase 
Bindungsmotiv für das Fusionsprotein beschreiben, dass das Verständnis für Abbauvorgänge des EWS/FLI1 
Proteins klar vertieft.  
Um nun potenzielle hemmende Ziele im Abbaumechanismus des EWS/FLI1 Proteins zu finden, haben wir die 
Hydrolase gesucht, die die Stabilität des Fusionsproteins beeinflusst und so die Hydrolase USP19 als 
Hauptkandidat gefunden. Die USP19 Hemmung führt zur direkten Destabilisierung des Proteins und verändert so 
auch die Expression von Zielgenen. Dieser Effekt wurde begleitet von einer erhöhten Ubiquitinierung des 
Fusionsproteins. Auf zellulärer Ebene führt die USP19 Reduzierung zu einem verminderten Tumorwachstum in 
vitro und in vivo. Damit zeigen wir auf, dass die Destabilisierung des EWS/FLI1 Proteins durch Hemmung von 
Zusammenfassung 
9 
Hydrolasen erreicht werden kann. Dies stellt eine neue und vielversprechende Strategie in der Ewing Sarkoma 
Therapie dar.  
Mit diesen Studien konnten wir die Abbauprozesse des EWS/FLI1 Fusionsproteins detailliert aufzeigen und 
haben die E3 Ligase WWP1 sowie die Hydrolase USP19 als potentielle Ziele einer neuen therapeutischen 
Strategie identifiziert. Da aktuelle Behandlungsprotokolle nur unspezifische Chemotherapeutika beinhalten, würde 
die Kombinationen mit Mitteln, die das Hauptprotein EWS/FLI1 direkt destabilisieren, einen weiteren wichtigen 
Schritt zu einer zielgerichteten Therapie in Ewing Sarkoma darstellen. 
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1.1. Pediatric cancers 
 
1.1.1. Cancer in childhood and adolescents – epidemiology, incidence and survival 
Cancer is a global and heterogeneous disease with many faces. It generally does not discriminate 
between age, country, race or gender (with the exception of reproductive system specific tumors). A 
total of 1’658’370 new cancer cases and 589’430 cancer deaths have been reported in the United 
States in 2015 (1). In Switzerland, around 35’000 people are diagnosed with cancer and more than 
16’000 cases result in death per year (2). However, around 1% of all newly diagnosed cases occur in 
children and adolescents in developed countries (3). In Switzerland, about 170 cases with various 
cancer subtypes are diagnosed every year in children and 37 cancer-related deaths are reported (Fig. 
1A, registered by the Federal Statistical Office (FSO), the National Institute for Cancer Epidemiology 
and Registration (NICER) and the Swiss Childhood Cancer Registry (SCCR)). Despite the low total 
numbers, pediatric cancers are the second most common cause of death in children only outreached 
by accidents (1, 3), (4). In the US, the overall incidence rate over the last five years (reported for 2007-
2011) for all cancers declined by 1.8% per year in men, remained stable in woman and adolescents 
while it increased in children by 0.6% (1). 
 
The spectrum of cancer is fairly different between children, adolescents and adults (Fig. 1B). While 
carcinomas like breast, lung, prostate, and colorectal cancers are predominant in adults; especially 
leukemia, brain and solid tumors arise most commonly in children (2, 4). Although acute lymphoblastic 
leukemia can occur in all age groups, it is presenting with specific subtypes and with high incidence 
rates in children (1, 5). Further, medulloblastoma or a variety of predominantly pediatric sarcoma 
subtypes like rhabdomyosarcoma, Ewing sarcoma, osteosarcoma and Wilms tumor can arise in 
adults, but are extremely rare (6).  
Pediatric cancers are classified into twelve subgroups (Fig. 1C). The most common subtypes in the 
age range from 1-14 years are acute lymphoblastic leukemia (26%), tumors of the central nervous 
system (21%), neuroblastoma (7%) and non-Hodgkin lymphoma (6%) (5). Similar numbers and 
incidences have been reported for Switzerland by the most recent SCCR report (SCCR report 2014). 
In adolescents (15-19 years), Hodgkin lymphoma (15%), thyroid tumors (11%) and tumors of the brain 
and the central nervous system (10%) are predominant (5, 7). Furthermore, the outcome of several 
cancers as acute lymphoblastic leukemia, Ewing sarcoma or kidney tumors are worse than for the 
younger age group (7).  
 
The survival rate for pediatric cancers is with around 80% much higher than in adults. The 5-year 
relative survival rate for children and adolescents for all cancers combined has dramatically increased 
from 61.7% in 1975–1977 to 81.4% in 1999–2006 analyzed by the SEER (Surveillance, Epidemiology 
and End Results) program of the National Cancer Institute (seer.cancer.gov). However, the outcome is 
still very heterogeneous within pediatric tumors (Fig. 1D) and highly depends on the disease state, 
genetic abnormalities and the age of the patient (8). Best survival rates with ≥90% have been reported 
for acute lymphoblastic leukemia, non-Hodgkin lymphoma and Hodgkin lymphoma (9). Even though 
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the survival rate is still improving for leukemia and lymphomas, the rates for solid tumors have reached 
a plateau since ten years (5). Ewing sarcoma stagnates at a survival rate of 72% and even lower 
numbers are reported for osteosarcoma (71%) and rhabdomyosarcoma (64%) (1, 5, 9). 
 
Treatment of pediatric patients generally includes cytotoxic chemotherapy, radiotherapy and surgery in 
the case of solid tumors. However, the exact treatment protocols are tumor-type dependent and can 
slightly vary between Europe and the US. The good survival rates for most pediatric cancers result 
from continuous efforts of prospective clinical trials, improved risk assessment and supportive care (8). 
However, treatment related toxicity and adverse side effects are still the most challenging problems for 
childhood cancer survivors. 
 
 
 
Fig. 1: The distribution, incidence and survival rates of pediatric cancers. (A) The incidence of childhood 
cancer is increasing from the early 1990s till 2007 for both genders while the mortality rate is dropping in 
Switzerland (modified after (2, 4)). (B) The spectrum of tumors highly differs between children (left) and adults 
(right). The graph chart represents the cancer distribution of the 2012 SEER data (6). (C) Childhood cancer 
distribution within the age groups in Switzerland. Cancers are classified within nine subgroups. The surfaces are 
proportional to the number of cases (modified after (2, 4)). (D) Comparison of 5-year survival rates for pediatric 
cancers for two time periods, data include 9 SEER registries until 2010 (5). ICCC=International Classification of 
Childhood Cancers. 
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1.1.2. Childhood cancer survivors 
Children who survived a pediatric cancer may still be influenced many years after diagnosis by 
treatment related long-term side effects. Secondary malignant neoplasms are much more likely for 
childhood cancer survivors than in adult cancer patients. A 30 year follow-up study (1970-1986) of the 
Childhood Cancer Survivor Study (CCSS) cohort in the US was showing a generally increased 
incidence of 9.3% for secondary malignancies (10). However, the risk highly depends on the subtype 
of the primary cancer and the use of radiotherapy in first line treatment. Another study of the CCSS 
cohort assessed the risk of late mortality for childhood cancer survivors. Generally, the incidence of 
mortality caused by recurrence or the primary disease declined while death rates increased due to 
secondary neoplasms, cardiac death and other treatment related causes. The overall cumulative 
mortality rate at 30 years after diagnoses was 18.1%, identifying long-term morbidity as a serious 
issue for later life (11).  
Clinically focused monitoring of childhood cancer survivors is highly necessary for secondary 
malignancies and general health issues as results of cancer treatment early in life. It is hoped that 
improved treatment protocols and newly discovered chemotherapies will decrease the risk for 
secondary malignancies and health problems in the future.  
 
 
1.1.3. The genomic landscape of pediatric tumors 
Cancer genomes are largely characterized by genomic instability, accumulation of gene mutations and 
epigenetic changes driving tumor initiation, progression and maintenance. The hallmarks of cancer are 
summarizing the most crucial pathways manipulated by tumor cells to ensure their own survival and 
spreading throughout the human body (12, 13). In most adult cancers, an accumulation of mutations is 
giving rise to tumor formation (14). It has been shown first for colorectal cancer that a sequential series 
of mutations resulting in activated oncogenes or loss of critical tumor suppressor genes leads to the 
progression of benign lesions to a malignant phenotype (15). Since then, various efforts have been 
done to characterize the human cancer genome. The identification of numerous different mutations 
even within the same tumor subtype revealed that not all mutations are causing cancer. So-called 
“driver” mutations conferred a growth advantage to cancer cells whereas “passenger” mutations do not 
(14, 16). Driver mutations are found with a high incidence in distinct tumor entities, but are more 
infrequent in others suggesting certain heterogeneity in adult cancers (17, 18). Nevertheless, there is a 
clear variation in the mutational landscape of all tumor types. Tumors such as gastric, lung or 
colorectal cancer are highly subjected to exogenous mutagen exposure. They exhibit a high 
prevalence for accumulation of somatic mutations due to their high cellular turnover rate and an 
epithelial surface. Several melanoma and lung cancer subtypes display more than 1000 mutations per 
mega base (Mb) DNA (18, 19).  
 
In contrast, pediatric cancers are characterized by a low frequency of mutations with usually less than 
one mutation/ Mb DNA (Fig. 2A). Ewing sarcoma has one of the lowest mutation frequencies of all 
pediatric cancers with less than 0.1 mutation/ Mb DNA (16, 19). The Pediatric Cancer Genome Project 
reported that mainly structural alterations such as inter- and intrachromosomal rearrangements are 
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common mechanism of mutagenesis in pediatric leukemia and solid tumors rather than accumulation 
of several mutational events. Further, whole-genome sequencing revealed that the spectrum of 
mutations underlying pediatric cancers is very different from adult cancer, even though they may have 
a similar histology (6). Overall, the genomics of pediatric cancers are highly distinct from adult 
cancers. While an accumulation of driver mutations is most commonly the cause of adult tumor 
development, pediatric lesions are thought to arise within developing tissues with high frequency of 
chromosomal rearrangements.  
 
 
1.1.4. Translocation derived tumors 
The Philadelphia chromosome in chronic myelogenous leukemia was the first described chromosomal 
rearrangement (20, 21). Later, it was precisely characterized as a reciprocal translocation involving 
chromosomes 9 and 22 leading to the BCR/ABL fusion gene (22). Generally, translocations and gene 
fusions are prominent in pediatric leukemias and solid tumors, but can also occur in carcinomas. A 
total of 352 gene fusions have been detected and characterized so far among all cancer subtypes with 
highest frequencies in hematological tumor subtypes like acute lymphoblastic leukemia or mature B-
cell neoplasm (Fig. 2B) (23). 
 
Translocations are also typical for mesenchymal cancers. In malignant solid tumors, fusion positive 
cancers account for less than 1% of all cases while 5-20% of bone and soft tissue tumors harbor a 
characteristic hybrid gene (23, 24). Here, balanced as well as unbalanced translocations are distinct 
for a certain tumor type and correlate with specific clinical features (25). In prostate cancers, gene 
fusions of E26-transformation-specific (ETS) family proteins are fused to ubiquitously expressed 
promoters or 5’ untranslated regions. This translocation event is leading to a deregulated protein 
expression than a classical fusion protein (26). These tumors also display a characteristic global gene 
expression profile as for acute lymphoblastic leukemia or fusion positive rhabdomyosarcoma (27, 28).  
Translocations are known to occur at any time, any age and cancer type. In adult cancers, 
chromosomal breakpoints can arise as a result of external inducing agents. Certain breakpoint 
hotspots in the genome are more prone to chromosomal instability than other regions. However, there 
is so far little evidence for any hypothesis why and how fusion positive cancer are created (23). For 
pediatric malignancies, translocation based tumors are suspected to arise already prenatally during 
fetal hematopoiesis as shown for several leukemia (29, 30). Several studies of monozygotic twins with 
the same subtype of pediatric leukemia support the in-utero hypothesis (31). 
 
1.1.5. Sarcoma – epidemiology, classification and treatment 
Sarcomas are classified into bone and soft tissue tumors with several distinct subtypes (32). The 
underlying genetic events of all sarcomas are either tumor-specific translocations or complex tumor 
karyotypes with severe genetic and chromosomal instabilities (33).  
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Fig. 2: The genomic landscape of tumors. (A) Somatic mutation frequencies are shown for selected cancers 
with the lowest to highest frequencies from the left to the right panel. The dots represent the mutation frequency in 
exomes from tumor versus normal pairs. Mutation frequencies highly vary between different caners, pediatric 
cancers cluster on the left site (modified after (19)). Mb= mega base (B) The distribution of gene rearrangements 
within fusion-positive cancers. A total of 45’472 cytogenetically abnormal malignant disorders reported by 
literature were included in the graph (modified after (23)).  
 
 
Soft tissue sarcomas can be divided into more than 50 histological subtypes with a unique pattern. 
Most importantly, soft tissue sarcoma can be discriminated into a benign and malignant subtype. The 
benign form includes lipomas, fibrohistiocytic and fibrous tumors or vascular tumors and has a rather 
high incidence of 300 cases/100’000 people per year. They are 99% superficial, in 95% with <5mm in 
diameter, present mostly without pain and are very uncommon in children (34). In contrary, malignant 
soft tissue sarcomas have an incidence of 3 cases/100’000 people per year which is generally 
increasing by age (32, 35). They are ubiquitously located to 75% in the extremities and mostly include 
malignant forms of high grade pleomorphic sarcoma, liposarcoma, leiomyosarcoma and synovial 
sarcoma (36). Pediatric forms are rhabdomyosarcoma, infantile fibrosarcoma and synovial sarcoma 
(37-39). Treatment includes surgery as first bases whereas the use of radiotherapy and chemotherapy 
is non standardized for all forms (40) and rather depends on resection of a non compartmented tumor 
(36, 39). 
 
Bone tumors divide into the main subtypes of osteosarcoma, chondrosarcoma and Ewing sarcoma. 
The incidence presents with 0.8 cases/100’000 people per year. The tumors mostly display a bimodal 
distribution peaking in the second decade of life and again at >60 years of age especially for 
osteosarcoma. Clinical features are rather non-specific with located constant pain as the major criteria, 
followed by regional swelling, general discomfort and fractures. Bone tissue tumors arise in pelvic 
bones, extremities, ribs and vertebral columns (32, 35, 41). Bone sarcomas are diagnosed by 
radiography, magnetic resonance imaging (MRI) and computer tomography (CT-) based methods 
respectively (42). Most frequently, cancer cells metastasize to the lung, bones and bone marrow (43). 
Treatment includes surgery and tumor-type specific established chemotherapy treatment protocols 
(41). 
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1.1.6. Targeted therapies in sarcoma 
Classical chemotherapeutics are still the standard of care in most bone and soft tissue sarcomas. 
Several clinically relevant anti-tumor agents have been developed over the years and are currently 
under FDA (Food and Drug Administration, US) approval or in clinical trials (Table 1) (44-46). Targeted 
therapy is most commonly based either on the presence of a molecular marker serving as a target or 
functional differences of cancer cells versus non tumorigenic cells. Several relevant targets have been 
investigated including receptors and growth factors (IGF1R, PDGF, c-kit), signaling pathways (mTOR), 
cell cycle regulators (CDKs) or angiogenic factors (VEGF, VEGFR) and brought to clinical trials (47). 
Over the last two decades, there was only little improvement in survival rates for children with pediatric 
sarcoma like rhabdomyosarcoma, osteosarcoma or Ewing sarcoma. A lack of interest by industrial 
companies needs to be compensated by academic research. However, translating research 
discoveries into clinics is even more challenging due to limited resources to conduct clinical trials and 
the low number of patients for trials in general. 
 
 
Table 1: Targets and targeted agents in sarcoma (modified after (44)). 
Disease Agents Targets 
Gastrointestinal stromal tumor Imatinib, sunitinib, sorafenib, regorafenib 
c-kit, platelet-derived growth factor 
receptor alpha 
Chordoma Imatinib Platelet-derived growth factor receptor alpha 
Alveolar soft part sarcoma Sunitinib, cediranib Alveolar soft part sarcoma/ transcription factor E3 
Angiosarcoma Sorafenib, bevacizumab Vascular endothelial growth factor 
Nonadipocytic sarcomas Pazopanib Vascular endothelial growth factor 
Ewing sarcoma Ganitumab, ﬁgitumumab Insulin-like growth factor 1 receptor 
Liposarcoma PD03329919 Cdk4 
Chondrosarcoma GDC0449, RO4929097 Hedgehog, Notch 
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1.2. Ewing sarcoma  
 
1.2.1. Epidemiology and survival 
In 1921, James Ewing described a series of adolescent tumors as diffuse endothelioma of bone which 
were highly distinct from osteosarcoma in their histology, appearance in the bone and sensitivity 
towards radiation (48). A few years later, the Boston surgeon Ernest Codman named the cancer after 
James Ewing (historical review Fig. 3, by (49)). Histologically, it is a blue small round cell and 
undifferentiated tumor with a characteristic rearrangement. 
 
Ewing sarcoma is the second most common bone tumor in the pediatric population with a general 
incidence of 0.3 cases /100’000 people per year with stable incidence numbers over the last decades 
(32, 50). It arises in bone and soft tissue with an age dependent distribution (Fig. 4A). The incidence 
peaks during the second decade of life in adolescence for the bone subtype. Further, a predilection for 
males with the ratio of 1.4 to 1 has been reported (32, 51). A racial difference in incidences of Ewing 
sarcoma has been observed throughout several studies and in the SEER registry with Caucasians to 
be more affected than other races (52). No racial differences have been observed for other tumors 
with a similar chromosomal rearrangement (53).  
 
The 5-year survival rate for localized disease is between 60%- 70%, with 68% reported for the SEER 
registries between 1973-2004 and with 39% for patients with metastasis at initial diagnosis (Fig. 4B). 
Tumor cells were migrating to the lung in 10% of patients, to the bone and bone marrow for another 
10% and to other locations for 5% of all cases (41, 50). Further, relapse patients have even a worse 
outcome and only 13.3% of those patients achieve a second complete remission (54). Secondary 
malignancies show a high rate for secondary bone or soft-tissue sarcomas, also carcinomas and 
hematologic malignancies have been reported (various studies are summarized by (55)). 
 
 
1.2.2. Treatment modalities 
First general symptoms of a bone tumor are pain and a mass in the involved area which can be 
accompanied by fever, anemia, leukocytosis and an increase in sedimentation. The tumor itself is tan–
grey, often necrotic and hemorrhagic (32). Ewing sarcoma most commonly arises in the diaphysis or 
metaphyseal-diaphyseal portion of long bones, pelvis and ribs (Fig. 4C). The skull, vertebra, scapula, 
and short tubular bones of hands and feet are rarely involved (32, 56).  
Standard imaging procedures of lesions include whole body MRI or CT scans (Fig. 4D). Diagnosis of 
Ewing sarcoma is performed by biopsy and the rearrangement detected by cytogenic fluorescence in 
situ hybridization (FISH) method on paraffin embedded tissue or by quantitative real time PCR (qRT-
PCR) from frozen sections. Further, a hematoxylin and eosin (H&E) and CD99 marker stain is used for 
immunohistochemical analysis (41). 
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Current treatment protocols include local neo-adjuvant chemotherapy and surgery. In case of an 
unfavorable location of the tumor, unfeasible surgery or for high-risk patients, radiotherapy with 45–
60Gy is given post-operationally. Next, chemotherapy combinations are given consisting of 
doxorubicin, ifosfamide, vincristine, and actinomycin (VAIA) for standard risk patients with a localized 
disease in 3-6 cycles in 2-3 week intervals for 10-12 month. High risk patients additionally receive 
etoposide (32, 41, 56). Chemotherapy for relapse patients are commonly based on 
cyclophosphamide, high-dose ifosfamide in combination with etoposide or irinotecan with 
temozolomide or gemcitabine with docetaxel (57, 58).  
 
 
1.2.2.1. Prognostic markers 
For many years, the only relevant predictor of outcome was the presence of metastasis with an 
unfavorable prognosis (59). Later, outcome could also be linked to the location of the primary tumor 
site and the age at presentation with the disease. Generally, treatment of younger patients achieves 
better disease control and subsequently outcome (60, 61). Patients with Ewing sarcoma over the age 
of 40 display much lower survival rates and have more likely an extraskeletal or axial primary tumor 
and a tendency to metastasize (62). A most current study identified discrete prognostic groups based 
on age, race and if the disease was localized or recurrent. In two independent cohorts, best outcome 
in overall survival was achieved for localized and non-pelvic tumors in patients with an age below 18 
while increasing age and metastasis lowered the prognosis significantly (Fig. 4D) (63). 
 
 
 
Fig. 3: Timeline of historical milestones for Ewing sarcoma (modified after (49)).  
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Fig. 4: Pediatric Ewing sarcoma. (A) Age distribution of patients with either bone or soft-tissue Ewing sarcoma 
in the Japanese population (51). (B) Kaplan–Meier estimates of overall survival for the European COG and US 
SEER cohorts according to the prognostic group (modified after (63)). (C) Ewing sarcoma primary sites of the 
tumor according to data from 1’426 patients of the European Intergroup Cooperative Ewing Sarcoma Studies 
(56). (D) Patient with Ewing sarcoma of the right humerus. MRI shows the position of the tumor and a bone scan 
with a high isotope uptake in the tumorigenic region. After surgery and several cycles of chemotherapy, the 
humerus was tumor free (51). 
 
 
1.2.2.2. Clinical trials 
The first selected chemotherapeutic for Ewing patients was cyclophosphamide in the 1960s. Then, a 
study was conducted with combinational chemotherapeutic treatment including cyclophosphamide and 
vincristine in addition to radiotherapy (summarized by (56)). IESS-I was the first large US study 
gathered from 1972 to 1978 demonstrating a strong advantage in survival by adding doxorubicin to the 
current three drug chemotherapeutics including cyclophosphamide, vincristine and actinomycin (VAC 
plus radiotherapy). Long-term follow-up studies revealed a dramatic increase of the 5-year survival 
rate from 24% (three drugs and radiotherapy) or 44% (three drugs and bilateral pulmonary radiation) 
to 60%. Further, a decreased number of patients developed metastasis (64). Following this, IESS-II 
was conducted from 1978 to 1982 and revealed a better outcome for patients treated with a higher 
dose of actinomycin (65, 66). Even though treatment protocols did not change dramatically over the 
next years, addition of ifosfamide and etoposide to the treatment protocol increased the 5-year survival 
rate again from 54% to 69% for non-metastatic disease (67). However, an evaluation of metastatic 
Ewing sarcoma revealed no beneficial impact due to the treatment change (68). Higher 
chemotherapeutic doses only increased the risk for secondary malignancies due to high toxicity while 
the event-free survival was not improving (69). Later, a comparison of ifosfamide and 
cyclophosphamide in patients with localized Ewing sarcoma could show that both drugs have the 
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same effect with less toxicity effects for ifosfamide (70, 71). An increased dose of ifosfamide was given 
to patients with metastatic disease and showed no improvement of survival (58, 72).  
 
 
1.2.2.3. EWING2008- the largest European study 
The EWING2008 trail aims to investigate better tolerable treatment doses and protocol arms for Ewing 
sarcoma patients. Initially, patients receive six cycles of standard chemotherapy consisting of 
vincristine, ifosfamide, doxorubicin and etoposide. Then, patients are subdivided into three groups):  
Standard risk patients (group 1) are good responders with localized disease. They receive additionally 
eight cycles of chemotherapy composed of vincristine and actinomycin with cyclophosphamide for 
females or ifosfamide for males. They are randomized to receive add-on treatment with fenretinide, 
zoledronic acid, fenretinide plus zoledronic acid, or no add-on treatment. High risk patients (group 2) 
are poor responders with a localized disease and additionally receive eight cycles of vincristine, 
actinomycin and ifosfamide chemotherapy or high-dose treatment with busulfan-melphalan. Patients 
with metastasis are in high risk group 3 and are randomized to either continued treatment with eight 
cycles of vincristine, actinomycin and cyclophosphamide or high-dose treosulfan-melphalan (73). 
 
Euro-Ewing 2012 is the second large following Phase III study for Ewing sarcoma patients. Here, the 
use of radiotherapy and peripheral stem cell transplantation in addition to different combinations of 
chemotherapeutics will be investigated. Study results are not yet published as both trials are still 
recruiting patients (source: euroewing.eu). 
 
 
1.2.3. Underlying genetics of Ewing sarcoma tumors 
Ewing sarcoma tumors harbor a balanced translocation of the chromosomes 11 and 22 leading to 
expression of the EWS/FLI1 fusion protein (74). This translocation occurs in 85% of all Ewing sarcoma 
cases, only 15% harbor EWSR1 fused to another member of the ETS family, most commonly ERG 
(75, 76). Many more different fusions with other ETS superfamily members have been reported 
(reviewed by (77)). 
 
As described before, Ewing sarcoma has one of the lowest mutation frequencies with 0.1 mutations/ 
Mb DNA (19). Besides the primary EWSR1-ETS translocation, the genomic landscape of Ewing 
sarcoma tumors is genetic rally rather normal with less than 15% of tumors displaying additional 
mutational events (Fig. 5A) (78). Secondary events driving tumor formation are subject of extensive 
sequencing efforts of pediatric tumor samples and established cell lines. Early studies by comparative 
genome hybridization revealed gain of chromosome 8 (35% of cases), chromosome 1 (25%) and 
chromosome 12 (25%) (79). With improving methods over the years, it has been shown that 
chromosome 8 and especially chromosome 1q gain are indeed the major detected copy number 
alteration (80-83). Next generation sequencing revealed in more detail that STAG2 (17%), CDKN2A 
(12%) and TP53 (7%) point mutations, rearrangements or other non-genetic mechanism are the major 
secondary events in Ewing sarcoma tumors (Fig. 5A) (78, 83, 84). Other less frequent mutations are 
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occurring in epigenetic regulators (83). Importantly, patients treated with common chemotherapeutics 
display increased somatic aberrations in their tumor genome (Fig. 5B) (83). Thus, the only consistent 
alteration found in all patient samples is the EWS/FLI1 fusion gene, or other EWS-ETS 
rearrangements. 
Chromosome 1q gain has been associated with poor outcome as well as rare chromosomal loss, like 
16q which was also linked to worse survival rate (Fig. 5C-D) (80-83). Several groups reported that 
especially TP53 inactivation is a prognostic marker for poor outcome (81, 85-87). Studies with larger 
cohorts like the Children’s Oncology Group could not confirm a prognostic relevance (88) or only in 
combination with STAG2 mutations (Fig. 5D) (83).  
 
 
 
Fig. 5: Genomic landscape of Ewing sarcoma tumors. (A) Profile of recurrent abnormalities in Ewing sarcoma 
detected by massively parallel sequencing (modified after (83)). (B) Circo plots of a primary and a recurrent tumor 
analyzed by whole exome sequencing. Cytobands are showing segmented copy number variations. 
Chromosomes are arranged end-to-end. Interchromosomal rearrangements are displayed as purple arcs (78). (C-
D) Prognostic significance of copy number alterations of chromosome 1q gain and chromosome 16q loss by 
Kaplan-Meier curves. Overall survival curves of patients according to the STAG2 mutation status and in 
combination with p53 using Kaplan-Meier curves (83). 
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1.2.3.1. The EWS/FLI1 fusion protein 
The balanced translocation t(11;22)(q24;q12) resulting in the EWS/FLI1 fusion protein has been 
discovered as the main genetic alteration for Ewing sarcoma. The N-terminal part of EWSR1 is fused 
to the C-terminal part of FLI1 (Fig. 6A) (74). Most commonly the EWSR1 exons 1 to 7 are fused to 
exons 6 to 9 of FLI1. This type 1 translocation occurs in 85% whereas in type 2 exon 7/5 fusions are 
present in 10% of all cases (Fig. 6B) (75). Many more infrequent variants have been described as well 
as several other ETS family fusion partners for EWSR1 (76, 89). In diagnostics, fusion based EWSR1 
translocations are detected by FISH analysis (Fig. 6C).  
 
In the 1990s, first indications suggested that patients with a type 1 translocations had an advantage 
over type 2 and other infrequent variants (90). However, analysis of the EURO-E.W.I.N.G.99 study 
cohort revealed that current treatment protocols have no prognostic benefit for any translocation type 
(91, 92). 
 
The EWS/FLI1 protein is indispensable for Ewing sarcoma pathogenesis as shown by antisense cDNA 
or antisense oligodeoxynucleotides towards the breakpoint region resulting in growth inhibition, 
decreased proliferation and viability (93-95). EWS/FLI1 is an aberrant transcription factor and a potent 
transcriptional modulator due to its DNA-binding domain (96, 97). The transforming capacity is more 
powerful than for FLI1 as it harbors a stronger transactivation domain in its N-terminal part (98). Even 
though DNA-binding of EWS/FLI1 and wild-type FLI1 occurs with the same sequence specificity, 
transcriptional activation properties are altered for EWS/FLI1 possibly due to its dependency on the 
EWSR1 activation domain (99). Differences in DNA-binding ability have also been reported for 
members of the ETS superfamily. ETS-binding profiles are clustering into four distinct classes, and all 
cancer associated members ERG, ETV1, ETV4 and FLI1 are clustering together indicating that a 
similar defined activation pattern is cancerogenous (100). 
 
The structure of the ETS domain of EWS/FLI1 consists of three α-helices and four stranded anti-
parallel β-sheets when bound to DNA. It belongs to the class of helix-turn-helix proteins. Defined 
residues in the DNA-binding domain are necessary for the DNA interaction including arginine 386 
(respectively arginine 340 for FLI1) (101, 102). EWS/FLI1 protein carrying point mutations in the ETS 
domain fails to interact with DNA, and these cells are subsequently incapable of tumor growth. 
However, DNA-binding independent properties are also contributing to the malignant phenotype of 
EWS/FLI1 transformation. These cells retained their ability to transform murine 3T3 cells which could 
be grown as xenografts in vivo (103).  
 
 
1.2.3.2. EWS/FLI1 target genes 
Modulation of target genes by EWS/FLI1 has been shown to be critical for tumorigenesis. The fusion 
protein activates and represses a wide range of target genes leading to activation or inhibition of 
distinct pathways (reviewed in (104, 105). Attempts to identify a defined target gene signature started 
with the discovery of the fusion protein itself (106). Most of the assays were using RNA interference 
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(siEWS/FLI1 or shEWS/FLI1) or introduction of recombinant EWS/FLI1 into mouse progenitor cells or 
other cell lines. This led to the discovery of a variety of EWS/FLI1 activated genes including CAV-1 
(107), Nkx2.2 (108), NR0B1 (109), IGF1 (110), SOX2 (111) and repressed genes as IGFBP3 (112) or 
PHLDA-1 (113). Further, not only protein coding genes are upregulated, but EWS/FLI1 also 
specifically influences long non-coding RNAs like EWSAT1 (114). Depletion of most of these direct or 
indirect target genes reduces cell growth and tumorigenesis. However, none of them was identified as 
a sole driver target gene responsible for Ewing sarcoma tumorigenesis. Until now, it is believed that a 
defined subset of target genes is responsible for the malignant phenotype rather than a single driver 
downstream gene. Further, several studies revealed that a much higher number of genes are 
repressed than activated by EWS/FLI1 which is mediated by interaction with the NuRD co-repressor 
complex (9, 105, 115). Despite the NuRD complex, it is not yet exactly clear by which other 
mechanism repression is controlled. Since, not only the DNA-binding domain of EWS/FLI1 is important 
for full oncogenic activity, also the C-terminus has been linked to support the transcriptional 
modulation of activated target genes (116). 
 
Most importantly, EWS/FLI1 expression and its target gene pattern is context dependent. In most cell 
lines, EWS/FLI1 induction leads to growth inhibition or a senescence like phenotype in human or 
mouse fibroblasts (117, 118). In rhabdomyosarcoma cells, induction of EWS/FLI1 changes histology 
and gene expression (119). Only few cell lines are known to be permissive for oncogenic 
transformation, and so NIH 3T3 or human mesenchymal stem cells are most commonly used to model 
EWS/FLI1 transformation (116, 120, 121).  
 
 
1.2.4. Cell cycle deregulation in Ewing sarcoma 
Due to its low mutation rate, cell cycle deregulation in Ewing sarcoma tumors is a direct effect induced 
by the EWS/FLI1 protein rather than a result of mutational burden. It was shown that depletion of 
EWS/FLI1 results in G0/G1 arrest which is accompanied by repression of cyclin D or cyclin E and 
activation of p21, p27, p57 or pRb. Unbalanced expression of G1/S regulatory factors supports 
tumorigenesis (122-126). Further, EWS/FLI1 mediates evasion of senescence most likely via the 
Skp2-p27 axis (125, 127). Thus, oncogenic transformation of Ewing sarcoma is highly dependent on 
EWS/FLI1 cell cycle control. Similar effects were observed for full length FLI1 which inhibited cell 
differentiation by downregulation of cyclin D2 or D3 and other genes implicated in cell cycle or cell 
proliferation control in Friend virus-induced erythroleukemia (128). 
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Fig. 6: The EWS/FLI1 fusion protein is solely characteristic for Ewing sarcoma tumor cells. (A) The 
EWS/FLI1 protein is a balanced translocation of EWSR1 and FLI1 gene rearrangement. It harbors a strong 
transactivation domain in the N-terminal part and the DNA-binding domain from FLI1. RGG= arginine-glycin-glycin 
repeats. (B) Several fusion types are described. Most common are type 1 fusion and type 2, many more 
infrequent variants are known (A and B modified after (75)). (C) EWSR1 translocations are detected diagnostically 
by FISH with probes for telomeric and centromeric EWSR1. The exact fusion partner is determined by additional 
methods (Images by P. Bode, University Hospital Zurich, Switzerland). 
 
 
 
1.2.5. EWS/FLI1 interacting proteins 
The fusion protein EWS/FLI1 is a chimera consisting of largely unstructured regions of the EWSR1 full 
length protein and a structured DNA-binding domain in its C-terminal FLI1 part. Consequently, the 
EWS/FLI1 interactome network is based on interactions originally arising from EWSR1 and FLI1 or is 
unique to the fusion protein in its cellular background. EWS/FLI1 is capable to self-associate and to 
interact with EWSR1 and FLI1 full length proteins (129, 130). Later, a phage display library screen 
revealed RNA helicase A (RHA) as an important interactor and transcriptional co-factor of EWS/FLI1, 
both binding to specific EWS/FLI1 target genes promoters. Functionally, both proteins together have a 
greater transforming capacity (131). Development of the small compound YK-4-279 resulted in the 
disruption of EWS/FLI1 and RHA interaction leading to apoptosis in Ewing cell lines and a reduction in 
tumor growth in vivo (132, 133). Despite this prominent example, EWS/FLI1 is highly involved in 
splicing processes by interacting with hsRBP7 RNA polymerase subunit (134) or small nuclear 
ribonucleoprotein U1 (135). However, EWS/FLI1 interferes and alters the splicing procedure by full 
length EWSR1 which is contributing to the malignant phenotype (136-138). Recent larger interactome 
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studies revealed that EWS/FLI1 interacts with a splicing network rather than with single components of 
the splicosome. EWS/FLI1 binds to several splicing factors and is alternatively splicing several genes 
implicated in oncogenesis (139).  
 
 
1.2.6. The ETS family and cancer  
E-26 transforming specific (ETS) family members are strong activators or repressors of transcription 
with a highly conserved ETS domain (140-143). The ETS transcription factors bind most commonly in 
complexes to a GGA core region in order to mediate gene expression (144, 145). Main biological 
functions include regulation of differentiation, lineage determination of the hematopoietic system and 
control of angiogenesis (146-148).  
Most of the ETS family members have oncogenic potential. Truncated or overexpressed ETS proteins 
have been linked to several cancer entities (149-152). ERG or ETV1 are frequently fused to the 
TMPRSS2 promoter in prostate cancer, whereas ETV6 is fused to AML1 and implicated in acute 
lymphoblastic leukemia (153, 154). Further, ETV6 germline variants resulting from mutational events 
are associated with onset of leukemia (155). 
 
 
1.2.7. The ETS member FLI1 
The Friend leukemia virus-induced erythroleukemia-1 (FLI1) full length protein is a member of the ETS 
family (156, 157). An alternatively spliced variant has been reported for human FLI1 (FLI1-1b) with the 
same transcriptional activation properties (158). FLI1 is nuclear localized and is harboring two 
independent nuclear import signals (one at the N-terminus and one in the ETS DNA-binding domain) 
and one export signal which is partly CRM1 dependent (159). Posttranslationally, FLI1 is sumoylated 
by PIASxα at lysine 67 located in the N-terminal activation domain in order to repress its 
transcriptional activation (160). Further, FLI1 is phosphorylated at threonine 312 in the DNA binding 
domain by Protein Kinase C δ disruption its interaction to the p300/ CREB binding protein-associated 
factor (PCAF) (161, 162). Phosphorylation was independently reported in T-cells resulting in a relative 
short half life time of approximately 2h (163). 
In a non-pathogenic context, FLI1 is preferentially expressed in hematopoetic or endothelial cells 
(164), and implicated in normal hematopoietic stem cell and megakaryocyte homeostasis (165). 
Further, it regulates megakaryocytic differentiation (159), erythropoiesis (166) and pre-thymic T-cell 
progenitors (167). However, deregulation of FLI1 leads to an imbalanced differentiation and 
proliferation with a tumorigenic potential (128, 168-170). Besides inducing the friend virus-induced 
erythroleukemia in mice (171), FLI1 is the major driver of several human erythroleukemia (157, 172) 
and involved in various gene fusions (74, 173). In diffuse large B-cell lymphoma, several clinical 
patient samples showed a higher expression of FLI1 which was associated with a gain of 11q24.3, the 
area where the Fli1 gene is located (174).  
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1.2.8. EWSR1 full length protein 
The EWSR1 full length protein belongs to the FET family of TATA-box binding and RNA-binding 
proteins (175). EWSR1, but also TLS and TAF15, harbor a strong activation domain, several RGG 
boxes, a RNA-binding domain and a Cys2–Cys2 zinc finger (176). EWSR1 also has an alternative 
splice variant, EWSR1-b both being ubiquitously expressed (177). Apart from Ewing sarcoma, gene 
fusions have been described such as the EWS/ATF1 fusion gene in clear cell sarcoma (178, 179).  
EWSR1 itself is expressed in the nucleus and only in secretory cells cytoplasmic. However, EWSR1 
seems to display a cell-specific expression patterns and is specifically targeted to stress granules 
when induced by heat shock and oxidative stress (180). While its N-terminal domain is intrinsically 
disordered, it has been reported that the aromatic side chains in the activation domain are critical for 
transcription and transforming activity of EWSR1 related fusions (181). 
Posttranslationally, EWSR1 is methylated (182) and phosphorylated at threonine 79 and serine 266. 
While serine 266 phosphorylation regulates transcriptional activity, threonine 79 is phosphorylated 
upon mitogens or in response to DNA damage by ERK1 and ERK2 (183, 184). 
 
Besides RNA-binding properties and being part of fusion proteins, the exact function of EWSR1 is not 
unraveled yet. Genetic depletion of EWSR1 was reported to affect mitosis and midzone formation 
during mitosis and accumulates at sites of DNA damage (185-187). Most importantly, several studies 
suggest the involvement of EWSR1 in mitochondrial homeostasis and energy metabolism. In EWSR1-
/- mice, loss of brown pre-adipocytes during development was observed (188). Later, it has been 
confirmed that depletion of EWSR1 reduces the abundance and activity of mitochondria which 
subsequently leads to a decrease in brown fat tissue and skeletal muscles (189).  
 
 
1.2.9. The Ewing sarcoma cell of origin and tumor models 
The cell of origin of bone and soft tissue Ewing sarcoma is in the focus of various debates. Proposed 
cells are derived from a neural crest or mesenchymal origin. Attempts to investigate the cell of origin 
usually include the comparison of Ewing sarcoma tumors to reference tissue gene expression pattern, 
overexpression of EWS/FLI1 in a permissive cell type as well as EWS/FLI1 silencing approaches in 
Ewing cell lines for comparison of the resulting gene expression pattern to other tissues.  
A very early study Ewing sarcoma cells were treated with cyclic AMP and TPA. It was observed that 
the morphology was similar to a neural differentiation pattern accompanied by an upregulation of 
neural markers (190). While EWS/FLI1 expression causes growth arrest in most primary cells and 
cannot transform most cell lines, induction of EWS/FLI1 in RD cells resulted in neuron-specific 
characteristics and neural crest development was abrogated upon direct transformation into neural 
crest cells (119, 191). 
Other attempts to characterize the origin were based on the observation that primary bone marrow 
derived mesenchymal progenitors could be transformed by EWS/FLI1 alone (192). EWS/FLI1 
silencing exhibited a gene expression pattern similar to that of mesenchymal stem cells (MSC). It was 
possible to differentiate Ewing cell lines along the adipogenic and osteogenic lineage upon inhibition of 
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EWS/FLI1 under appropriate conditions (193). Further, human MSCs seem to be permissive for stable 
EWS/FLI1 integration and maintenance. The resulting expression pattern was similar to that of Ewing 
cells (121). Several other groups found further evidence for a mesenchymal onset leading to changes 
in morphology and gene expression pattern (194-196).  
The most recent study suggested embryonic osteochondrogenic progenitors as another possible 
origin. Injection of EWS/FLI1 transformed embryonic osteochondrogenic progenitors from the 
embryonic superficial zone of the long-bone induced a Ewing sarcoma like small round cell sarcoma 
(197). 
 
Consequently, no genetically engineered mouse model exists up-to-date. Cell line or patient-derived 
mouse xenografts enable in vivo experiments. Attempts to use mice with conditional EWS/FLI1 
expression in mesenchymal cells resulted in embryonic lethality. Even though mice were presenting 
with a number of developmental defects in the limbs, none of them developed tumors (198). Another 
cre-inducible EWS/FLI-1 expression based system resulted in the rapid onset of myeloid and erythroid 
leukemia (199). The only present alternative has been shown by an EWS/FLI1 zebrafish model (200). 
 
 
1.2.10. Drug screenings to identify new therapeutic targets for Ewing sarcoma treatment 
As described earlier, Ewing sarcoma treatment protocols and clinical outcomes have barely changed 
during the last decades. Even though the underlying molecular mechanism like the EWS/FLI1 fusion 
protein or the target gene signature are well characterized, little progress has been made towards a 
more targeted therapy approach.  
One of the first screenings directed to Ewing sarcoma was performed with a small molecule library 
enriched for FDA approved drugs. Using a ligation mediated amplification assay to validate changes in 
EWS/FLI1 expression signature, cytosine arabinoside highly modulated expression profiles similar to a 
EWS/FLI1 depletion state as well as affected Ewing tumor growth in vitro and in vivo (201). However, 
when used in a phase II clinical trial, cytosine arabinoside (cytarabine) showed high toxicity with only 
minimal activity leading to termination of the clinical trial (202). Two other drug screenings also 
focused on the target gene signature as a read-out for Ewing sarcoma cell sensitivity. An NR0B1 
promoter based luciferase screen revealed mithramycin as a potential candidate (203). Even though 
administered for few metastatic Ewing sarcoma patients decades ago (204, 205), it just entered Phase 
I/II trials for pediatric and adult solid tumors and especially Ewing sarcoma in 2012 in the US with yet 
unpublished results (Clinical trial identifier: NCT01610570). Another compound midostaurin has been 
identified in a screening using activated and repressed target genes as a read-out with a similar library 
(113). Midostaurin entered various phases of clinical trials for leukemia, but not sarcoma patients.  
 
The search for new therapeutic strategies revealed Ewing sarcoma cells to be especially sensitive to 
PARP inhibitors. EWS/FLI1 complexes with PARP1 in order to activate PARP1 gene expression and 
induce a transcriptional positive feedback loop (206). The sensitivity to PARP1 inhibitors is highly 
dependent on ETS-based fusions (206, 207). However, Ewing sarcoma cells with the EWS/FLI1 fusion 
transcript are the most sensitive among a panel of several hundred cancer cell lines screened for 
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preclinical and clinical targeting agents (208). Several combinations with PARP inhibitors have been 
proposed revealing that combinations with DNA damaging agents like irinotecan or temozolomide 
even increased efficacy (209). 
 
The most intensively studied pathway in Ewing sarcoma tumorigenesis involves the insulin-like growth 
factor (IGF) signaling cascade. First biological responses have been observed in Ewing sarcoma cells 
by addition of labeled recombinant IGF1 or inactivation of the IGF1 receptor (IGF1R) by receptor 
binding antibodies (210, 211). Implications for Ewing pathogenesis have first been shown by 
transformation of mouse fibroblasts with EWS/FLI1. Only wild type, but not IGF1R knockout fibroblasts 
were capable to form colonies in soft-agar (212). Inhibition of Ewing cell growth in vitro has been 
shown by treatment with monoclonal antibodies against IGF1R, antisense IGF1R and by expression of 
a dominant-negative mutant form (213-215). On target gene level, IGF1 has been characterized as an 
activated and IGFBP3 as a repressed target gene (110, 112). Several EWS/FLI1 repressed miRNAs 
are targets of the IGF signaling pathway (216).  
Clinically IGF1R inhibition by monoclonal antibodies like Figitumumab, AMG479 or R1507 is well 
tolerated with only rare severe side effects. Phase I studies with small patient numbers demonstrated 
promising results(217-219). The hope for a new efficient treatment option rapidly decreased in Phase 
II trials as only a subset of patients had benefits while most of them showed only modest responses 
and quickly developed resistances towards IGF1R therapy (219-221).  
 
It is still to be elucidated which biomarkers are predictive for response. While the ratio of IGF1 to 
IGFBP3 did not correlate with outcome data (222), it has been first suggested that patients with low 
free IGF1 levels do not benefit from anti-IGF1R therapy (223). However, two independent studies 
observed the opposite: A smaller Phase I/II study revealed that patients with high free IGF1 levels 
showed a lower overall survival rate. An immunohistochemical analysis of 290 patient samples 
showed that reduced activity of the IGF1 system correlated with a poor treatment response (224, 225). 
 
 
1.2.11. Challenges and opportunities for novel treatment strategies 
To summarize, outcome and survival rates of Ewing sarcoma patients are among the worst for all 
pediatric cancers and have not changed for the last two decade. Tumor metastasis and relapse are 
the two biggest challenges in Ewing sarcoma treatment. At the molecular level, research has focused 
on EWS/FLI1 induced target genes and their impact on tumorigenesis. Only in the last years, it 
became clear that other important mechanisms like splicing or epigenetic modulation are central 
characteristics in Ewing sarcoma tumorigenesis and of EWS/FLI1 function itself (139, 226, 227). One 
of the least studied regulations is EWS/FLI1 degradation and its impact in Ewing sarcoma 
pathogenesis. Drugs globally interfering with parts of the ubiquitin system like the proteasome inhibitor 
Bortezomib, the Nedd8-activating enzyme inhibitor MLN4914 or MDM2 inhibitor RG7112 have been 
tested in Ewing sarcoma cells and xenografts with differential results, but none of them are currently in 
Ewing sarcoma clinical trials (82, 228-232). Depletion of EWS/FLI1 protein itself by enhancing the 
turnover rate has not been in the focus of research.  
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1.2.12. Turnover in Ewing sarcoma pathogenesis 
EWS/FLI1 regulation occurs over posttranslational modifications as glycosylation, phosphorylation and 
acetylation have been reported (233, 234). EWS/FLI proteasomal degradation has not been 
investigated so far even though a recent publication proposed that EWS/FLI1 degradation might be 
lysosomal as they have found the cation-independent mannose 6-phosphate receptor (CIMPR) as an 
interactor of EWS/FLI1 in HEK293T cells (235).  
 
However, targeting the ubiquitin system could be of therapeutic benefit as it has been shown that the 
ubiquitin proteasome system was among the pathways which were differentially regulated in resistant 
Ewing tumors towards standard chemotherapy (236). So far, EWS/FLI1 proteasomal turnover 
presents a yet uncharacterized mechanism in Ewing sarcoma tumorigenesis which would have the 
potential to uncover novel therapeutic strategies for Ewing sarcoma therapy. 
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1.3. The ubiquitin proteasome system  
 
1.3.1. A historical overview 
Regulation of protein turnover is a crucial feature necessary for cell homeostasis, function and 
maintenance. Proteins are continuously synthesized and degraded by the ubiquitin proteasome 
system (UPS)- an efficient recycling machinery in eukaryotic cells. The proteasome is a ubiquitously 
expressed multisubunit protein complex responsible for destruction of the majority of all proteins. 
Although lysosomal proteolysis, discovered in the mid 1950s (237), was thought to be the only existing 
cellular degradation system, a pioneering article discovered ATP-dependent protein turnover in the 
late 1970s in a lysosomal-free reticulocyte lysate system (Fig. 7A) (238, 239). 
 
Deservedly, the discovery made by Aaron Ciechanover, Avram Hershko and Irvine Rose (Fig. 7B) was 
jointly awarded with the Nobel Prize for Chemistry in 2004 for “the discovery of ubiquitin-mediated 
protein degradation" (press release at Nobelprize.org). Since then, many researchers contributed to 
unravel the puzzle of ubiquitination signaling and proteasomal turnover (historical timeline Fig. 7C). 
 
 
 
Fig. 7: Historical overview of UPS-mediated degradation. (A) Original article describing the initial discovery of 
a non-lysosomal and ATP-dependent proteolytic system (239). (B) The Nobel Prize for Chemistry was jointly 
awarded in 2004 for “the discovery of ubiquitin-mediated protein degradation" to Aaron Ciechanover, Avram 
Hershko and Irwin Rose (240). (C) Timeline of important discoveries and milestones in research on intracellular 
protein degradation (modified after (241)). 
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1.3.2. Mechanism of intracellular proteolysis 
The regulation of protein stability is a highly conserved and multistep system most necessary to 
ensure cell homeostasis or to react to exogenous stimuli. It is a well balanced multi-complex system 
which not only triggers the destruction of proteins, but has many more functions (242-244). The 8kDa 
protein ubiquitin determines the fate of proteins upon its intrinsic lysine linkages and linkage to 
substrate lysines. Proteolysis can be mediated by proteasomal, lysosomal or autophagosomal 
degradation (241). 
 
 
1.3.3. Proteasomal degradation 
Ubiquitin-mediated proteolysis occurs primarily over the 26S proteasome, a large multisubunit 
complex for around 70% of all intracellular proteins (245). Assembly of this large construct occurs 
most commonly in the cytosol, but also nuclear proteasomal degradation has been observed (246-
248). 
First evidence for ubiquitin-mediated degradation of substrates via an ATP-dependent protease came 
from the observation that ubiquitin-conjugated lysozyme was much faster degraded in the presence of 
ATP (249-251). This high molecular weight protease consists of the multisubunit complexes 26S and 
20S proteases which are highly conserved in size and shape and were later termed as the 
proteasome (252-254). The 20S subunit is the catalytic core of the complex and requires ATP for 
proteolysis. It is composed of seven different α-subunits and seven different β-subunits (255, 256). 
Later, the mammalian proteasome was found to consist of a barrel like structure, the 20S, and two 
19S lids on each site with a rather flexible linker in between (Fig. 8B) (257, 258). The association of all 
multisubunit components to the full 26S proteasome is reversible (259-261). Substrate bound ubiquitin 
chains are recognized by proteasome receptors as S5a (262). Activation of the proteasome by 
ubiquitinated proteins occurs over the binding to USP14, an enzyme associated with the proteasome 
complex. This results in gate opening of the 20S subunit, providing an additional mechanism of 
substrate selectivity for degradation (263). 
 
1.3.4. The process of protein ubiquitination 
The process of ubiquitin attachment involves a sequential cascade of an E1 activating, E2 conjugating 
and E3 ligating enzyme. E1 mediates the initiation of the cascade by activating the C-terminal glycine 
residue of the ubiquitin in an ATP-dependent step. The E2 then accepts the activated ubiquitin, 
operating as a carrier which subsequently binds to the E3 ligase. The E3 ligase catalyzes the transfer 
of the E2-ubiquitin complex to the substrate. The dynamics of the E2-E3-substrate complex pairing 
determines substrate specificity (Fig. 8A). Subsequently, the ubiquitinated proteins are degraded by a 
proteolytic complex like the proteasome or trigger different signaling events. For the transfer of 
ubiquitin, two E1, approximately 40 E2 and more than 600 E3 ligases are possible components of the 
enzymatic cascade in eukaryotes (Fig. 8C) (242-244, 264-270). 
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Fig. 8: The ubiquitin system. (A) An enzymatic cascade transfers an ubiquitin molecule from the E1 activating 
enzyme to the E2 conjugating enzyme to the E3 ligating enzyme to a substrate. The poly-ubiquitinated substrate 
can either be a trigger for a signaling event, rescued or modified by deubiquitination or subsequently degraded by 
the proteasome. (B) Three-dimensional structure of the 26S proteasome as displayed by electron microscopy 
(257). (C) The number of enzymes involved in the attachment of ubiquitin is organized in a hierarchical way with 
only two E1 enzymes to more than 600 existing E3 enzymes. (D) Possible ubiquitin linkages and their implication 
in cellular processes (modified after (271)). (E) Estimated ubiquitin pools in Hek293 cells (left circle). From 
ubiquitin linked chains, the prevalence of a particular lysine linked fraction was investigated in Hek293 cells 
(middle) or Saccharomyces cerevisiae (right) (272).  
 
 
 
E3 ligases are subdivided into three main classes which are characterized according to their active 
domain: RING (really interesting new gene), HECT (homologous to the E6-AP carboxyl terminus) and 
U-box related domain (273-275). According to the sequential addition model, several rounds of 
ubiquitin transfer are resulting in a poly-ubiquitin chain of various length and linkage. The chain is 
initiated by a single ubiquitin molecule attached to a substrate lysine via an isopeptide bond (269, 
276).  
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1.3.5. The ubiquitin code 
Ubiquitin is encoded by four distinct genes. Single copies of the UBA52 and RPS27a genes lead to 
ubiquitins fused to ribosomal subunits. Transcription of the UBB and UBC genes results in three, 
respectively nine, head-to-tail repeats of ubiquitins which are then cleaved into single units for the free 
ubiquitin pool (277, 278). A poly-ubiquitin chain is formed by the attachment of the C-terminal glycine 
76 of one ubiquitin to one of the internal lysine residues of an adjacent ubiquitin (279). The internal 
lysines are situated along the ubiquitin molecule at residues K6, K11, K27, K29, K33, K48 and K63. 
Poly-ubiquitin chains can be formed by ubiquitins of the same linkage type or as a combination of 
different linkages (Fig. 8D). Poly-ubiquitin chains starting at the first methionine of the amino acid 
sequence are also possible and can mediate substrate degradation (280, 281). According to the 
ubiquitin chain conjugation, different outcomes are triggered, indicating a wide working spectrum of the 
ubiquitin code (269, 282).  
 
K48-linked ubiquitins were the first linkage to be reported as a signal for proteasomal degradation 
(283, 284). They are the most prevalent linkage type among all chains (Fig. 8E). At least four 
ubiquitins were shown to be the minimum signal for efficient targeting by the proteasome (285). The 
process of K48-linked poly-ubiquitination is a two step process as shown for the E3 ligase complex of 
CDC4 and its substrate SIC1. Attachment of the first ubiquitin is rate-limiting and slow while the 
elongation process to K48-linked ubiquitin chain is fast (276). However, recent data suggest that 
multiple ubiquitinated lysine residues are more efficiently degraded by the proteasome than tetra-
ubiquitin chains even with the same total number of conjugated ubiquitins as shown for APC/C E3 
ligase substrates. Different studies showed that also mono-ubiquitin can be sufficient for proteasomal 
recognition as shown for the PAX3 protein (286). However, later it was investigated that only mono-
ubiquitinated substrates with a size less than ~150 residues are efficiently degraded by the 
proteasome (287).  
 
Regarding the specificity of directing proteins for proteasomal degradation, it was shown that K6- and 
K11-linked chains were also recognized by the proteasome (288, 289). K11-linked chains were 
preferentially found during mitosis and cell divisions (290, 291).  
The linkages K29 and K63 have first been reported under stress-related conditions and as a response 
to DNA damage (292, 293). K63-linked chains have later been mapped to degradation of plasma 
membrane proteins in lysosomes (294). Especially EGF receptor degradation is targeted via this 
mechanism (295, 296).  
The functions of atypical chains including Met1, K6, K27 or K29-linked ubiquitins have barely been 
uncovered (Fig. 8D). Most of them possibly contribute to non-proteolytic events and trigger signaling 
events (297). The prevalence of those linkages is only very small compared to the total pool of 
linkages (Figure 8E) (272, 298). 
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1.3.6. E3 ligases 
 
1.3.6.1. Cullin-RING ligases 
The superfamily of E3 cullin-RING ubiquitin ligases (CRLs) incorporates single subunit, multi-subunit 
and cullin-like complexes. The diversity of CRL-E3s is mainly achieved by multi-subunit complexes 
which also represent the largest class. In multisubunit CRLs, the human cullins CUL 1, 2, 3, 4A, 4B, 5, 
7 and 9 serve as backbones with their distinct rigid architecture (299-302). The C-terminal region 
harbors the highly conserved sequence Cys-X2-Cys-X(9-39)-Cys-X(1-3)-His-X(2-3)-Cys-X2-Cys-X(4-48)-Cys-
X2-Cys necessary for a zinc binding RING-H2-domain protein (like Rbx1 or Roc1) serving as an E2-
ubiquitin docking site (273). In close proximity, a conserved lysine residue is conjugated to NEDD8, a 
small and ubiquitin-like protein. For most CRLs, a variable region on the N-terminal domain of cullins 
allows binding of an adaptor protein to a substrate receptor (300). Both proteins, adaptor and 
substrate receptor, are specific for cullin scaffolds and determine substrate specificity (Fig. 9). For 
CRL1, the adaptor SKP1 binds CUL1 to the F-box protein substrate receptors whereas CUL3 binds its 
corresponding substrate receptor directly via BTB substrate receptors (broad complex, tramtrack, bric-
a-brac) (303-306). 
 
The ubiquitin transfer from the E2 to the substrate occurs over a conformational change of the 
complex. NEDD8 attachment results in the reduction of the 50Å gap between the ubiquitin and the 
substrate mediating the ubiquitin transfer (307, 308). Deneddylation (NEDD8 deconjugation) of cullin 
releases an ubiquitin tagged protein and disassembles the CRL complex. This process is regulated by 
the deneddylase activity of the COP9 signalosome (CSN), a major regulator of all CRLs. The CSN 
stabilizes CRL complex formation by serving as an assembly platform and mediates the various cycles 
of CRL assembly and disassembly leading to subsequent poly-ubiquitination of substrate proteins 
(309-314). In the non-complexed form, cullin backbones are bound by the inhibitory protein CAND1 
(cullin-associated Nedd8-dissociated 1). Its interaction with CRL blocks both attachment sites and 
ensures availability of cullins for new complexes and substrate poly-ubiquitin chain elongation (315-
319). 
 
The best studied example of CRL formation is the SCF (SKP1-CUL1-F-box protein) complex which 
was originally discovered in Saccharomyces cerevisiae and later on in all other investigated species 
so far. All F-box proteins share a ~45 amino acid F-box domain and can additionally harbor WD40 
repeats or leucine rich repeats (320-323). SCF function is crucially important for cell cycle progression 
(324, 325).  
 
 
1.3.6.2. HECT E3 ligases 
The class of HECT E3 ligases is characterized by a ~350 amino acid long region with a conserved 
cysteine residue within the last 32-34 C-terminal amino acids necessary for ubiquitin thioester 
formation (Fig. 9) (274). They are classified into the three main subgroups: HERC with RLD motifs 
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(RCC1-like domains), NEDD4/NEDD4-like with WW domains and a third diverse class without a 
consensus motif (reviewed in (326, 327)). Also HECT E3 ligases have been shown to transfer a 
variety of ubiquitin linkages (328).  
In particular, NEDD4 family proteins with their conserved motif have been characterized in greater 
detail. Several different WW domains coexist within the members of the NEDD4 family to modulate 
protein-protein interaction between the E3 ligase and the substrate. The ten human WW domains 
recognize PPxY motifs, PPLP motifs, proline/arginine-containing (PR) sequences as well as 
phosphorylated serine/threonine-proline sites (pSP or pTP) (329-334) and serve as a platform for 
multi-protein networks (335). Like all HECT E3 ligases, NEDD4 members bind their substrate directly 
to mediate ubiquitin transfer.  
The best characterized member is NEDD4 which was implicated in LATS1, SMAD4 or PTEN 
degradation and this seems to have a pro-oncogenic role (336-338). Further, other HECT E3 ligases 
are mediating degradation of oncogenic factors, but regulation can also be context or tissue 
dependent. 
 
 
1.3.6.3. WWP1 
WW-containing protein1 (WWP1) is a member of the NEDD4 subfamily containing a C2 domain, four 
WW domains and a HECT domain (339-341). High expression of WWP1 was found in heart and 
skeletal muscle tissue (342). The first identified WWP1 substrate was Krüppel-like factor 2 which is 
directly targeted for degradation by K48-linked ubiquitination (343, 344). Other substrates are TGFβ, 
p63, ERbB2/4, EGFR, HER4, and LATS1 whose degradation is mostly associated with a proliferative 
phenotype (345-350). Further, overexpressed WWP1 resulted in a delay of senescence in human 
fibroblasts by a p27Kip1-mediated degradation (351). WWP1 was found to be overexpressed due to 
gene amplifications or point mutations in breast cancer, prostate cancer and hepatocellular carcinoma 
and to promote tumorigenesis (352-357).  
 
 
1.3.6.4. U-box domain E3 ligases 
The first identified U-box containing protein was UFD2 in yeast as an additional part of an E3-
substrate complex (275). UFD2 and other proteins harbor a U-box core which was shown to display 
similarity to RING fingers by multiple alignments of their sequences (Fig. 9). However, the U-box E3 
scaffold uses a system of salt-bridges and hydrogen bonds of conserved charged and polar residues 
to mediate ubiquitin transfer instead of a zinc-binding motif in RING E3 ligases (Aravind 2000).  
 
Conserved amino acids are critical for U-box E3 function as deletion or mutation of the conserved 
region abolished the ubiquitination activity. UFD2a, UFD2b, CHIP, UIP5, CYC4 and PRP19 are 
predominantly poly-ubiquitinating lysine residues with linkages other than lysine 48 (358). All E3 U-box 
members can additionally harbor RING finger or WD40 repeats which are not required for the physical 
interaction with E2 conjugation enzymes (359). 
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Fig. 9: E3 ligases present a diverse class of proteins. Cullin-RING ligases are multi-protein complexes with 
eight different cullins serving as scaffolds for complex assembly. They all harbor an E2 docking site and bind 
substrates via defined substrate receptors. HECT E3 ligases contain a backbone on which the ubiquitin transfer of 
the E2 enzyme to the substrate is mediated. U-box containing E3 ligases present a relatively small class of E3 
ligases. The U-box is necessary for ubiquitin transfer to the substrate (modified after (360)). 
 
 
Functionally, U-box proteins have been shown to facilitate the ubiquitination of chaperone substrates 
and thereby are involved in protein quality control and stress response. Most studied, CHIP combines 
with molecular chaperones to mediate ubiquitination of heat-shock protein substrates in a larger E3 
complex (reviewed in (361, 362)). 
 
 
1.3.7. Deubiquitinating enzymes  
The family of deubiquitinating enzymes (DUBs) is comprised of around 100 family members classified 
into six subgroups according to their catalytical core domains USP, UCHs, OTU, MJD, JAMM and 
MCPIP with the USP family exhibiting more than half of all members (Fig. 10A) (363, 364). The USP 
family harbors a catalytic domain which consists of the two short and well conserved cysteine and 
histidine boxes which comprise the critical catalytic residue (365, 366). All DUBs are cysteine 
proteases except the JAMM subgroup as a metallo protease. Both groups primarily catalyze a non 
covalent intermediate with the substrate to release ubiquitins (363, 367). 
DUBs are either substrate specific to an ubiquitin moiety or target specific to a protein or protein 
complex (363, 368, 369). Due to their ubiquitin specific capacity, DUBs are capable to discriminate 
between chain linkages, the site of the chain (end or intrinsic cleavage) and the length of poly-ubiquitin 
chains (Fig. 10B). Further, several DUBs like USP5 are responsible to recycle ubiquitin chains in order 
to maintain the free ubiquitin pool whereas others can edit existing poly-ubiquitin chains as shown for 
A20 in NF-κB signaling (370-372). DUBs are usually specific for a number of proteins, pathways or 
ubiquitin linkages. Identification of the overall DUB landscape using a mass spectrometry interactome 
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approach and platform for interaction proteomics (COMPASS) revealed that most DUBs are frequently 
associated with multi-protein complexes. Thereby, they regulate ubiquitination events to model 
complex activity (373). Several distinct processes are regulated by a variety of DUBs including protein 
stability, activation and interaction, chromatin structure remodeling or histone modification, DNA-
damage response, immune response and many more (282, 374-376). 
 
Few DUBs are proteasome associated as USP14, UCHL5, PSMD14 and PSMD7 which are cleaving 
ubiquitin and ubiquitin chains from degraded substrates to ensure availability of the free ubiquitin pool 
(377-379). USP14 is only activated upon association with the proteasome which results in ubiquitin 
binding to the catalytic cleft. This conformational change leads to an active state. The subsequent 
deubiquitination of the bound target enhances the catalytic activity of the proteasome (263, 380). 
However, most other USP members are highly activated when bound to the ubiquitin C-terminus 
(381). For another proteasome-associated DUB, UCHL5 is actively recruited to the proteasome by 
ADMR1 and incorporation of the complex to the 19S subunit allowing deubiquitination of substrate 
proteins (382-384). 
 
 
 
Fig. 10: Around 100 distinct human DUBs are described so far. (A) Human DUBs are classified into six main 
groups according to their catalytical core domain: USPs (red), UCHs (yellow), OTUs (dark green), MJDs (bright 
green), JAMMs (blue) and MCPIPs (purple) (364). (B) DUBs can modify the substrate ubiquitin chains in many 
different layers. They are capable to cleave at the start, middle or end of a poly-ubiquitin chain. Their activity can 
be substrate or linkage specific (modified after (370)). (C) Amino acid sequence of ubiquitin-specific protease 19 
(USP19). TMD: transmembrane domain (385). 
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1.3.8. Ubiquitin specific protease 19 (USP19) 
USP19 belongs to the USP family and has a size of 1318 amino acids. Several splice isoforms have 
been reported. At the N-terminus, USP19 harbors a CHORD and SGT1 (CS/p23) domain necessary 
for chaperone function. In the USP domain, a myeloid translocation protein 8, Nervy and Deaf1 
(MYND) domain exists which mediates protein-protein interactions. At the C-terminal end, USP19 
harbors a transmembrane domain (Fig. 10C) (385). USP19 cleaves K48- and K63-linked chains with a 
preference for the latter (386). Due to this transmembrane domain, USP19 function was mapped to 
substrate rescue of endoplasmic-reticulum-associated degradation (385). Further, stability of c-IAP1, 
cIAP2, HIF1α as well as the E3 ligases KPC1 and MARCH6 are regulated by USP19 (387-390). 
USP19 itself is regulated at the N-terminal site by the E3 ligases SIAH1 and SIAH2 as identified in a 
yeast-two hybrid screen (391). Most relevant, chaperone Hsp90 was characterized as an interaction 
partner of USP19 whereby binding promotes the deubiquitination activity (392). 
 
The identification of the substrate KPC1, which itself regulates p27 stability, suggested that USP19 
might also be implicated in cell cycle deregulation and subsequent cancer. Stabilized KPC1 resulted in 
enhanced proliferation whereas USP19 siRNA-mediated knockdown led to G1 arrest and delayed S-
phase entry (388). Further, USP19 depletion was capable to inhibit proliferation of prostate cancer and 
breast epithelial cell lines suggesting USP19 to be oncogenic (393).  
A second important function of USP19 is associated with muscle homeostasis. USP19 is highly 
expressed in muscle tissue of rats and myofibrillar muscle cells (394, 395). The presence of the 
endoplasmatic-reticulum localized form is critical for muscle cell differentiation and myogenesis (396, 
397). 
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1.4. The role of the ubiquitin system in cancer 
 
1.4.1. Deregulation of UPS components in cancer 
Several cancer entities are associated with pathways of deregulated degradation. That usually 
accounts for activating mutation of E3 ligases or inhibition of DUBs which subsequently leads to the 
degradation of tumor suppressor genes or cell cycle inhibitory proteins. On the contrary, decreased 
degradation as a result of inhibited E3 ligase or increased DUB activity may contribute to stabilization 
of oncoproteins and therefore increased tumorigenesis (398, 399). 
 
Several E3 ligases are known to be mutated or overexpressed in a variety of cancers (reviewed in 
(400)). Mutations of E3 ligases often occur in recognition motifs interfering with substrate or 
degradation complex binding. A prominent example is SKP2 as a member of the SCF. Its 
overexpression accelerates the degradation of p27 as the major substrate increasing cell cycle and 
proliferation. SKP2 is frequently overexpressed in prostate cancer, breast cancer and other epithelial 
tumor subtypes (401-403). The SCF substrate receptor FBW7 is characterized as a tumor suppressor. 
Mutation or loss of FBW7 leads to accumulation of the substrate CyclinE in most of the cases and was 
reported for breast, ovarian, gastric and endometrial cancer (404-408). While FBW7 mutations 
account usually for a small subset of cancer types, the mutation incidence can be up to 30% in 
endometrial cancer (405, 406). 
 
Altered DUB activity often causes protein deregulation (364, 409). DUB mutations are well described 
for several members like BAP1 in metastasizing uveal melanoma, basal cell carcinomas or malignant 
mesothelioma. Inactive BAP1 increases proliferation due to its inability to stabilize substrates like the 
tumor suppressor BRCA1 (410-413). Further research focuses on the deubiquitinating role of DUBs on 
several substrates implicated in tumorigenesis. As Mdm2 targets p53 for degradation, USP7 induces a 
p53 dependent cell growth arrest and triggers apoptosis as direct deubiquitination rescues and 
stabilizes p53 (414). Further, oncogenic c-myc was shown to be stabilized by USP37 in lung cancer 
(415). 
However, USP9X is a very prominent example on how DUBs can be context-dependent. One of the 
main USP9X substrates is MCL1 whose overexpression was reported in B- and mantle-cell 
lymphomas, chronic myeloid leukemia and multiple myeloma. Stabilization of MCL-1 by 
deubiquitinating activity of USP9X is tumorigenic (416). However, MCL-1 overexpression has also 
been observed in colon and lung cancer correlating with USP9X expression. USP9X inhibition 
sensitizes solid tumors to chemotherapeutic agents (417). In contrast, USP9X was found to be inactive 
or mutated in over 50% of pancreatic ductal adenocarcinoma. The respective low mRNA and protein 
levels correlated with an adverse outcome (418).  
 
The UPS is not only pathogenic in cancer, deregulation is also highly implicated in several 
neurodegenerative diseases by aggregate accumulation of ubiquitin conjugates in neurofibrillary 
tangles in Alzheimer, in brainstem Lewy bodies in Parkinson or Bunina bodies in Amyotrophic Lateral 
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Sclerosis. Further, pathophysiological processes in the muscle can be affected leading to muscle 
atrophy and wasting (399, 419, 420). The complexity of disease-associated deregulation highlights 
UPS targeting to be a promising strategy for a variety of fields (421). 
 
 
1.4.2. UPS associated targeting for cancer therapy  
Targeting strategies of UPS associated pathways can be based on interference with differentially 
regulated levels of UPS components like mutated or overexpressed E3 ligases (422). However, 
cancers not associated with UPS deregulation are even though dependent on functional regulation 
networks which can also serve as specific targeting points for anti-neoplastic and pro-apoptotic effects 
(423-425). 
 
Pharmacological inhibition of the proteasome uncovered many unique mechanisms of protein 
breakdown. Several different inhibitors targeting the catalytic proteasomal core (active subunits are 
β1, β2, and β5) are currently available with MG-132, Bortezomib or Lactacystein as the most widely 
used examples in research (426-431). Interestingly, proteasome inhibitors influence the degradation of 
not only abnormal and short-lived proteins and peptides, but also long-lived peptides in contrast to 
lysosomal inhibitors (427, 432). Even though the effects of proteasome inhibition cannot be pinpointed 
to a specific pathway, proteasome inhibitor induced apoptosis is likely to be most relevant for the 
sensitivity of a wide range of cancer cell lines or primary cells (reviewed in (433-436)). Next generation 
proteasome inhibitors like Carfizomib provide more specificity and less toxicity and might improve the 
clinical application beyond hematologic malignancies (437). 
 
As described, transfer of an ubiquitin molecule to the substrate protein is dependent on an enzymatic 
cascade. The three enzymes E1, E2 and E3 can be inhibited by several compounds. While E1 
inhibitor PYR-41 (438) inhibits formation of any further complexes, compounds targeting E2 
conjugating enzymes like the CDC34 inhibitor CC0651 interfere with a subclass of degradation 
complexes (439). However, none of E1 or E2 inhibitors show high specificity or a potential for clinical 
trials yet. 
Considering the hierarchical structure of the enzymatic cascade, E3 ligases provide most specificity 
with the greatest potential for targeted therapy. The millennium compound MLN4924 inhibits cullin 
neddylation, and subsequently activity, of all single and multisubunit cullin-RING ligases by interfering 
with the NEDD8-activating enzyme (440, 441). Quantitative proteomic analysis of MLN4924 treated 
melanoma cell lines not only revealed new cullin-RING ligase substrates, but also a defined subset of 
substrate proteins was shown to regulate MLN4924 cytotoxicity. Most of them were implicated in cell 
cycle regulation, DNA damage repair or ubiquitin transfer (442). Even more specific, several 
compounds have been developed which directly inhibit activity of very specific subclasses or even 
single ligases. Exemplarily, the small molecule SMER3 targets SCF-MET30 based cullin complexes 
and SCF-I2 interferes with the WD40 propeller from SCF-CDC34 ligases and other particular F-box 
proteins (443, 444). 
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However, most specificity would be achieved by directly targeting substrate binding sites of E3 ligases. 
Only few targeting compounds are developed which disrupt E3 substrate interaction. One of the best 
studied examples is the MDM2-p53 axis. The tumor suppressor protein p53 generally activates genes 
involved in cell cycle regulation and apoptosis. It accumulates upon DNA-damage or oncogene 
activation to ensure that cells do not become tumorigenic (reviewed in (445)). However, p53 is 
frequently mutated or absent in cancer cells (446, 447). The E3 ligase MDM2, which is frequently 
overexpressed in a variety of cancers, binds to the transactivation domain of p53 and thereby impairs 
its function (448, 449). The small molecule Nutlin-3 interferes with the binding of MDM2 to p53 by 
occupying the p53 binding pocket (450). Restored p53 activity induces cell cycle arrest and triggers 
apoptotic pathways in tumor cells. Like Nutlins, other MDM2-p53 disrupting compounds as MI-219 
display similar effects (451, 452). 
 
Selectivity in substrate targeting can also be achieved by DUB inhibition. USP7 is involved in p53 
stabilization. Moreover, USP7 inhibitors like HBX41,108 and P5091 reveal anti-proliferative effects and 
cell cycle inhibition by p53 induction (453, 454). Further, P5091 demonstrated apoptotic effects and 
might be of therapeutic benefit for Bortezomib resistant patients (455). As described earlier, USP9X is 
highly implicated in several cancers. The small molecule WP1130 is mainly inhibiting USP9X, but also 
several other DUB members as USP5, USP14, and UCH37. Originally derived from a screen for 
Janus-activated kinase 2, it revealed pro-apoptotic function for several cancers (456-458). One of the 
most promising preclinical compounds is bAP-15, an inhibitor of USP14 and UCHL5 which are 
proteasome associated. In vivo, tumor progression was inhibited in solid tumors and multiple myeloma 
while organ filtration was decreased for acute lymphoblastic leukemia when bAP-15 was administered 
(459, 460). 
 
Beyond targeting the main players in the UPS field (461), ubistatins block the binding of ubiquitinated 
substrates to the proteasome and therefore inhibit cell cycle progression. Mechanistically, ubistatins 
bind the ubiquitin-ubiquitin interface of selectively Lys48-linked chains (462).  
 
Considering the variety and complexity of compounds targeting all parts of the UPS in a more or less 
specific way (Fig. 11), the UPS provides one of the most diverse fields for inhibitor development (463, 
464). As proteasome inhibition already provided evidence for a successful treatment option, the 
combination of targeting E3 ligases or DUBs even exceeds the number of existing cancers. Most 
importantly, not only inhibition, but also E3 or DUB activation adds a second level of therapeutic 
possibilities. However, ongoing efforts are needed to develop new compounds or to characterize the 
effect of existing drugs on UPS components in order to provide better treatment strategies. 
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Fig. 11: UPS-based drugs. (A) The cascade of the ubiquitin proteasome system has a variety of target points. 
(B, C) List of drugs (name and target) capable to interfere with selected steps in the cascade. Underlined drugs 
are FDA approved and used in clinics (modified after (425, 465)). 
 
 
1.4.3. Inhibitors of the ubiquitin system in clinics 
Proteasome inhibitors have been shown to inhibit proliferation and induce apoptosis of human multiple 
myeloma cell lines and primary cells while sparing normal blood cells (466). Also several other cells 
have been shown to be susceptible like acute myeloid leukemia or B-cell malignancies (467, 468). 
Bortezomib was the first FDA approved proteasome inhibitor used in clinics, followed by Carfizomib 
(469-471). Bortezomib (Velcade®) is applied in relapsed and refractory multiple myeloma treatment. 
As a phase II study showed promising results, nearly 700 relapsed multiple myeloma patients were 
enrolled to compare dexamethasone to Bortezomib. An overall of 38% of patients revealed a 
combined complete and partial response rate (222, 472, 473). Later, Bortezomib was approved as a 
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first line treatment (471). Currently, proteasome inhibitors are included in clinical trials for multiple 
myeloma, hematologic malignancies and solid tumors (clinicaltrials.gov). 
MLN4924 is the second UPS associated drug that entered clinical trials and is currently implicated in 
different phase studies for melanoma, solid tumors, hematologic malignancies and specifically multiple 
myeloma (clinicaltrials.gov). 
 
 
1.4.4. Degradation of fusion proteins as a novel strategy in targeted therapy 
Gene fusions present an attractive target as tumor cells are usually highly dependent on continuous 
expression of these proteins. Several target specific drugs are indirectly enhancing or modulating 
turnover of fusion proteins. The BCR/ABL fusion in chronic myelogenous leukemia is a tyrosine kinase 
which is specifically targeted with imatinib mesylate (Gleevec). Binding to the ATP-binding site of the 
ABL kinase domain inactivates BCR/ABL activity (474). However, imatinib mesylate treatment 
resistant CML remains sensitive to several other compounds like heat shock protein 90 inhibitors 
which are all implicated in final degradation of the BCR/ABL fusion and subsequently trigger apoptosis 
(475-477). For another fusion protein, our laboratory could recently show that PLK1 kinase inhibitors 
trigger regression of alveolar rhabdomyosarcoma. On a molecular level, PLK1 depletion increased 
PAX3/FOXO1 ubiquitination and subsequently reduced protein level and target gene activation (478). 
 
Understanding and modulating turnover of fusion proteins presents a novel strategy for initial or 
resistant therapy. Thus, general inhibition of proteasomal processes with broad range inhibitors are 
leading to general cell collapse while more precise targeting of specific E3 ligases or DUBs may 
selectively induce apoptosis in cancer cells. However, two different mechanisms involving 
degradation-dependent targeting are well characterized for fusion proteins in prostate cancer and 
acute promyelocytic leukemia. 
 
 
1.4.4.1. Degradation of ERG and ERG fusions in prostate cancer 
The ETS family member ERG is also highly implicated in cancer development. Around 40% of 
prostate cancer patients are diagnosed with a truncated ERG version fused to the promoter of the 
TMPRSS2 gene (151). Most commonly, the 5’-untranslated region of TMPRSS2 is fused with exons 4 
or 5 of ERG. Much less cases are reported to involve additionally TMPRSS2 exon 3 or already ERG 
exons 1 or 2 (479). However, also non-truncated ERG was reported to be frequently overexpressed in 
prostate cancer (152). Both, overexpressed ERG and TMPRSS2/ERG fusion genes, mediate cell 
invasion, migration and tumor progression (480, 481). 
 
Most interestingly, proteasomal degradation of full length ERG proteins has recently been 
investigated. Protein turnover is regulated over CUL3 based complexes with the E3 ligase SPOP as 
the central substrate receptor (482, 483). SPOP is binding to a degron motif in the N-terminal region of 
ERG in order to ubiquitinate and subsequently degrade the protein which is suppressing prostate 
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cancer. In 4-15% of the prostate cancer patients, SPOP harbors mutations in the MATH domain 
necessary for substrate binding. Upon loss of proteasomal regulation, ERG is stabilized and is driving 
tumorigenesis (483). Further, the SPOP binding motif is located at amino acids 42-46 of full length 
ERG. The regulation is consequently lost in TMPRSS2/ERG Δ99 fusions, but also in TMPRSS2/ERG 
Δ39 fusions as SPOP requires the full N-terminal domain for binding. Hence, the truncated ERG 
protein is differentially degraded than its full length counterpart (482). Nevertheless, phosphorylation of 
ERG by CKI is a necessary modification to trigger SPOP mediated degradation. CKI-mediated 
phosphorylation partially triggers TMPRSS2/ERG Δ39 fusions for degradation. DNA-damaging agents, 
like topoisomerase inhibitors, are capable to activate CKI and enhance ERG degradation (483). Even 
though specificity of DNA damaging agents to selectively target ERG or TMPRSS2/ERG Δ39 fusions 
is questionable, it still represents a novel strategy of targeted therapy. 
In contrast, DUB targeting presents another mechanism of ERG repression. USP9X was identified in 
an interactome study as an interacting protein and a deubiquitinase of ERG. The USP9X inhibitor 
WP1130 mediates ERG repression which subsequently reduces prostate cancer growth in vivo. It has 
not been reported if ERG fusions are regulated by USP9X (484). 
 
Both described strategies, E3 ligase SPOP activation and DUB USP9X inhibition, highlight the pivotal 
role of ERG turnover in prostate cancer for targeted therapy approaches. Most interestingly, prostate 
cancer harboring SPOP mutations or TMPRSS2/ERG fusions are mutually exclusive indicating that 
these two distinct clinical subgroups might benefit from different targeted therapy approaches in closer 
future. 
 
It is noteworthy to mention that the ETS member ETV1 has also been linked to proteasomal 
degradation. The E3 ligase COP1 binds at the N-terminal part of ETV1 and poly-ubiquitinates the 
protein. A truncated version fused to the TMPRSS2 promoter in prostate cancer exhibits this 
regulation and shows a prolonged half life similar to TMPRSS2/ERG (485). Speculatively, proteasomal 
turnover might be conserved among ETS proteins while E3 ligase binding differs. 
 
 
1.4.4.2. Selective degradation of PML/RARα in acute promyelocytic leukemia therapy 
Acute promyelocytic leukemia (APL) expressing the fusion proteins PML/RARα is sensitive to 
treatment with retinoic acid (RA) while APL patients with PLZF/RARα fusions respond poorly. 
However, nowadays APL treatment additionally implicates the combination of RA with arsenic trioxide 
(As2O3). It was shown that the combination treatment resulted in prolonged survival of leukemic mice 
harboring PML/RARα, but not PLZF/RARα fusions (486). 
 
On a molecular level, RA treatment alone accelerates PML/RARα degradation resulting in cell 
differentiation and apoptosis. Treatment with RA and the proteasome inhibitor lactastatin rescued the 
degradation effect indicating a degradation-mediated targeted therapy (487). Even though RA 
treatment induces PLZF/RARα degradation, it did not result in cell differentiation (488). However, RA 
triggers proteasomal degradation of the RARα part in fusion proteins, respectively of the RARα full 
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length protein (489). Certainly, sensitivity to RA is based on an additional mechanism. Transgenic 
mice with PML/RARα fusions develop RA sensitive leukemia while PLZF/RARα fusions are indeed RA 
insensitive as shown in clinical settings. Interestingly, RA sensitivity has been shown to be regulated 
by different fusion associated co-repressor complexes (490). Later, it has been revealed that arsenic 
trioxide is involved in PML/RARα mediated degradation. PML/RARα was observed to be sumoylated 
at K160 residue by the sumo E3 ligase PIAS1 (491-493). Sumoylation at the K160 is critical for APL 
development. Transgenic mice with a PML/RARα mutation to K160R develop myeloproliferative 
syndromes, but not APL (493). PML sumoylation allows attachment of poly-ubiquitin chains by E3 
ligase RNF4 in order to subsequently degrade PML/RARα (494, 495).  
Even though the targeted effect of RA and arsenic trioxide on PML/RARα degradation was discovered 
a posteriori, it still represents an impressive example for UPS-mediated treatment of fusion-positive 
cancers. In APL combination therapy, the accelerated degradation of PML/RARα results in a cure rate 
of above 90% (496, 497). 
 
 
1.4.5. Ewing sarcoma – therapeutic potential of UPS targeted therapy 
As neither upstream nor downstream targets have brought the success of a targeted therapy approach 
in Ewing sarcoma, the EWS/FLI1 protein is now the main subject of investigation (reviewed in (33, 
498). Considering the central role of the EWS/FLI1 protein, unraveling its underlying proteolytic and 
non-proteolytic mechanisms is a key for the development of novel therapeutic strategies. The rising 
number of developed inhibitors against many parts of the ubiquitin cascade promises a great potential 
to identify new agents for Ewing sarcoma treatment. 
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Treatment protocols for pediatric Ewing sarcoma are still based on “old” drug combinations including 
doxorubicin, ifosfamide and vincristine. These well known chemotherapeutics are very effective in a 
large variety of cancers; however, they display high toxicity and act in a non-specific manner. The 
problematic of refractory and relapsed tumors as well as secondary neoplasms and severe side 
effects in children demand a high need for less toxic and highly tumor-specific treatment strategies. In 
Ewing sarcoma, the aberrant transcription factor EWS/FLI1 is the only consistent genetic abnormality. 
The protein is crucially required for tumor formation, maintenance and progression. Depletion of the 
oncogenic fusion results in tumor loss. The EWS/FLI1 protein therefore serves as an ideal target. 
Transcription factors can be targeted indirectly by modulation of their downstream effector targets, by 
disruption of important protein-protein interactions or by altering posttranslational modifications of the 
protein. Over the last years, targeting components or pathways of the ubiquitin proteasome system 
have become an emerging field in cancer therapy. Due to their presence and regulatory ability in every 
cell, they present a variety of novel therapeutic targets.  
 
In this thesis, we aim to develop novel strategies for Ewing sarcoma treatment based on targeting the 
turnover of the EWS/FLI1 fusion protein. First, we aim to elucidate how EWS/FLI1 stability and 
turnover is regulated on a molecular level. Using mass spectrometry, we will identify possible ubiquitin 
acceptor sites to better understand how regulation of stabilization is implicated in Ewing sarcoma 
pathogenesis (Fig. 12 part 1). In a second part, we aim to determine E3 ligase(s) responsible for 
EWS/FLI1 poly-ubiquitination and to characterize their interaction with the fusion protein. 
Speculatively, activation of E3 ligases would result in destabilization of the EWS/FLI1 fusion protein 
(Fig. 12 part 2). Finally, we will characterize a possible mechanism of stabilization by deubiquitination 
of EWS/FLI1. An siRNA-based screening approach will be used to identify DUBs that modulate 
EWS/FLI1 stability. A possible candidate will be characterized on the molecular and physiological level 
(Fig. 12 part 3).  
 
 
 
Fig. 12: Specific aims to unravel EWS/FLI1 protein turnover. In part 1, we aim to investigate ubiquitin acceptor 
lysine(s) mediating EWS/FLI1 protein degradation. Part 2 and 3 focus on the identification of the E3 ligases and 
deubiquitinating enzymes modulating EWS/FLI1 protein ubiquitination. 
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Abstract  
E-26 transformation specific (ETS) 
proteins are transcription factors directing gene 
expression through their conserved DNA-
binding domain. They are implicated as 
truncated forms or interchromosomal 
rearrangements in a variety of tumors including 
Ewing sarcoma, a pediatric tumor of the bone. 
Tumor cells express the chimeric oncoprotein 
EWS-FLI1 from a specific t(22;11)(q24;12) 
translocation. EWS-FLI1 harbors a strong 
transactivation domain from EWSR1 and the 
DNA-binding ETS domain of FLI1 in the C-
terminal part of the protein. Even though Ewing 
cells are crucially dependent on continuous 
expression of EWS-FLI1, its regulation of 
turnover has not been characterized in detail.  
Here, we identify the EWS-FLI1 protein 
as a substrate of the ubiquitin proteasome system 
with a characteristic poly-ubiquitination pattern. 
Using a Global Protein Stability approach, we 
determined the half life of EWS-FLI1 to lie 
between 2h-4h whereas full length EWSR1 and 
FLI1 were more stable. By mass spectrometry, 
we identified two ubiquitin acceptor lysine 
residues of which only mutation of K380 in the 
ETS domain of the FLI1 part abolished EWS-
FLI1 ubiquitination and stabilized the protein 
posttranslationally. Expression of this highly 
stable mutant protein in Ewing cells, while 
simultaneously depleting the endogenous wild 
type protein, differentially modulates two 
subgroups of target genes to be either EWS-FLI1 
protein dependent or turnover dependent. The 
majority of target genes is in an unaltered state 
and cannot be further activated.  
Our study provides novel insights into 
EWS-FLI1 turnover, a critical pathway in Ewing 
sarcoma pathogenesis and lies new grounds to 
develop novel therapeutic strategies in Ewing 
sarcoma. 
 
 
Introduction 
E-26 transforming specific (ETS) family 
members are strong activators or repressors of 
transcription with a highly conserved ETS 
domain (1-3). ETS transcription factors (TFs) 
bind most commonly in complexes to a GGA 
core region in order to mediate gene expression 
(4,5). Their main biological functions include 
regulation of differentiation, lineage 
determination of the hematopoietic system and 
control of angiogenesis (6,7). Most of the ETS 
family members have oncogenic potential, since 
truncated or overexpressed ETS proteins have 
been linked to several cancer entities (8-11). 
ERG or ETV1 are frequently fused to the 
TMPRSS2 promoter in prostate cancer, whereas 
ETV1 and ETV6 are implicated in leukemia 
(12,13). Like other aberrant fusion proteins, they 
act as drivers of uncontrolled cell growth and 
survival (14,15). However, most TFs do not 
harbor an enzymatic pocket and are therefore 
difficult to target directly. Novel strategies which 
uncover vulnerable sites in TFs are urgently 
needed to develop novel targeted therapies (16).  
Ewing sarcoma is a rare pediatric bone 
and soft tissue tumor with an aggressive 
behavior and prevalence to metastasize (17,18). 
Its main genetic abnormalities are EWS–ETS 
rearrangements, among them most commonly 
the EWS gene on chromosome 22 fused to FLI1 
on chromosome 11 which results in expression 
of the chimeric transcription factor EWS-FLI1 
(19-21). Continuous expression of the fusion 
protein is crucial for tumor formation, 
progression and maintenance (22,23) and its 
downregulation inhibits proliferation and 
reduces tumor cell growth (24-26). EWS-FLI1 is 
thought to function mainly as modulator to 
activate and repress a wide range of target genes, 
but also to regulate splicing processes or being a 
component of large interaction networks (27-31). 
However, inhibition of a single downstream 
target gene has not been proven effective yet for 
Ewing sarcoma therapy.  
The turnover of most intracellular 
proteins is mediated via the ubiquitin proteasome 
system (UPS) which triggers protein degradation 
(32). Several ETS proteins can be poly-
ubiquitinated by different E3 ligases and 
subsequently degraded by the proteasome (33-
36). Considering their high conservation, 
proteasomal degradation is likely to be the main 
mechanism of turnover for most ETS family 
members. Most interestingly, truncated ERG and 
ETV1 are lacking the N-terminal E3 binding 
domain which results in a delayed turnover of 
aberrant ETS proteins (34, 36). Here, we focus 
specifically on the turnover of the fusion protein 
EWS-FLI1 which only harbors the ETS and the 
C-terminal domain from FLI1. The impact on 
the turnover of this domain fused to N-terminal 
region of EWSR1, has not been investigated yet. 
Hence, EWS-FLI1 proteasomal turnover 
represents a so far uncharacterized mechanism in 
Ewing sarcoma tumorigenesis, even though 
EWS-FLI1 degradation has already been linked 
Manuscript I 
52 
to the lysosomal pathway (37). Moreover, the 
exact lysine acceptor residues for poly-
ubiquitination have not yet been identified for 
any wild type or truncated ETS protein.  
In the present study, we demonstrate that 
EWS-FLI1 is predominantly a proteasomal 
substrate with an unexpectedly high turnover 
rate mediated by poly-ubiquitination at a single 
lysine residue. Surprisingly, expression of this 
highly stable mutant protein in Ewing cells 
specifically induced subgroups of high-level 
expressed or turnover sensitive target genes, 
while the majority of target genes are unaltered.  
Hence, our study provides novel insights 
into EWS-FLI1 turnover suggesting that 
deflecting its stability could contribute to new 
therapeutic concepts in Ewing sarcoma. 
 
 
Results 
EWS-FLI1 turnover is proteasome 
dependent. Since EWS-FLI1 expression is 
crucial for tumor cell survival (24-26), we were 
interested to analyze degradation and turnover 
rate of the fusion protein. To address this, we 
first used a panel of six different inhibitors 
targeting proteasomal, lysosomal and 
autophagosomal protein degradation pathways. 
Incubation with 20µM of the various inhibitors 
resulted in a 2-fold upregulation of EWS-FLI1 
protein levels only upon MG-132 and 
Bortezomib treatment, both inhibitors of the 
chymotrypsin-like proteasome activity (Fig. 1A). 
We next confirmed this result by selectively 
inhibiting the proteasomal and lysosomal 
degradation pathways with two compounds in 
three different Ewing sarcoma cell lines. 
Incubation with 20µM of the proteasome 
inhibitor MG-132 resulted in stabilization of 
endogenous EWS-FLI1 fusion protein by at least 
2-fold while this was not the case for the 
lysosomal inhibitor chloroquine (Fig. 1B). P27 
and LAMP1 were used as positive controls and 
showed upregulation after treatment as expected. 
In addition, stabilization of the fusion protein in 
Ewing cells by MG-132 increased over a 2h-8h 
treatment period in a time- dependent manner 
(Fig. 1C). Hence, degradation of EWS-FLI1 is 
primarily proteasome dependent under steady-
state conditions. However, incubation with 
20µM cycloheximide (CHX) had only limited 
reducing effect on the endogenous fusion protein 
in the Ewing cells over the same 8h time period 
(Fig. 1D).  
Next, we investigated whether the fusion 
protein is ubiquitinated. To this end, 3xflag-
EWS-FLI1 was co-expressed with HA-ubiquitin 
in HEK293T cells and immunoprecipitated after 
48h using anti-flag antibody. Western blotting 
with an anti-HA antibody revealed at least four 
distinct ubiquitin bands for EWS-FLI1 which 
could not be increased by prior treatment with 
MG132 (Fig. 1E), suggesting a constant 
ubiquitination of the fusion protein. We next co-
expressed 3xflag-EWS-FLI1 with wild type HA-
ubiquitin or ubiquitin mutants which are 
deficient for K48- and K63- linked chains. 
Immunoprecipitation of the ubiquitinated 3xflag-
EWS-FLI1 revealed mainly a decrease of the 
ubiquitination pattern using K48R HA-ubiquitin 
(Fig. 1F) indicating that this is the major, but not 
only, linked ubiquitin chains of the fusion 
protein 
To further validate the fusion protein 
turnover and to overcome the limitations of 
classical CHX treatment to determine protein 
half lives, we next used the Global Protein 
Stability (GPS) approach (38) (Fig. 2A). Briefly, 
HEK293T cells were transduced with a reporter 
construct DsRed-IRES-EGFP in which EGFP is 
fused to EWS-FLI1. The ratio EGFP/DsRed was 
determined by FACS and represents a measure 
for protein stability. Known degron motifs with 
distinct half lives were used as internal standards 
and allowed to estimate the half life of EWS-
FLI1 to be between 1h and 4h (Fig. 2B). 
Incubation with MG-132 shifted the ratio closer 
to 4h, confirming that EWS-FLI1 is a substrate 
of the proteasome system with a high turnover 
rate. Additionally, we treated cells with the 
nuclear export inhibitor leptomycin B (LMB) for 
4h and 8h. Treatment with 50nM LMB stabilized 
EWS-FLI1 in a time-dependent manner (Fig. 
2C) indicating that the proteasomal degradation 
mainly occurs in the cytosol. Similar results 
were obtained in transiently or stably transduced 
Ewing cells (Fig. 2D-E), suggesting that the high 
turnover of EWS-FLI1 is mostly independent of 
the cellular background. Interestingly, incubation 
with 20µM CHX again displayed a limited effect 
on the EGFP/DsRed ratio of EWS-FLI1 reporter 
construct (Fig. 2B,2E) indicating that classical 
CHX barely reflects the steady- state turnover 
rate of the EWS-FLI1 protein and possibly other 
proteins. 
Taken together, our results indicate that 
EWS-FLI1 is a poly-ubiquitinated protein with 
an unexpectedly high turnover rate in Ewing 
sarcoma cells. 
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 EWS-FLI1 turnover depends on one 
critical lysine residue. To better understand 
fusion protein turnover, we aimed to identify the 
lysine residue(s) that are important for 
degradation. To this, we purified large amounts 
of 3xflag-EWS-FLI1 or a dominant-negative 
R386N mutant (39,40) from HEK293T cells. 
The inactive mutant was included as the inability 
to bind DNA increases the possibility for 
ubiquitination. Both samples were then 
enzymatically digested and subjected to mass 
spectrometry to identify peptide shifts due to 
covalently attached ubiquitin. This identified two 
peptides with the characteristic glycine-glycine 
shift including residues K298 and K380 (Fig. 
3A, supplementary S1A). To determine whether 
both sites are important for fusion protein 
turnover, we mutated them individually to 
arginine. After co-expressing the mutant EWS-
FLI1 with HA-ubiquitin and 
immunoprecipitation from A673 Ewing cells, we 
found that the K298R mutant was still 
ubiquitinated comparable to the wild type, while 
the K380R lost this characteristic pattern (Fig. 
3B). In addition, transient expression of the 
mutants in both A673 and SKNMC Ewing cells 
revealed that the K380R and the double mutant 
K298/380R were 2.5-fold, 3.5-fold respectively, 
more stable than wild type or the K298R mutant 
(Fig. 3C-D). As wild type EWS-FLI1, also the 
K380 mutant was still localized in the nucleus 
(Fig. 3E). We then investigated the role of both 
lysines in proteasomal turnover by GPS. The 
half life of the K298R was comparable to wild 
type EWS-FLI, while K380R shifted close to 
24h (Fig. 3F). Wild type EWS-FLI1 and the 
K298R could be stabilized by an additional 
incubation with MG-132, however the 
EGFP/DsRed ratio of the K380R mutant did not 
change upon treatment (Fig. 3G). Hence, our 
findings suggest that K380 is the major site 
required to regulate EWS-FLI1 protein turnover 
by the proteasome. 
 
EWS-FLI1 fusion protein and wild 
type FLI1 share a unique site for turnover. To 
investigate whether turnover by K380 is unique 
to the fusion protein, we subsequently compared 
stability and ubiquitination pattern to the full 
length proteins EWSR1 and FLI1. Surprisingly, 
both wild type proteins were more stable with 
half lives of >4h (FLI1) and close to 24h 
(EWSR1) (Fig. 4A). While FLI1 could be 
stabilized by incubation with MG-132 (or 
destabilized by CHX), EWSR1 did not change 
its already long half life by these treatments (Fig. 
4B). As FLI1 was clearly poly-ubiquitinated 
similar to the fusion protein, EWSR1 showed 
strong mono- and di-ubiquitination (Fig 4C). 
Next, we mutated the previously identified lysine 
residue to arginine (FLI1: K334). By GPS, the 
K334R also increased its half life towards 24h 
(Fig. 4D). Additionally, mass spectrometry of 
purified 3xflag-FLI1 revealed glycine-glycine 
shifts for peptides containing lysines K172 and 
K252 (peptide spectra in supplementary S1B-C). 
Whereas K172 is located in the N-terminal part 
and therefore not present in the fusion protein, 
K252 corresponds to the EWS-FLI1 K298 
residue. Single arginine mutants of both residues 
display EGFP/DsRed ratios comparable to wild 
type FLI1 (Fig. 4D, dotted lines) indicating that 
both fusion and full length protein turnover is 
regulated by one single lysine residue. Indeed, 
incubation of FLI1 and K334R with MG-132 
only shifted the wild type, but not the K334R 
mutant ratio (data not shown). Interestingly, the 
K334/K380 residue is conserved within most 
ETS family members (Fig. 4E). 
Together, our findings indicate that, 
despite differences in turnover, stability of both 
EWS-FLI1 and wild type FLI1 is regulated by 
the same critical conserved residue in the ETS 
domain. 
 
EWS-FLI1 target genes expression is 
subdivided into three major groups. 
Modulation of EWS-FLI1 target gene signature 
is one of the best studied mechanisms in Ewing 
sarcoma. EWS-FLI1 is activating a wide range 
of target genes like NKX2.2, NR0B1 or IGF1 
(30,31,41-43), but has also repressive functions 
as shown for IGFBP3, PHLDA1 and LOX (44-
46). Consequently, this is thought to be critical 
for oncogenic properties as depletion of the 
fusion protein results in growth inhibition and 
cellular senescence (24,47). To better understand 
the effect of EWS-FLI1 stability on the target 
gene signature, we established inducible 
exchange cell lines which were capable to knock 
down the endogenous EWS-FLI1 while 
simultaneously expressing 3xflag-EWS-FLI1 or 
the K380R mutant. To this, we first sorted cells 
expressing these flag tagged overexpression 
constructs by flow cytometry for the same low 
EGFP expression (the selection marker of the 
pInducer21 vector) to obtain a homogeneously 
expressing population (Fig. 5A). We then 
subsequently transduced each of these clonal 
pools with two different shRNA constructs 
against the 3’UTR of EWS-FLI1 (Fig. 5B). 
Upon doxycyline induction for 48h, endogenous 
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EWS-FLI1 was exchanged with ectopic wild 
type or mutant 3xflag-EWS-FLI1versions (Fig. 
5C). As observed before, the K380R mutant 
stabilized the protein posttranslationally by at 
least four-fold (Fig. 5C) while EWS-FLI1 
mRNA levels were comparable as shown for 
shEF#2 (Fig. 5D, not shown for shEF#1 based 
cell lines). We then extracted total RNA for 
microarray expression profiling and analyzed the 
EWS-FLI1 target genes signature for their 
differential expression upon stabilized fusion 
protein (supplementary S2). A total of 497 probe 
sets were downregulated by at least 1.5-fold due 
to EWS-FLI1 depletion from which 250 could be 
rescued to at least normal levels by induction of 
EWS-FLI1 wild type (Fig. 6A-B). Only if the 
EWS-FLI1 target genes were modulated and 
recovered in the paired comparison of EWS-
FLI1 induction and knockdown at each 24h and 
48h, they were considered as rescued. This 
pattern was similar for repressed target genes as 
333 probe sets were at least 1.5-fold upregulated 
from which 164 could be again repressed by 
ectopic EWS-FLI1 (Fig. 6A, 6C). However, we 
were most interested in the target genes which 
were further modulated with stabilized protein 
levels. Surprisingly, the large majority of these 
genes appeared to be unmodified and displayed 
no difference in target gene expression between 
wild type and mutant EWS-FLI1. However, two 
subgroups were modulated differentially by the 
mutated fusion protein. One subgroup seems to 
be protein sensitive as 15 individual genes 
displayed higher RNA levels by at least 1.5-fold 
upon expression of stabilized EWS-FLI1 protein. 
From the other subgroup, 29 rescued candidates 
were fusion protein turnover sensitive and could 
only partly be modulated by the mutant in 
comparison to wild type EWS-FLI1 (Fig. 6A-B, 
list supplementary S2). Among the protein 
sensitive candidates, IGF1 and long non-coding 
RNA EWSAT1 have been already characterized 
(41,48) while most other target genes have not 
been implicated in EWS-FLI1 oncogenesis. 
Selected target genes from the protein dependent 
and unmodified group were validated by 
quantitative RT-PCR level for two different 
shEWS-FLI1 sequences (Fig. 6D, shown for 
shEF#2). Even though the exact mechanism of 
EWS-FLI1 gene repression is not fully 
understood, the pattern of target gene modulation 
resembled that of activated target genes. The 
majority of repressed genes were unmodified, 
but also here two subgroups differentially 
modulated repression upon expression of 
stabilized protein levels (Fig. 6C, 6E, list 
supplementary S2). 
Taken together, our results indicate that 
82% of activated, and 93% of repressed target 
genes have unaltered levels and cannot be further 
increased by higher EWS-FLI1 protein levels. 
Only subsets of the target gene signature are 
differentially modulated implying that stability 
of EWS-FLI1 directs these important subgroup 
or primarily modulates other mechanisms. 
 
 
Discussion 
Here, we demonstrated that EWS-FLI1 
is a polyubiquitinated substrate that is primarily 
degraded by the proteasome. The high turnover 
of the fusion protein is controlled by one critical 
lysine residue located in the conserved ETS 
domain. By exchanging the wild type EWS-FLI1 
with its turnover deficient mutant, we could 
show that protein stabilization differentially 
modulates two subsets of target genes whose 
expression could either be enhanced (protein 
dependent) or only partially rescued (turnover 
dependent). However, the majority of target 
genes are in an unmodified state and independent 
of protein stabilization. 
Attachment of ubiquitins to a substrate 
triggers a variety of outcomes including 
degradation and signaling depending on the 
ubiquitin acceptor site and ubiquitin chain 
linkage (32). Here, we identified the fusion 
protein EWS-FLI1 as a substrate of the 
proteasome system in a time and dose dependent 
manner. The previously suggested lysosomal 
degradation route (37) possibly contributes to 
turnover, but appears less relevant compared to 
the proteasomal pathway under steady state 
conditions.  
During the last decades, a variety of different 
technologies have been developed to dissect and 
understand ubiquitin mediated processes (49). 
GPS profiling was initially established to 
identify novel proteasomal or cullin-RING ligase 
substrates (38,50,51). Thus, we applied this 
approach to analyze EWS-FLI1 turnover. 
Displaying the EGFP/DsRed ratio for the fusion 
protein and known standard reporter constructs, 
we confirmed EWS-FLI1 turnover as 
proteasome dependent and mapped the half life 
to be between 1h-4h. As most potent 
transcription factors, also EWS-FLI1 displays a 
fast turnover (52,53). Using Leptomycin B, we 
could show that EWS-FLI1 is indeed exported 
out of the nucleus for degradation suggesting 
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that the fusion protein tightly keeps balance of 
its cytosolic proteolysis. The apparent exclusive 
nuclear localization might therefore be due to its 
rapid cytosolic degradation. 
However, incubation of cells with the 
translation synthesis inhibitor CHX barely 
reflected the high turnover observed in the GPS 
under steady-state conditions. Using this assay, 
others already suggested EWS-FLI1 as a stable 
protein (37). In contrast, by using antisense 
oligodeoxynucleotides (26) and RNAi 
approaches, it is known that the fusion protein 
can be efficiently downregulated within a short 
24h time frame which would not be possible 
with a highly stable protein. The discrepancy 
between the GPS/RNAi data and CHX treatment 
therefore remains. However, complete inhibition 
of protein synthesis by CHX also affects other 
components of the ubiquitin system such as E2 
conjugating enzymes or E3 ligases. Possibly, if a 
required E3 ligase is unstable and immediately 
depleted, EWS-FLI1 turnover might be 
prolonged as seen here with classical CHX 
treatment. 
While EWS-FLI1 has been shown to be 
posttranslationally modified (54-56), 
ubiquitination remained unknown. Here, we 
demonstrated that the fusion protein is 
polyubiquitinated with a clear and distinct 
pattern which supports the concept of a constant 
turnover. To better understand how the 
ubiquitinated fusion protein is degraded, we used 
affinity purified EWS-FLI1 for mass 
spectrometry and searched for glycine-glycine 
modifications in the fragmented peptide 
sequence. From two possible ubiquitin acceptor 
sites, only mutation of the K380 clearly 
abolished ubiquitination and posttranslationally 
stabilized the protein. While focusing on EWS-
FLI1 degradation, we do not exclude that this 
critical lysine may also trigger non-proteolytic 
signaling via alternative linked polyubiquitin 
chains. It is also worth to mention here that we 
have analyzed our mass spectrometry data for 
occurrence of glycine-glycine shifts of the 
ubiquitin moieties. We have identified peptide 
shifts mainly for K48-, but also K63-linked 
ubiquitins (data not shown) confirming our 
findings that K48-linked chains are highly 
abundant, but not the exclusive EWS-FLI1 
ubiquitination pattern. Other ubiquitin linked 
chains or mixed chains might also be relevant. 
Further, mutation of this residue may 
also inhibit other modifications such as 
sumoylation. Acetylation of this residue has not 
been detected in contrast to the K298 site (55).  
 
The comparison of EWS-FLI1 with its 
full length proteins revealed that the 
polyubiquitin pattern is similar to FLI1. Indeed, 
mutation of the corresponding lysine residue in 
the ETS domain posttranslationally stabilizes 
both proteins. As the K380/K334 residue is 
highly conserved among most ETS family 
members, it might contribute to proteasomal 
degradation in other ETS proteins and their 
fusion proteins. Most interestingly, EWS-FLI1 
displays a higher turnover compared to its full 
length proteins EWSR1 and FLI1. In contrast, 
the ETS proteins ERG or ETV1 which are fused 
to the TMPRSS2 promoter in prostate cancer 
stabilize the protein and confer a physiological 
advantage to cancer cells (33,34,36). The 
truncated protein versions display increased 
stability due to loss of the N-terminal E3 ligase 
motif. However, EWS-FLI1 is not a truncated 
version of FLI1, instead the N-terminal domain 
is dominated by EWSR1 with a stronger 
transactivation domain. If the turnover and 
subsequent E3 ligase binding of ETS members is 
conserved, EWS-FLI1 might possibly interact 
with E3 ligases via its EWSR1 domain giving 
rise to a new regulatory mechanism. However, 
the basic concept that truncated oncogenic TFs 
are more stable than their wild type counterparts 
(36) might not apply for fusion proteins 
consisting of two unrelated protein domains. 
Whether this is indeed a general paradigm or 
rather specific for EWSR1 related fusion 
proteins needs to be further elucidated.  
We then deciphered the role of EWS-
FLI1 turnover in transcriptional regulation of 
target genes. To investigate the influence of 
stabilized EWS-FLI1 on target gene expression, 
we established an inducible Ewing cell system 
allowing to deplete endogenous EWS-FLI1 
protein while simultaneously expressing the wild 
type fusion protein or a turnover deficient 
mutant. This system largely circumvents 
interference with endogenous fusion protein, 
enabling us to study the dynamic behavior of 
posttranslationally stabilized EWS-FLI1 protein 
on transcriptional regulation. Surprisingly, 
around 85% of both activated and repressed 
target genes are in an unaltered state including 
well characterized target genes such as NR0B1 
or STEAP1 (30,57).  
Even though our EWS-FLI1 wild type 
overexpression constructs are around 2-fold 
above the endogenous EWS-FLI1 levels, it is 
possible that co-factors expressed at endogenous 
levels or interacting proteins are limiting further 
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modulation. The knowledge of the EWS-FLI1 
interactome is continuously expanding (28,29), 
however, it still remains unsolved which co-
factors or interacting proteins are most important 
or influence the fusion protein in a context 
dependent matter. Nevertheless, longer induction 
of wild type or mutated ectopic EWS-FLI1 up to 
96h induced cell death irrespective of the 
construct (data not shown).  
Besides the majority of unmodified 
target genes, two other subgroups display a 
different behavior. 15 activated target genes are 
higher expressed upon stabilized EWS-FLI1 
protein levels. This group includes protein-
coding genes such as IGF1 (41) or LEMD1 and 
RNA-coding genes such as EWSAT1 (48). 
Interestingly, EWSAT1 was also observed to be 
elevated upon higher EWS-FLI1 expression in a 
different experimental setting (48) suggesting 
that our approach reflects a global pattern. 
Further, 29 activated target genes are less 
expressed upon stabilized EWS-FLI1. None of 
these turnover sensitive target genes have yet 
been characterized even though few interesting 
candidates as ALK or TP63 appeared.  
Most interestingly, the activity of TFs 
can be influenced by their own turnover as 
shown for estrogen receptor α or c-MYC 
(58,59). It was recently shown that the 
proteasomal turnover of c-myc is required for 
full activity. Lysine mutated c-MYC failed to 
induce tumorigenesis as inhibitory complexes 
could not be removed during target gene 
activation (58) while other TFs are independent 
of ongoing degradation for their transcriptional 
activity (60). Surprisingly, EWS-FLI1 induced 
distinct behavior in three subgroups of target 
genes. Speculatively, the two small subgroups of 
EWS-FLI1 protein sensitive and turnover 
sensitive target genes might be of greater 
importance and their dynamics might trigger 
different response pathways in Ewing sarcoma 
oncogenicity. Even though it is not yet clear how 
these subgroups are defined at their regulatory 
regions, possible driver target genes might be 
found in these two subgroups. Alternatively, 
since we see most target gene levels unaltered, 
oncogenic properties might depend also on 
additional mechanisms such as interacting 
proteins and/or influence on the splicing 
machinery. 
 
Taken together, turnover regulation of 
the major oncogenic driver EWS-FLI1 
represents an important regulatory mechanism in 
Ewing sarcoma pathogenesis. Interference with 
fusion protein degradation might not only be a 
novel therapeutic strategy in Ewing sarcoma 
treatment, but might also be applicable to other 
ETS based fusion proteins.  
 
 
Experimental procedure 
Cell lines and reagents- HEK293T cells 
were cultured in DMEM (Sigma Aldrich, Buchs, 
Switzerland) supplemented with 10% FBS 
(Sigma Aldrich), 2mmol/L glutamine 
(BioConcept, Allschwil, Switzerland) and 
100U/ml penicillin/streptomycin (ThermoFisher 
Scientific AG, Reinach, Switzerland) at 37°C in 
5% CO2. Ewing sarcoma cell lines A673, 
SKNMC and TC71 were cultured in RPMI as 
described above. Additionally, dishes were pre-
coated with 0.2% gelatine (Sigma Aldrich). All 
cell lines have been tested mycoplasma negative. 
The following reagents were used: Bortezomib 
(Selleckchem, Houston, TX, USA), Chloroquine, 
cycloheximide, DMSO, doxycycline, E64, 
leptomycin B (all Sigma Aldrich), LY294002, 
MG-132 (Millipore, Billerica, MA, USA) and 3-
Methyladenine (ApexBio, Houston, TX, USA). 
 
Plasmids and cloning- The coding 
sequence for human EWS-FLI1, FLI1 and EWS, 
were subcloned into the Not1 site of pCMV-
3xflag vector (Sigma Aldrich). For Global 
Protein Stability, the coding sequences of 
DsRed-IRES-EGFP or d24-EGFP or d4-EGFP 
or d1-EGFP (addgene #41941, #41944, #41943, 
#41942) were cloned into the EcoR1 site of pR-
EF1 (Cellecta Inc., Mountain View, CA, USA). 
All cDNAs (EWS-FLI1, FLI1, EWS and 
mutants) were inserted into the BSTB1 site at the 
3’ end of DsRed-IRES-EGFP. 
3xflag-EWS-FLI1 cDNA was cloned into the 
Spe1-BamH1 sites of pInducer21 ORF (Addgene 
#46948). The pRSIT-U6Tet-shRNA-
PGKTetRep-2A-GFP-2A-puro vector with 
shRNAs against EWS-FLI1 was purchased from 
Cellecta Inc. with the following target 
sequences: shEF#1 5’ 
ATAGAGGTGGGAAGCTTATAA 3’ 
(previously described in (31)) and shEF#2 5’ 
CGTCATGTTCTGGTTTGAGAT 3’ (designed 
against the C-terminal FLI1 part according to 
RefSeq# NM_002017.4). 
Cloning was performed by In-Fusion cloning 
HD (Clontech Laboratories Inc., Mountain 
View, CA, USA) according to manufacturer’s 
protocol. All mutations were introduced using 
site-directed mutagenesis. Detailed information 
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of plasmids, cloning and mutagenesis primers 
can be found in supplementary table ST1. All 
clonings were verified by sequencing. 
 
Transient transfection- For HEK293T 
cells, DMEM complete medium was mixed with 
PolyethylenimineMax (Polyscience, Cham, 
Switzerland) and plasmids for 15min and added 
to the cells for 48h. For Ewing sarcoma cells, 
JetPrime (Polyplus Transfections, Illkirch, 
France) reagent was used according to 
manufacturer’s instruction in antibiotics-free 
RPMI medium.  
 
Viral production and transduction- 
HEK293T cells were transfected with cDNA 
vectors and pMDL, pREV, and pVSV with 
JetPrime according to manufacturer’s instruction 
in antibiotics-free DMEM medium. Medium was 
replaced 24h after transfection and virus was 
harvested after additional 48h. Viral supernatant 
was cleared by centrifugation, filtered and 
concentrated if necessary (Amicon® Ultra 15 
mL, Millipore). Ewing sarcoma cells were 
infected with the viral supernatant supplemented 
with 10µg/ml polybrene (Sigma Aldrich) for 16-
18h. 
 
Global Protein Stability Assay and 
flow cytometry- Lentivirus from HEK293T 
transfected with pR-EF1-DsRed-IRES-
d1/d4/d24/EGFP-cDNA, pMDL, pREV and 
pVSV was used to transduce HEK293T or 
Ewing sarcoma cells as described to about 5-
10% of DsRed positive cells. Cells were 
harvested 72h after transduction, incubated with 
cycloheximide, leptomycin B or MG-132 for 4-
8h as indicated and analyzed by FACS. Cells 
were resuspended in PBS and filtered using a 
40μm cell strainer (BD Becton, Dickinson and 
Company, Franklin Lakes, NJ, USA). FACS 
analysis was performed on a FACS CantoTM II 
Cytometry system (BD) and data were analyzed 
by FlowJo software (Treestar Inc., Ashland, OR, 
USA). At least 50000 cells were recorded for 
each experiment. Cell sorting was done with a 
FACS AriaTM III Cytometry system (BD).  
 
Cell lysis, western blotting and 
antibodies- Cells were harvested and lysed in 
standard lysis buffer (50mM Tris/HCl, 150mM 
NaCl, 50mM NaF, 5mM Na4P2O7, 1mM Na3VO4 
and 10mM ß-glycerolphosphate, 1% TritonX 
with protease inhibitor cocktail, Complete 
Mini® (Sigma Aldrich)). Lysates were sonicated 
and cleared by centrifugation. Proteins were 
separated by 4%-12% or 10% BisTris NuPAGE 
pre-cast gels (ThermoFisher Scientific AG) and 
transferred to nitrocellulose membranes (GE 
Healthcare). Membranes were blocked with 5% 
milk powder in 0.2% PBS-Tween and primary 
antibodies were incubated over night at 4°C 
followed by 2h of HRP-linked secondary 
antibody at room temperature. Proteins were 
detected by chemiluminescence using 
Amersham ECL detection reagent (GE 
Healthcare, Glattbrugg, Switzerland) or 
SuperSignalTM Western blotting reagent 
(ThermoFisher Scientific AG). Quantification of 
blots was performed by using ImageJ (version 
1.46r). The following commercial antibodies 
were used: anti-Actin (dilution 1:1000, Cell 
Signaling), anti-Flag (clone M2, 1:1000, Sigma 
Aldrich), anti-FLI1 (1:1000, MyBiosource LLC, 
San Diego, CA, USA), anti-GAPDH (1:1000, 
Cell Signaling), anti-HA (1:1000, Millipore), 
anti-LAMP1 (1:500, DSHB, Iowa City, Iowa, 
USA), anti-p27 (1:1000, Cell Signaling and 
1:200 ThermoFisher Scientific AG) and anti-
Tubulin (1:40000 Sigma Aldrich).  
 
Immunoprecipitation of ubiquitinated 
proteins- Cells were transfected for 48h and 
treated with 10µM MG-132 prior to lysis in 
ubiquitin lysis buffer (2% SDS, 150mM NaCl, 
10mM Tris/HCl, 2mM Na3VO4, 50mM NaF 
with Complete Mini Protease inhibitor cocktail), 
boiled for 10min and sonicated. Lysates were 
diluted 1:10 in dilution buffer (150mM NaCl, 
10mM Tris/HCl, 2mM EDTA, 1% Triton X), 
incubated for 30min at 4°C and cleared by 
centrifugation for 30min at maximum speed. 
Immunoprecipitation was performed using anti-
Flag antibody (Sigma Aldrich) coupled to 
Dynabeads ProteinG (ThermoFisher Scientific 
AG). Lysates were incubated for 1h at 4°C, 
washed three times, eluted at room temperature 
using 3xflag peptide (Sigma Aldrich) and 
prepared for western blot analysis. Extended 
description for detection of EWS-FLI1 
ubiquitination sites by mass spectrometry can be 
found in supplementary S1. 
 
Immunofluorescence and microscopy- 
A673 cells were seeded on cover slides for 24h 
and transiently transfected with flag tagged 
plasmids for additional 48h. After fixing with 
4% PFA (Carl Roth, Arlesheim, Switzerland), 
cells were permeabilized and stained with anti-
Flag antibody (1:300, Sigma Aldrich) in 4% 
horse serum (Sigma Aldrich) and 0.1% PBS-
TritonX over night. Fluorescent secondary 
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antibody (Alexa-488 anti-mouse, Sigma Aldrich) 
in PBS with 4% horse serum was applied for 1h. 
Cover slides were fixed on objective glass with 
DAPI Vectashield® mounting medium (Vector 
laboratories Inc., Burlingame, CA, USA) and 
analyzed by an Axioskop 2 MOT Plus (Carl 
Zeiss Microscopy LLC, Thornwood, NY, USA). 
 
Quantitative PCR and microarray 
analysis- Total RNA was extracted from Ewing 
sarcoma cells using Qiagen RNeasy Kit (Qiagen 
Instruments AG, Hombrechtikon, Switzerland). 
cDNA synthesis was carried out using High-
Capacity Reverse Transcription Kit (Applied 
Biosystems by ThermoFisher Scientific AG). 
Quantitative PCR was performed using TaqMan 
gene expression master mix (ThermoFisher 
Scientific AG) and assays on demand (Applied 
Biosystems by ThermoFisher Scientific AG). A 
complete list can be found in supplementary 
table ST1. Replicate values were pooled and 
represented as geometric mean values with a 
95% confidence interval. Microarray expression 
analysis with total RNA was performed using 
GeneChip® Human Gene 2.0 ST Array (Atlas 
Biolabs, Berlin, Germany). Data are accessible 
under GSE81018.  
 
Microarray data analysis- The raw 
microarray data were processed and normalized 
using the RMA algorithm (61). Differential 
expression was computed using the 
Bioconductor package limma providing a 
moderated t-test that is adapted to low number of 
replicates (62). Differential expression results 
were filtered based on fold-change and p-values. 
All computations were done using 
R/Bioconductor. Extended description for target 
gene grouping can be found in supplementary 
S2. 
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Figure Legends 
Figure 1: EWS-FLI1 protein turnover is proteasome dependent. (A) Western blot analysis 
of EWS-FLI1 protein levels. A673 cells were treated with 20µM of indicated compounds for 8h, 
EWS-FLI1 protein levels were detected with anti-FLI1 antibody. Quantification represents ratio of 
FLI1 over GAPDH compared to DMSO control. (B) EWS-FLI1 turnover in various Ewing sarcoma 
cell lines. A673, SKNMC and TC71 cells were treated with 20µM MG-132 or chloroquine (CQ) for 
10h (A673), 8h (SKNMC) and 9h (TC71), and immunoblotted with anti-FLI1 antibody. Quantification 
represents ratio of FLI1 over tubulin compared to DMSO control. (C) EWS-FLI1 stabilizes in a time-
dependent manner. Western blot of A673 cells treated with 10µM MG-132 for indicated time points. 
Three independent experiments were quantified and are represented in the scatter blot with n=3 (2h-
8h) or n=5 (DMSO), error bars as SD. (D) Half-life of endogenous EWS-FLI1 protein. Western blot of 
A673 cells treated with 20µg/ml CHX for indicated hours. Quantification of three independent 
experiments with n=3 (2h-8h) or n=5 (DMSO), error bars as SD. (E) EWS-FLI1 is ubiquitinated. 
3xflag-EWS-FLI1 and HA-ubiquitin were co-expressed for 48h in HEK293T cells and incubated with 
10µM MG-132 for indicated hours. After immunoprecipitation of EWS-FLI1 with anti-Flag, 
ubiquitination was visualized by anti-HA antibody. (F) EWS-FLI1 ubiquitination consists of K48-
linked ubiquitin chains. 3xflag-EWS-FLI1 and wild-type or mutant HA-ubiquitins were co-expressed 
for 48h in HEK293T cells, immunoprecipitated and ubiquitination was visualized by anti-HA 
antibody. 
 
 
Figure 2: The EWS-FLI1 protein displays a high turnover. (A) Scheme illustrating GPS 
approach in which a reporter construct of DsRed-IRES-EGFP is fused at the C-terminus of EGFP to a 
protein of interest. The EGFP/DsRed ratio is determined by FACS and represents a measure for 
protein stability. (B) EWS-FLI1 turnover measured by GPS. HEK293T were transduced for 72h with a 
reporter construct fused to EWS-FLI1 or degron (d) motifs with half lives of 1h (d1h), 4h (d4h) and 
24h (d24h) and analyzed by FACS. The reporter construct fused to EWS-FLI1 was additionally 
incubated with 20µM MG-132 or 20µg/ml CHX for 8h or (C) with 50nM Leptomycin B (LMB) for 4h 
and 8h (dotted line). (D) EWS-FLI1 stability in Ewing cell line A673. GPS analysis of reporter 
constructs fused to EWS-FLI1 or standard degron motifs 72h after transduction. (E) A673 cells stably 
transfected with reporter-EWS-FLI1 construct were sorted and incubated with DMSO, 20µM MG-132 
or 20µg/ml CHX for 8h. 
 
 
Figure 3: Mass spectrometry identifies K380 residue as the main ubiquitination site. (A) 
Two lysine residues were identified to be ubiquitinated by mass spectrometry. Peptide spectra with 
glycine-glycine shift for residue K380 (peptide spectra for the K298 site in supplementary S1A). (B) 
Mutation of lysine residue K380 prevents EWS-FLI1 ubiquitination. 3xflag-EWS-FLI1, K298R and 
K380R mutants were co-expressed with HA-ubiquitin for 48h in A673 cells, purified ubiquitinated 
EWS-FLI1 was analyzed using anti-HA antibody by western blotting. (C) Mutated K380 residue 
stabilizes EWS-FLI1 protein. 3xflag-EWS-FLI1, single and double mutants were transiently 
overexpressed for 48h in A673 and SKNMC cells and analyzed with an anti-Flag antibody by western 
blot. (D) Scatter blot for quantification for n=3 independent experiments, error bars as SD. (E) EWS-
FLI1 mutant show nuclear localization. 3xflag-EWS-FLI1 and K380R single mutant were transiently 
expressed for 48h in A673 cells. Cells were fixed, stained with anti-Flag antibody and used for 
immunofluorescence (40x magnification). (F) Mutation of K380 stabilizes EWS-FLI1 
posttranslationally. HEK293T cells were transduced for 72h with reporter constructs of EWS-FLI1, 
mutants K298R and K380R and standards. EGFP/DsRed ratios were analyzed by FACS, (G) after 
additional incubation with DMSO or 20µM MG-132 for 8h. 
 
 
Figure 4: Regulation of proteasomal turnover is conserved between EWS-FLI1 and 
FLI1. (A) EWS-FLI1 displays fastest turnover. GPS analysis of EWS-FLI1, EWSR1 and FLI1 
reporter constructs and standards transduced into HEK293T cells and analyzed after 72h by FACS. 
(B) Full length proteins EWSR1 and FLI1 were additionally treated with 20µM MG-132 or 20µg/ml 
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CHX for 8h. (C) Immunoprecipitation of EWS-FLI1, EWSR1 and FLI1 proteins. 3xflag tagged 
versions were co-expressed with HA-ubiquitin for 48h and stabilized for additional 5h with 20µM 
MG-132. After immunoprecipitation of tag proteins, ubiquitin pattern was analyzed by anti-HA 
antibody. (D) Mutation of conserved residue K334R stabilizes FLI1 in GPS analysis. HEK293T cells 
were transduced for 72h with reporter constructs of FLI1, mutants K172R, K252R, K334R and 
standards. EGFP/DsRed ratio was analyzed by FACS. (E) Turnover dependent lysine residue is 
conserved within most ETS family members. ClustalW alignment of conserved ETS domain sequence, 
K334/K380 residue is marked in red.  
 
 
Figure 5: Generation of exchange Ewing cell lines. (A) EGFP (selection marker) sorting of 
pInducer21 vector transduced cells. A673 cells with 3xflag, 3xflag-EWS-FLI1 or 3xflag-K380R 
mutant were sorted for same low EGFP expression. After sorting, all cell pools were analyzed by 
FACS for EGFP and plotted for corresponding mean fluorescent intensity (MFI). (B) ShEF sequences 
shRNA against the 3’ UTR of EWS-FLI1 are sufficient to downregulate EWS-FLI1 protein. Western 
blot of A673 cells with shEF constructs #1 and #2 after incubation with 0.1ng/µl doxycycline for 48h. 
(C) Inducible EWS-FLI1 exchange cell lines. Double transduced A673 cells were incubated with 
0.1ng/µl doxycycline for 48h. Endogenous and exogenous EWS-FLI1 protein levels were analyzed by 
western blotting using anti-FLI1 antibody, (D) and mRNA levels were analyzed by quantitative RT-
PCR, with n=4 and error bars represent 95% confidence intervals. 
 
 
Figure 6: Differential regulation of target gene expression by EWS-FLI1 protein levels. 
(A) Analysis of microarray expression data of A673 exchange cell lines reveals three subgroups of 
target gene regulation. Pie chart distribution for EWS-FLI1 activated (upper) and repressed (lower) 
target genes and their differential modulation of stabilized over wild type EWS-FLI1. (B-C) Heat map 
of activated-rescued (B) and repressed-rescued (C) target gene signature. The comparison of stabilized 
over wild type EWS-FLI1 target genes resembled in three distinct groups. (D-E) Validation of selected 
activated (D) or repressed (E) target genes by quantitative RT-PCR based on RNA extracted from 
shEF#2 exchange cell lines, with n=4 and error bars represent 95% confidence intervals.  
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Mass spectrometry (MS) – extended description for sample preparation and analysis 
 
Purification and sample preparation for MS. 
Proteins were purified from HEK293T cells under denaturing conditions and separated by gel electrophoresis as 
described. The gel was stained with coomassie (Instant blue, Expedeon, Harston, UK) for 20min followed by 
washing with water for each 30min twice. Bands corresponding to the molecular weight of ubiquitinated EWS-
FLI1 were excised from the gel and dried by speed vacuum for 10min. Digestion was performed with 50ng 
Trypsin (Promega, V511C) overnight at 37°C and stopped by addition of 0.2µl formic acid (FA). Peptides were 
extracted from the gel by adding twice 50% acetonitrile (ACN)- 5% trifluoroacetic acid (TFA). 
After drying by speed vacuum for 1h, peptides were cleaned with ZIP-TIP C18 tips (ThermoFisher Scientific 
AG) by resuspending in 3% ACN- 0.1% TFA and eluted with 60% ACN- 0.1% TFA twice. Final resuspension 
was in 3% ACN- 0.2% FA with 10mM citric acid before injection into an LTQ-OrbitrapVelos mass 
spectrometer (ThermoFisher Scientific AG) coupled to an EksigentNanoLC-Ultra 1D plus (Eksigent 
Technologies, Dublin, CA, USA). Solvent composition at the two channels was 0.1% FA for channel A and 
0.1% FA, 99.9% ACN for channel B. Peptides were loaded on a self-made frit column (75μm × 150mm) packed 
with reverse phase C18 material (ReproSil-Pur 120 C18-AQ, 1.9µm, Dr. Maisch GmbH, Ammerbuch, Germany) 
and eluted at a flow rate of 250nl per min by a gradient from 3 to 30% of B in 56min. Full-scan MS spectra 
(300−1700 m/z) were acquired in profile mode at a resolution of 30’000 at 400 m/z, an accumulation gain 
control (AGC) of 1x106 and a maximum injection time of 200ms. Collision induced dissociation (CID) MS/MS 
spectra were recorded in data dependent manner in the ion trap from the twenty most intense signals above a 
threshold of 1000, using a normalized collision energy of 35% and an activation time of 10ms. The AGC value 
for MS/MS analysis was set to 1x104 (ion trap detection, 100ms injection time) and the isolation width was set to 
2amu. Charge state screening was enabled and singly charge states were rejected. Precursor masses already 
selected for MS/MS were excluded for further selection for 45s and the exclusion window was set to 10ppm. The 
size of the exclusion list was set to a maximum of 500 entries. The samples were acquired using internal lock 
mass calibration on m/z 429.088735 and 445.120025. 
 
Data analysis.  
The raw-files from the mass spectrometer were converted into Mascot generic files (mgf) with Mascot Distiller 
software 2.4.3.3 (Matrix Science Ltd.,London, UK). The peak lists were searched using Mascot Server 2.3.02 
against the forward UniProtKB/Swiss-Prot database for human, concatenated to a reversed decoyed FASTA 
database consisting of a total of 135,183 proteins with accessions in Gene Ontology compatible format and 260 
common protein contaminants (NCBI taxonomy ID 9606, release date 2012-04-12). The protein sequence of 
EWS-FLI1 (B1PRL2_HUMAN) was included in the database. 
The parameters for precursor tolerance and fragment ion tolerance were set to ± 5ppm and ± 0.8Da, respectively. 
Gly-Gly and oxidation (M) were set as variable modifications. Enzyme specificity was set to trypsin, allowing 
up to 1 missed cleavage. Peptides having an expectation value higher of 0.05 and/or a Mascot score lower of 20 
were excluded. Only peptides with internal lysine modified by glycine-glycine were considered. For the 
localization of glycine-glycine modification, the results of Mascot Site Analysis were used. All the spectra of 
ubiquitinated peptides were manually validated. 
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Abstract  
Ewing sarcoma is the second most common bone tumor in children and adolescents and is 
characterized by a chromosomal translocation leading to expression of the unique oncogenic fusion 
protein EWS-FLI1. Although the fusion protein represents an attractive target for treatment, only little 
is known about enzymes regulating EWS-FLI1 stability and turnover. In this study, we found that 
EWS/FLI1 ubiquitination and stability is regulated by its PPxY motif, which is a known recognition and 
binding motif for NEDD4 family E3 ligases. Mutation of this motif decreased ubiquitination and hence 
increased stability of the fusion protein. Furthermore, a functional screen of NEDD4 family members 
identified WWP1 to negatively regulate EWS/FLI1 stability by direct binding to the PPxY motif of the 
fusion protein. Physiologically, WWP1 overexpression reduced Ewing sarcoma cell growth and colony 
formation, thereby suggesting that this E3 ligase has a tumor suppressive function in Ewing sarcoma 
cells. Taken together, these results lead to a better understanding of the molecular biology underlying 
Ewing sarcoma and offers novel treatment options by modulating the turnover of the oncogenic fusion 
protein EWS-FLI1. 
 
 
Keywords 
WWP1, EWS-FLI1, protein turnover, 
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Introduction 
Ewing sarcoma is a rare and aggressive cancer of bone and soft tissues, which mostly presents in the 
second decade of life (1). 20-30% of patients already exhibit metastasis at diagnosis, which reduces 
10-year survival from about 70% in patients with non-metastatic disease to less than 30% (2). 
Therefore, novel therapeutic strategies improving overall survival are urgently needed.  
At the molecular level, 85% of all Ewing sarcoma tumors are characterized by the chromosomal 
translocation t(11;22)(q24;q12) which fuses the 5' end of the EWSR1 gene with the 3' end of the FLI1 
gene (3,4). This leads to expression of the diagnostically characteristic oncogenic fusion protein EWS-
FLI1, which acts as an aberrant transcription factor by activating and repressing various target genes 
(5,6). Importantly, EWS-FLI1 is the main driver of oncogenesis in Ewing sarcoma and essential for 
tumor cell survival (7,8). Even though EWS-FLI1 is a potential target for treatment, direct 
pharmacologic interference with transcription factor activity remains therapeutically challenging. Thus, 
alternative strategies to indirectly interfere with the expression and stability of the fusion protein need 
to be developed.  
The turnover of most proteins is controlled by the ubiquitin-proteasome system (UPS) which involves 
the covalent attachment of ubiquitin chains to substrate proteins for subsequent proteasomal 
degradation. Substrate specificity of ubiquitination is mainly determined by E3 ligases, which transfer 
ubiquitin to substrate proteins in the last step of the ubiquitination cascade. Targeting the UPS, 
especially the highly specific E3 ligases, has become an emerging field for anti-cancer therapy over 
the past years (9,10). As example, targeting fusion proteins such as BCR/ABL and PML/RARA for 
degradation has been shown to be a promising therapeutic approach in leukemia (11,12). We could 
recently demonstrate that the turnover of EWS-FLI1 is controlled by ubiquitination at its lysine residue 
K380 leading to proteasomal degradation of the fusion protein (Gierisch et al. 2016a submitted). 
Furthermore, reduction of EWS-FLI1 protein levels by inhibition of its deubiquitinating enzyme USP19 
resulted in cell growth inhibition in vitro and in vivo (Gierisch et al. 2016b submitted). However, it is not 
yet known which E3 ligase is involved in regulating turnover and stability of the fusion protein.  
The WW domain containing E3 ubiquitin protein ligase 1 (WWP1) belongs to the NEDD4 family of E3 
ligases within the homologous to E6 carboxy-terminus (HECT) E3 ligases main class (13,14). 
Members of the NEDD4 family are characterized by a C-terminal HECT domain and an N-terminal 
substrate recognition domain (15). WW domains within the substrate recognition domain are known to 
recognize and bind proline-rich sequences such as PPxY motifs of substrate proteins (16,17). WWP1 
is involved in essential cellular processes and ubiquitinates various substrate proteins including the 
TGF-β type 1 receptor (18), SMAD4 (19), TRAF6 (20), HER4 (21) as well as p53 (22) and p63 (23). 
WWP1 has been shown to be overexpressed in various cancers such as prostate and breast cancer 
(24-26) and plays an oncogenic role in osteosarcoma (27). However, whether WWP1 is involved in 
Ewing sarcoma pathogenesis by regulating EWS-FLI1 turnover has not yet been explored. 
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In this study we found that ubiquitination and stability of EWS-FLI1 is regulated by its PPxY motif 
located in the EWS domain. Furthermore, we observed that the E3 ligase WWP1 negatively regulates 
EWS-FLI1 protein levels and has a tumor suppressive function in Ewing sarcoma cells. 
 
 
 
Materials and Methods 
Cell lines 
A673, SKNMC and HEK293T cells were obtained from the American Type Culture Collection ATCC 
(Manassas, USA). A673 and SKNMC cells were cultured in RPMI medium (Sigma-Aldrich, Buchs, 
Switzerland), HEK293T cells were cultured in DMEM medium (Sigma-Aldrich, Buchs, Switzerland) 
supplemented with 10% FBS (Sigma-Aldrich, Buchs, Switzerland), 1% (2mM) L-glutamine (Bioconcept 
AG, Allschwil, Switzerland) and 1% (100U/ml) penicillin/streptomycin (Thermo Fisher Scientific AG, 
Reinach, Switzerland) at 37°C and 5% CO2.  
 
Transfection and transduction 
A673 and HEK293T cells were transiently transfected using jetPRIME transfection (Polyplus 
transfection, Illkirch, France) according to the manufacturer's instructions. For co-immunoprecipitation 
and ubiquitination assays, HEK293T cells were transfected with PolyethylenimineMax (Polyscience, 
Cham, Switzerland). For virus production, HEK293T cells were transfected with the plasmid of 
interest, together with pVSV, pMDL and pREV plasmids and viral particles were collected 72h after 
transfection. Cells were transduced overnight with viral particles supplemented with 10µg/ml of 
polybrene (Sigma-Aldrich, Buchs, Switzerland). 
 
Plasmids 
pCMV-3xFlag-EWS-FLI1, pCDNA3-HA-ubiquitin and pCDNA3-HA-EWS-FLI1 plasmids were 
generated as described before (Gierisch et al 2016a submitted). Plasmids expressing HA- or 3xFlag-
EWS-FLI1 PPxY mutated and 3xFlag-WWP1-C890A were generated by site-directed mutagenesis 
using AccuPrime polymerase and Dpn1 (both Thermo Fisher Scientific AG, Reinach, Switzerland) 
digest of parental DNA template. 3xFlag-tagged E3 ligases from the NEDD4 family were generated by 
PCR of cDNA clones (see Supplementary Table S1) purchased from Dharmacon (Thermo Fisher 
Scientific Biosciences GmbH, St. Leon-Rot, Germany) and subcloning into pCMV-3xFlag vector. 
DsRed-IRES-EGFP construct was amplified from retroviral vector (Addgene, No. 41941) and 
subcloned into pR-EF1 lentiviral vector (Cellecta Inc., Mountain View, CA, USA). For functional 
assays, 3xFlag-WWP1 was cloned into pBABE retroviral vector (Addgene, No. 33336). 3xMyc-WWP1 
was generated by subcloning of WWP1 into pCDNA3-3xMyc vector. All subcloning was performed by 
In-Fusion Cloning technology (Clontech Laboratories Inc., Mountain View, CA, USA). See 
Supplementary Table S2 for all primers used for cloning and site-directed mutagenesis.  
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Cell harvesting and western blotting 
Cells were harvested and proteins of cell lysates were separated by 4-12% NuPAGE® Bis-Tris Gels 
(Thermo Fisher Scientific AG, Reinach, Switzerland) and transferred to nitrocellulose membranes (GE 
Healthcare, Glattbrugg, Switzerland) which were blocked in 5% milk and incubated with the primary 
antibody overnight. After washing with 1xTBS/ 0.1% Tween, HPR-linked secondary antibody was 
added and proteins were analyzed with ECL detection reagent (GE Healthcare, Glattbrugg, 
Switzerland). 
 
Co-immunoprecipitation and ubiquitination assay 
For co-immunoprecipitation, HEK293T cells were lysed 48h after transfection and incubated for 
30min-1h at 4°C with anti-flag antibody (Sigma-Aldrich, Buchs, Switzerland) coupled Dynabeads 
Protein G (Thermo Fisher Scientific AG, Reinach, Switzerland). Thereafter, beads were washed and 
proteins were eluted with 3xFlag-Peptide (Sigma-Aldrich, Buchs, Switzerland) diluted 1:24 in 50mM 
Tris/ 150mM NaCl. Proteins were analyzed by Western blotting. For ubiquitination assay, HEK293T 
cells were lysed 48h after transfection with SDS containing lysis buffer, boiled and sonicated. Samples 
were diluted ten times in a dilution buffer and incubated for 30 min at 4°C. Immunoprecipitation was 
performed using anti-flag antibody as described above.  
 
Stability analysis by FACS 
Stability analysis was performed as described before (28). HEK293T and A673 cells were transduced 
with lentiviral particles containing the reporter construct DsRed-IRES-EGFP-EWS/FLI1 wt or PPxY 
mutated at a low multiplicity of infection in order to obtain ~5% (HEK293T) and ~10% (A673) double-
positive cells. 72h after transduction, cells were harvested and prepared for FACS analysis in PBS 
suspension, and fluorescence was measured by in a FACSCantoTM II (BD Becton, Dickinson and 
Company, Franklin Lakes, NJ, USA). Data were further analyzed using FlowJo software (Tree Star 
Inc., Ashland, OR, USA). 
 
Fluorescence immunohistology and microscopy 
A673 cells were grown on round cover slides, transfected with 3xFlag-EWS/FLI1 wt or PPxY mutated 
and prepared for microscopy 48h after transfection. Cells were fixed with 4% PFA, permeabilized with 
PBS/0.1% Triton X and incubated overnight with anti-Flag antibody diluted in horse serum followed by 
incubation with anti-mouse antibody labeled with Alexa-488 (Sigma-Aldrich, Buchs, Switzerland). Cells 
were washed and fixed with mounting media containing DAPI (Vector laboratories Inc., Burlingame, 
CA, USA). Immunofluorescence was analyzed by an Axioskop 2 MOT Plus microscope (Carl Zeiss 
Microscopy LLC, Thornwood, NY, USA).  
 
Functional assays 
SKNMC cells stably expressing 3xFlag-WWP1 or the control construct were generated by infection 
with retroviral particles and sorting for EGFP positive cells using a FACSAriaTM III (BD Becton, 
Dickinson and Company, Franklin Lakes, NJ, USA). To determine cell number over time, cells were 
plated in a 6-well plate and counted after four and eight days. 3xFlag-WWP1 overexpression was 
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confirmed by western blot analysis. For colony formation assays, 100 to 200 cells were plated in a 6-
well plate. 14 days after plating, cells were fixed with 4% PFA, stained with crystal violet and colonies 
were counted. 
 
Antibodies  
The following antibodies were used: FLAG (clone M2; Sigma-Aldrich, Buchs, Switzerland), HA (clone 
6E2; Cell Signalling Technology, Berverly, MA, USA; and clone 05-904; Millipore, Billerica, MA, USA), 
Fli1 (MBS 300723; MyBioSource LLC, San Diego, CA, USA), Myc (clone 9B11; Cell Signalling 
Technology, Berverly, MA, USA), WWP1 (H00011059-M01; Abnova, Taipei City, Taiwan), tubulin 
(clone DM 1A; Sigma-Aldrich, Buchs, Switzerland). All antibodies are used in a dilution 1:1000. 
 
qRT-PCR 
Cells were lysed in RLT lysis buffer and total RNA was extracted using RNeasy Mini kit (Qiagen 
Instruments AG, Hombrechtikon, Switzerland). cDNA was synthesized using High-Capacity cDNA 
Reverse Transcription kit (Thermo Fisher Scientific AG, Reinach, Switzerland). qRT-PCR was 
performed for WWP1 and GAPDH (Hs00366931_g1, Hs04420697_g1, Applied Biosystems by 
Thermo Fisher Scientific AG, Reinach, Switzerland) using TaqMan gene expression master mix 
(Thermo Fisher Scientific AG, Reinach, Switzerland) on a 7900HT Fast Real-Time PCR System 
(Thermo Fisher Scientific AG, Reinach, Switzerland). Data was analyzed using SDS software (Thermo 
Fisher Scientific AG, Reinach, Switzerland) and the ΔΔCt method and Ct values were normalized to 
GAPDH. 
 
 
 
Results 
EWS-FLI1 ubiquitination and stability is regulated by its PPxY motif 
E3 ubiquitin ligases from the NEDD4 family are known to interact with PPxY motifs of substrate 
proteins (16,29). Since EWS-FLI1 contains a PPxY motif in the EWS domain of the fusion protein, we 
used site-directed mutagenesis to investigate whether this motif might play a role in EWS-FLI1 
turnover (Fig. 1A). To examine first whether the mutation affects EWS-FLI1 cellular localization, we 
used fluorescence immunohistology of wild type (wt) or PPxY motif mutated 3xFlag-EWS-FLI1 in A673 
Ewing sarcoma cells. We observed that the nuclear localization of the fusion protein was not altered 
upon PPxY mutation (Fig. 1B).  
We could recently show that EWS-FLI1 is a substrate of the ubiquitin-proteasome system and its 
turnover is controlled by polyubiquitination (Gierisch et al. 2016a submitted). Since we hypothesize 
here that mutation of the PPxY motif influences EWS-FLI1 ubiquitination and stability, we next directly 
investigated EWS-FLI1 polyubiquitination. We observed clearly reduced ubiquitination of the fusion 
protein in A673 Ewing sarcoma cells upon PPxY mutation (Fig. 1C). Hence, EWS-FLI1 ubiquitination 
seems to be regulated at least in part by its PPxY motif, which might be the binding site for NEDD4 
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family E3 ligases. To assess whether decreased EWS-FLI1 ubiquitination also leads to increased 
stability of the fusion protein, we next used a FACS-based approach which has been used previously 
to investigate global protein stability (GPS) (28). GPS analysis is based on a reporter construct 
containing DsRed, an internal ribosome entry site (IRES) and EGFP fused to EWS-FLI1, which leads 
to the expression of the two florescent proteins DsRed and EGFP from the same mRNA transcript. 
Thus, DsRed serves as an internal control, whereby the EGFP/DsRed ratio measures EWS-FLI1 
stability. We generated HEK293T and A673 cell lines stably expressing DsRed-IRES-EGFP fused to 
either EWS-FLI1 wt or EWS-FLI1 PPxY mutated and analyzed fluorescence by FACS. Mutation of the 
PPxY motif led to increased EGFP/DsRed ratios compared to the wt protein in both cell lines, thereby 
indicating stabilization of the fusion protein (Fig. 1D). These results suggest that the PPxY motif of 
EWS/FLI1 plays an essential role in the regulation of EWS-FLI1 ubiquitination and stability, which 
likely involves the binding of E3 ubiquitin ligases from the NEDD4 family to the PPxY motif of the 
fusion protein.  
 
E3 ligases from the NEDD4 family regulate EWS-FLI1 protein levels 
To investigate which members of the NEDD4 family are involved in EWS-FLI1 degradation, we 
performed gain-of-function experiments. To this end, we cloned all NEDD4 family members (except 
HECW1) with a 3xflag tag and transiently overexpressed HA-EWS-FLI1 together with two different 
concentrations of flag-tagged E3 ligases in HEK293T cells. EWS-FLI1 protein levels were analyzed by 
western blotting after 48h. We observed both stabilization as well as destabilization of the fusion 
protein upon E3 ligase overexpression. NEDD4L, WWP2, HECW2 and ITCH all increased EWS-FLI1 
protein levels, whereas NEDD4, SMURF1, SMURF2 and WWP1 clearly reduced EWS-FLI1 protein 
levels (Fig. 2A). Importantly, overexpression of both NEDD4 and WWP1 reduced EWS-FLI1 protein 
levels by almost 50% (Fig. 2B). These findings indicate that NEDD4, SMURF1, SMURF2 and WWP1 
are candidate E3 ligases that might be involved in the degradation of the fusion protein EWS-FLI1. 
 
WWP1 negatively regulates endogenous EWS-FLI1 protein levels in Ewing sarcoma cells 
Since cellular context plays an important role in EWS-FLI1 biology, we further examined the effect of 
the candidate E3 ligases NEDD4, SMURF1, SMURF2 and WWP1 on endogenous EWS-FLI1 protein 
levels in Ewing sarcoma cells. Thus, A673 cells were transiently transfected with two concentrations of 
the four candidates and endogenous EWS-FLI1 protein levels were analyzed by western blotting. We 
found that WWP1 was the only E3 ligase which significantly reduced endogenous EWS-FLI1 protein 
levels, whereas the other candidates had inconsistent effects (Fig. 3A). Overexpression of WWP1 
reduced EWS-FLI1 protein levels by 30-40% (Fig. 3B). Taken together, the E3 ligase WWP1 from the 
NEDD4 family seems to play an important role in the degradation of the fusion protein EWS-FLI1. 
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WWP1 regulates EWS-FLI1 protein levels by interaction via the PPxY motif of the fusion protein 
The HECT domain of NEDD4 family E3 ligases is highly conserved and contains the active site 
cysteine, which is essential to accept and transfer ubiquitin (13). In order to investigate the activity of 
the E3 ligase WWP1 for EWS-FLI1 degradation, we co-expressed HA-EWS-FLI1 together with wt 
WWP1 or the catalytic inactive WWP1 C890A mutant in HEK293T cells and analyzed EWS-FLI1 
protein levels by western blotting. We found that exogenous EWS-FLI1 protein levels were reduced by 
almost 50% upon overexpression of wt WWP1, whereas this effect was clearly diminished when 
overexpressing the catalytic inactive WWP1 C890A mutant (Fig. 4A). However, EWS-FLI1 
degradation was not completely blocked by the mutant, which might be due to remaining WWP1 
activity or an indirect effect of WWP1 on EWS-FLI1 protein levels. Since we found that the PPxY motif 
plays an essential role in EWS-FLI1 stability, we examined whether the PPxY motif is important for 
WWP1-mediated degradation. Thus, we co-expressed HA-EWS-FLI1 PPxY mutated together with 
3xFlag-WWP1 wt in HEK293T cells and analyzed protein levels by western blotting. Overexpression 
of WWP1 led to a diminished reduction of PPxY mutated EWS-FLI1 protein levels compared to wt, 
even though degradation could not be completely prevented (Fig. 4B). Since these findings suggest 
alternative binding sites for WWP1 within the fusion protein, we directly investigated interaction of 
WWP1 with the PPxY motif of EWS-FLI1 by co-immunoprecipitation experiments. To this end, 
HEK293T cells were transiently transfected with 3xFlag-EWS-FLI1 or control together with 3xMyc-
WWP1 and cell lysates were immunoprecipitated using anti-flag antibody. Western blot analysis 
revealed specific interaction of WWP1 with EWS-FLI1 since WWP1 did not interact with the control 
vector (Fig. 4C). Importantly, this interaction was clearly reduced when mutating the PPxY motif of the 
fusion protein, thereby indicating that WWP1 indeed binds to the PPxY motif of EWS-FLI1. However, 
interaction of WWP1 with PPxY mutated EWS-FLI1 was not completely abolished suggesting that 
alternative binding sites within the fusion protein might be present. Furthermore, this residual binding 
might be sufficient to induce low level EWS-FLI1 degradation as observed before. In summary, these 
data suggest that WWP1 is a negative regulator of EWS-FLI1 protein levels by binding to the PPxY 
motif as well as to other binding sites in the fusion protein. 
 
WWP1 has a tumor suppressive function in Ewing sarcoma cells 
To further explore the physiological function of WWP1 in Ewing sarcoma, we analyzed its protein 
levels in different Ewing sarcoma cell lines (A673, SKNMC, TC71, SKES, RDES) as well as in a 
peripheral neuroectodermal tumor cell line (SKPNDW), which belongs to the Ewing sarcoma tumor 
family (30). QRT-PCR and western blot analysis revealed that WWP1 mRNA and protein are 
expressed at different levels in the various cell lines (Fig. 5A, B). To analyze the cellular localization of 
WWP1 in Ewing sarcoma cells, we transfected A673 cells with 3xFlag-WWP1. Fluorescence 
immunostaining indicated that WWP1 is localized both in the nucleus as well as in the cytoplasm (Fig. 
5C), thereby suggesting a broad function in Ewing sarcoma cells. 
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Continuous expression of EWS-FLI1 is essential for Ewing sarcoma cell survival and proliferation 
(7,8). Since we found that WWP1 is a negative regulator of EWS-FLI1 expression, we hypothesized 
that WWP1 overexpression also reduces Ewing sarcoma cell growth. To address this hypothesis, we 
generated SKNMC cell lines stably expressing 3xflag-WWP1 or control and used them to investigate 
proliferation as well as anchorage independent cell growth. Overexpression of WWP1 led to reduced 
cell proliferation after four as well as after eight days (Figure 5D). To investigate anchorage 
independent growth, cells were plated at reduced density and number of colonies was determined 
after 14 days. We observed less colonies upon WWP1 overexpression compared to the control cells 
(Fig. 5E). These results suggest that WWP1 might have a tumor suppressive function in Ewing 
sarcoma cells. 
 
 
Discussion 
Here, we identify the first E3 ubiquitin ligase that is involved in EWS-FLI1 turnover and stability. The 
results reveal an important role of the PPxY motif in the regulation of EWS-FLI1 ubiquitination which is 
modulated by the E3 ubiquitin ligase WWP1 and which also shows a tumor suppressive function in 
Ewing sarcoma cells. 
Even though proteomic approaches have been applied earlier to identify substrate proteins for certain 
E3 ubiquitin ligases such as cullin RING ligases (31,32), the identification of E3 ligases regulating the 
degradation of a specific protein of interest remains challenging. Degradation of several ETS family 
members is known to be regulated by the E3 ligase COP1 binding to the N-terminal part of these ETS 
proteins (33,34). Since the fusion protein EWS-FLI1 lacks the N-terminal part of the ETS family 
member FLI1, other binding sites for E3 ligases might be important. Indeed, we identified the PPxY 
motif, which is present in the EWS part of the fusion protein, as a potential recognition site for NEDD4 
family E3 ligases since mutation of the PPxY motif led to reduced ubiquitination and increased stability 
of EWS-FLI1. Our hypothesis that E3 ligases from the NEDD4 family bind to the PPxY motif of EWS-
FLI1 is supported by a study showing that EWS full length protein interacts with WW domains of 
NEDD4 family members (35). It is important to note that the change in ubiquitination might also affect 
signaling pathways other than proteasomal degradation. Furthermore, we observed only slight EWS-
FLI1 stabilization upon PPxY mutation by GPS analysis suggesting alternative binding sites for 
NEDD4 family E3 ligases. This is consistent with earlier reports demonstrating that E3 ligases from the 
NEDD4 family can also bind substrate proteins lacking a PPxY motif (35).  
To identify the specific NEDD4 family E3 ligase which negatively regulates EWS-FLI1 protein levels, 
we overexpressed all family members in HEK293T cells. We found that NEDD4, SMURF1, SMURF2 
as well as WWP1 reduced EWS-FLI1 protein level upon overexpression. Thus, the regulation of EWS-
FLI1 protein levels might involve several E3 ligases presumably also from the same E3 ligase family. 
This notion is supported by our attempts to knockdown WWP1 in Ewing cells, which did not lead to 
EWS-FLI1 stabilization (data not shown), thereby indicating compensatory mechanisms. Similarly, 
involvement of several E3 ligases from the same family in protein turnover has been observed for 
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LATS1, whose degradation is regulated by several NEDD4 family members including NEDD4 (36), 
WWP1 (37) and ITCH (38). Nevertheless, WWP1 was the only candidate having a consistent effect on 
endogenous EWS-FLI1 protein levels in Ewing sarcoma cells, thereby indicating a predominant role of 
WWP1 for EWS-FLI1 degradation.  
Further validation of WWP1 as a regulator of EWS-FLI1 turnover revealed that WWP1 interacts with 
the PPxY motif of the fusion protein. Interaction of WWP1 with PPxY or proline-rich domains of 
substrate proteins has been reported before (22,23). However, we observed that overexpression of 
WWP1 still reduced EWS-FLI1 protein levels upon PPxY mutation. This might be due to alternative 
binding sites within the fusion protein, as also observed by co-immunoprecipitation, which might be 
sufficient to induce EWS-FLI1 degradation. Furthermore, overexpression of the catalytic inactive 
WWP1 protein still slightly decreased EWS-FLI1 protein levels, thereby suggesting degradation 
mechanisms additionally to the active site cysteine of WWP1 or indirect effects. Importantly, regulation 
of EWS-FLI1 stability might involve not only WWP1 but also other E3 ligases such as RING E3 ligases 
since redundancy within the ubiquitin-proteasome system (39) or collaboration between different E3 
ligases (40) has been reported before. Interestingly, EWS-FLI1 has been shown to interact with the 
RING domain of BARD1, which is part of a E3 ligase complex (41). Furthermore, the conserved ETS 
domain of FLI1 has been shown to interact with the SUMO E3 ligase PIAS (42), which might be 
another candidate to regulated EWS-FLI1 turnover.  
Physiologically, we observed that WWP1 has a tumor suppressive function in Ewing sarcoma cells 
since overexpression of WWP1 led to reduced cell growth and colony formation. WWP1 has been 
shown to have various cellular functions including modulation of EGF and TGFß signaling as well as 
apoptosis (43). Interestingly, WWP1 is overexpressed and has oncogenic properties in various 
cancers (25,27,44). However, a tumor suppressive function of WWP1 in cancer cells was less 
characterized until now. Whether the inhibitory effect of WWP1 on Ewing sarcoma cell growth is due 
to its direct role in EWS-FLI1 degradation or other molecular mechanisms remains to be further 
investigated. Other additional properties of WWP1 are likely to contribute to its rather small inhibitory 
effect on Ewing sarcoma proliferation.  
The importance of regulating the turnover of transcription factors has been highlighted by the tumor 
suppressor p53, whose stability is controlled by several E3 ligases (45). Furthermore, E3 ligases have 
become an attractive target for cancer therapy over the past years since they are often aberrantly 
expressed in cancers (9,10). Here, we found that the E3 ubiquitin ligase WWP1 is an important 
regulator of EWS/FLI1 turnover. Since the fusion protein is the main driver of tumorigenesis in Ewing 
sarcoma, we suggest that interference with EWS-FLI1 turnover might be a novel strategy to induce 
tumor growth inhibition. 
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Figures  
 
 
 
Fig. 1: EWS-FLI1 ubiquitination and stability is regulated by its PPxY motif. (A) The PPxY motif 
of EWS-FLI1 was mutated by site-directed mutagenesis in order to prevent binding of NEDD4 family 
E3 ligases. (B) A673 cells were transfected with pCMV-3xFlag-EWS-FLI1 wt or pCMV-3xFlag-EWS-
FLI1 PPxY mutated. After 48h, cells were fixed and immunostained by Alexa-488 linked antibody and 
DAPI. EWS-FLI1 localization and cell nucleus were analyzed by fluorescence microscopy using 63x 
magnification. (C) A673 cells were transfected with pCMV-3xFlag-EWS-FLI1 wt or PPxY mutated 
together with HA-ubiquitin as indicated. 48h after transfection, cell lysates were immunoprecipitated 
under denaturing conditions using anti-flag antibody. Polyubiquitinated EWS-FLI1 was analyzed by 
western blotting using anti-HA and anti-flag antibodies. Representative western blot is shown. (D) 
HEK293T and A673 cells were transduced with lentiviral particles containing the reporter construct 
DsRed-IRES-EGFP fused to EWS/FLI1 wt or PPxY mutated. 72h after transduction, fluorescence was 
measured by FACS and data were further analyzed using FlowJo software. Representative 
histograms show EGFP/DsRed ratios of double-positive cells. 
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Fig. 2: E3 ligases from the NEDD4 family regulate EWS-FLI1 protein levels. (A) HEK293T cells 
were transfected with pCDNA3-HA-EWS-FLI1 and two increasing concentrations of pCMV-3xFlag-E3 
ligases as indicated. 48h after transfection, cell lysates were analyzed by western blotting using anti-
FLI1 and anti-flag antibodies. Representative western blots are shown. Samples separated by dotted 
lines were on the same blot. (B) Quantification of two independent experiments as shown in (A) using 
ImageJ software. Controls are represented as mean of 35 replicates ± SD. 
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Fig. 3: WWP1 negatively regulates endogenous EWS-FLI1 protein levels in Ewing sarcoma 
cells. (A) A673 cells were transfected with two increasing concentrations of pCMV-3xFlag-E3 ligases 
as indicated. 48h after transfection, cell lysates were prepared for western blot analysis using anti-
FLI1 and anti-flag antibodies. Representative western blot is shown. Samples separated by dotted 
lines were on the same blot. (B) Quantification of endogenous EWS/FLI1 protein levels shown in (A) of 
4 independent replicates ± SD using ImageJ software. **p<0.01, *** p<0.001, n.s.=not significant by 
two-tailed Student‘s t test. 
  
Manuscript II 
93 
 
 
 
 
 
Fig. 4: WWP1 regulates EWS-FLI1 protein levels by interaction via the PPxY motif of the fusion 
protein.  (A) HEK293T cells were transfected with pCDNA3-HA-EWS-FLI1 and pCMV-3xFlag-WWP1 
wt or C890A as indicated. 48h after transfection, cell lysates were prepared for western blotting using 
anti-HA and anti-flag antibodies. Data were quantified using ImageJ software and represented as 
mean ± SD. Representative western blot is shown. (B) HEK293T were transfected with pCDNA3-HA-
EWS-FLI1 wt or PPxY mutated and pCMV-3xFlag-WWP1 as indicated. Protein levels were analyzed 
and shown as in (A). (C) HEK293T cells were transfected with pCMV-3xFlag-EWS-FLI1 wt or PPxY 
mutated together with pCDNA3-3xMyc-WWP1 as indicated. After 48h, EWS-FLI1 was 
immunoprecipitated using anti-flag antibody and interaction was analyzed by western blotting using 
anti-myc and anti-flag antibodies. Representative western blot is shown. 
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Fig. 5: WWP1 has a tumor suppressive function in Ewing sarcoma cells. (A, B) Cell lysates of 
different Ewing sarcoma (A673, SKNMC, TC71, SKES, RDES) and peripheral neuroectodermal tumor 
(SKPNDW) cell lines were prepared for qRT-PCR analysis (A) and western blot analysis using anti-
WWP1 antibody (B). (C) A673 cells were transfected with pCMV-3xFlag-WWP1, fixed and 
immunostained with anti-Flag and secondary Alexa-488 labeled antibody. DAPI was used for nuclear 
staining. Cells were analyzed by fluorescence microscopy at 63x magnification. (D) SKNMC cells were 
transduced with retroviral titer containing 3xFlag-WWP1 or a control vector together with a GFP 
selection marker. GFP-positive cells were sorted by FACS and WWP1 overexpression was analyzed 
by western blotting. Cells were plated in a 6-well and counted after 4 and 8 days. Data are 
represented as mean ±SD, **p<0.01 by two-tailed Student‘s t test. (E) SKNMC cells stably expressing 
WWP1 were plated for colony formation assay. Colonies were stained with crystal violet after 14 days 
and counted. Data are represented as mean ±SD, ****p<0.0001 by two-tailed Student‘s t test. 
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Supplementary tables 
Supplementary table S1: Clone IDs ordered from Dharmacon Inc. (Buckinghamshire, UK). 
Gene Clone ID 
NEDD4 9020595 
NEDD4L 5528964 
ITCH (only partial sequence was available) 3451168 
SMURF1 9052935 
SMURF2 7939721 
WWP1 5296005 
WWP2 3453212 
HECW2 40125745 
 
 
Supplementary table S2: Primers used for In-Fusion Cloning. 
3xFlag-/3xMyc-E3 ligases in mammalian expression vector 
3xFlag-NEDD4 FW GACAAGCTTGCGGCCGCAGCACAAAGCTTACGATTG RS GATGAATTCGCGGCCGCCTACTAATCAACTCCATC 
3xFlag-NEDD4L FW GACAAGCTTGCGGCCGCAGCGACCGGGCTCGGGG RS GATGAATTCGCGGCCGCCTATTAATCCACCCCTTC 
3xFlag-SMURF1 FW GACAAGCTTGCGGCCGCATCGAACCCCGGGACACG RS GATGAATTCGCGGCCGCCTATCACTCCACAGCAAACCC 
3xFlag-SMURF2 FW GACAAGCTTGCGGCCGCATCTAACCCCGGAGGC RS GATGAATTCGCGGCCGCCTATCATTCCACAGCAAATCC 
3xFlag-HECW2 FW GACAAGCTTGCGGCCGCAGCTAGTTCAGCCCG  RS GATGAATTCGCGGCCGCCTATCACTCAAGTCCAAAAG 
3xFlag-WWP1 FW GACAAGCTTGCGGCCGCAGCCACTGCTTCACCAAGG RS GATGAATTCGCGGCCGCCTATCATTCTTGTCCAAATC 
3xFlag-WWP2 FW GACAAGCTTGCGGCCGCAGCATCTGCCAGCTC RS GATGAATTCGCGGCCGCCTATTACTCCTGTCCAAAGCC  
3xFlag-ITCH FW GACAAGCTTGCGGCCGCACAAGAGATTGATTTG RS GATGAATTCGCGGCCGCCTATTACTCTTGTCCAAATC 
3xMyc-WWP1 FW CTGGAATTCAGGATCCAATCTGGCGGGGCCAGTGC RS GCGGATATCAGGATCCCTATCATTCTTGTCCAAATC 
 
WWP1 in retroviral vector 
3xFlag-WWP1  FW GAATTCAGATCTCGAGATGGACTACAAAGACCATGACG  RS ATTGATCCCGCTCGAGCTATCATTCTTGTCCAAATC  
 
Site-directed mutagenesis 
EWS/FLI1-AAxA FW TCACTGCAGCTGCATCCGCCCCTCCTACCAGCTATTCC RS GGTAGGAGGGGCGGATGCAGCTGCAGTGACTGGCTGCAT 
WWP1 C890A FW 5' CCAAGAAGCCATACAGCTTTTAATCGCTTGGATCTACC 3' RS 5' GGTAGATCCAAGCGATTAAAAGCTGTATGGCTTCTTGG 3' 
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Abstract  
Ewing sarcoma is the second most common pediatric bone and soft tissue tumor with an aggressive 
behavior and prevalence to metastasize. The diagnostic translocation t(22;11)(q24;12) leads to 
expression of the chimeric oncoprotein EWS-FLI1 harboring a strong transactivation and a DNA-
binding domain. The EWS-FLI1 protein is uniquely expressed in all tumor cells and maintains their 
survival. Constant EWS-FLI1 protein turnover is precisely regulated by the ubiquitin proteasome 
system. Here, we identified ubiquitin specific protease 19 (USP19) as a regulator of EWS-FLI1 
stability. Depletion of USP19 resulted in diminished EWS-FLI1 protein levels and, vice versa, 
upregulation of active USP19 stabilized EWS-FLI1 in a dose-dependent manner. Importantly, 
stabilization appears to be specific for the fusion protein as it could not be observed neither for 
EWSR1 and nor FLI1 wild type proteins. Mechanistically, we show USP19 to directly interact with the 
N-terminal EWS part to induce deubiquitination at a specific acceptor lysine in the FLI1 domain. 
Further, stable shRNA expression to deplete USP19 resulted in decreased cell growth and diminished 
colony forming capacity in vitro, and significantly delayed tumor growth in vivo. Hence, our findings not 
only provide novel insights into the regulation of EWS-FLI1 protein stability, but also identify USP19 as 
a novel therapeutic target for the treatment of Ewing sarcoma. 
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Introduction 
Ewing sarcoma is a rare bone and soft tissue tumor which is highly distinct from other sarcoma 
subtypes due to its histology, molecular characteristics and prevalence to metastasize (1). It most 
commonly arises in children and adolescents with an age dependent distribution. Histologically, it 
presents as an undifferentiated and blue small round cell tumor. The 5-year survival rate for localized 
disease is around 70% whereas it is less than 40% for patients with metastasis at initial diagnosis 
(1,2). Current treatment includes surgery and chemotherapy with long known standard agents like 
doxorubicin and vincristine (3). High chemotherapeutic toxicity, relapsed tumors and an unfavorable 
prognosis of patients with metastasis are demanding for novel therapeutic strategies.  
In contrast to adult cancers harboring an accumulation of multiple driver mutations, pediatric lesions 
display a high frequency of chromosomal rearrangements and a comparably low mutational burden (4-
6). Indeed, recent sequencing efforts revealed that, besides a recurrent translocation, the genomic 
landscape of Ewing sarcoma is characterized by only very few additional mutational events such as 
STAG2 and TP53 point mutations in a subset of patients (7,8). The main genetic event therefore is the 
balanced translocation between chromosomes 11 and 22 leading to expression of the chimeric 
transcription factor EWS-FLI1, in the majority of the cases (9). This aberrant fusion protein is 
indispensable for tumor formation and progression as its depletion induces tumor growth inhibition 
(10-12). EWS-FLI1 triggers a defined program of target gene activation and repression and is further 
implicated in remodeling a wide network of protein-protein interactions (13-17). Given the fact that 
Ewing sarcoma cells are highly dependent on continuous expression of the fusion protein, reduction of 
EWS-FLI1 levels represents an attractive therapeutic avenue. 
Regulation of protein stability is a highly conserved system ensuring maintenance of cell homeostasis 
and/or response to exogenous stimuli. Most intracellular proteins are degraded by the ubiquitin 
proteasome system. Ubiquitin tagged proteins are either subjected for destruction or induce signaling 
cascades (18,19). The process of ubiquitin chain attachment and elongation is regulated by an 
enzymatic cascade whereby E3 ligases mediate the ubiquitin transfer (20). The poly-ubiquitin chains 
can be removed or modified by deubiquitinating enzymes (DUBs) whose family is comprised of around 
100 members classified into six subgroups according to their catalytical core domains (21). 
Ubiquitin specific protease 19 (USP19) is a USP family member with several splice isoforms. The N-
terminus is responsible for chaperone function whereas the USP domain mediates protein-protein 
interactions. At the C-terminal end, USP19 harbors a transmembrane domain which mapped its 
function initially to substrate rescue of endoplasmic-reticulum-associated degradation (22,23). USP19 
is known to play a critical role in cellular homeostasis by supporting protein quality control and clearing 
misfolded proteins (24). Also muscle homeostasis is maintained by USP19, its inactivation protects 
against muscle wasting (25-27). However, the identification of the substrate KPC1, a regulator of p27 
stability, suggested that USP19 might also be implicated in cell cycle deregulation. Finally, USP19 
knockdown inhibited proliferation of prostate cancer and breast epithelial cell lines suggesting USP19 
to be oncogenic (28,29).  
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We have recently identified EWS-FLI1 as a substrate of the proteasome system with a distinct 
turnover (30). In the present study, we utilized a siRNA-based screening approach to identify the 
deubiquitinating enzyme USP19 as a specific stabilizer of the EWS-FLI1 fusion protein. Depletion of 
USP19 increased EWS-FLI1 ubiquitination and enhanced its degradation. USP19 inhibition 
subsequently resulted in decreased tumor cell growth in vitro and in vivo. Our data suggest selective 
EWS-FLI1 destabilization by means of DUB inhibition to be an entirely new class of targeting 
mechanism for Ewing sarcoma treatment. 
 
 
Material and methods 
Cell lines 
HEK293T and HEK293 cells were cultured in DMEM (Sigma Aldrich, Buchs, Switzerland) with 10% 
FBS (Sigma Aldrich), 2mmol/L glutamine (BioConcept, Allschwil, Switzerland) and 100U/ml 
penicillin/streptomycin (ThermoFisher Scientific AG, Reinach, Switzerland) at 37°C in 5% CO2. All 
Ewing sarcoma cell lines and primary cells were cultured in RPMI medium with the same 
supplements. A673, RDES and primary cells were plated on 0.2% gelatine (Sigma Aldrich) pre-coated 
dishes. G418 selection of A673 and RDES clonal cell lines was carried out with 1.5mg/ml G418 for 
one week, and kept in 0.2mg/ml G418 for further culturing. Puromycin selection was performed with 
1.5µg/ml, whereas 0.5µg/ml was used for maintenance. All cell lines have been tested mycoplasma 
negative. Ewing cell lines were authenticated by cell line typing analysis (STR profiling) 2016/05. 
Primary Ewing cell lines were characterized by karyotyping at the diagnostic laboratory of the 
Children´s Hospital Zurich, Switzerland and described before (31). 
 
Reagents and antibodies 
The following reagents were used: DMSO, doxycycline (both Sigma Aldrich), G418 (Promega, 
Duebendorf, Switzerland), puromycin (ThermoFisher Scientific AG). The following commercial 
antibodies were used: anti-Flag (clone M2, dilution 1:1000, Sigma Aldrich), anti-FLI1 (1:1000, 
MBS300723 MyBioSource LLC, San Diego, CA, USA), anti-GAPDH (1:1000, D16H11 Cell Signaling 
Technology, Beverly, MA, USA), anti-HA (both 1:1000, clone 6E2 Cell Signaling Technology and 05-
904 Millipore), anti-Myc (1:1000, clone 9B11 Cell Signaling Technology) anti-p27 (1:200, clone DCS-
72.F6 ThermoFisher Scientific AG), anti-Tubulin (1:1000, clone DM1A Sigma Aldrich) and anti-USP19 
(1:1000, WB: A301-587A Bethyl Laboratories, Montgomery, TX, USA and 1:200, IHC or 1:1000 WB: 
ab93159 Abcam, Cambridge, UK). 
 
Plasmids and cloning 
The pRSIT-U6Tet-shRNA-PGK-TetRep-2A-GFP-2A-puro vector with shRNA sequences against 
USP19 or a negative control construct were purchased from Cellecta Inc. (Mountain View, CA, USA) 
with the following target sequences: shControl 5’-TTGGTGCTCTTCATCTTGTTG-3’, shUSP19#1 5’-
GTGAAACAGAAGGTGCACTGC-3’ and shUSP19#2 5’-AAGTGATGGAGACCTTGGCAC-3’. USP19 
cDNA (Addgene #36306) was introduced into pCMV-3xflag or pCDNA-3xmyc vectors (tag N-terminal 
Manuscript III 
101 
of USP19) by In-Fusion cloning HD (Clontech Laboratories Inc., Mountain View, CA, USA) according 
to manufacturer’s protocol. USP19 C506A was mutated by site-directed mutagenesis using the 
forward primer 5’-CAATTAGGCAACACCGCCTTCATGAACAGCGTC-3’ and reverse primer 5’-
GACGCTGTTCATGAAGGCGGTGTTGCCTAAATTG-3’. pCMV-3xflag-EWS-FLI1, pCMV-3xflag-
EWSR1 and pCMV-3xflag-FLI1 have been described previously (30). All clonings have been verified 
by sequencing.  
 
In silico candidate selection and screening method 
Twelve publicly available microarray data sets of Ewing cell lines and tumors were used to select DUB 
candidates (Supplementary Table ST1). Genes were ranked according to the total number of present 
calls from all data sets and their expression values. For the screen, cells were reversely seeded with 
single siRNAs in a 96-well plate. After 48h, cells were lysed in standard lysis buffer (50mM Tris/HCl, 
150mM NaCl, 50mM NaF, 5mM Na4P2O7, 1mM Na3VO4 and 10mM ß-glycerolphosphate, 1% Triton X-
100 with protease inhibitor cocktail, Complete Mini®, Sigma Aldrich) and cleared by centrifugation. For 
each well, 1/10 of the lysate was used to determine protein concentration by Pierce BCA Protein 
Assay Kit (ThermoFisher Scientific AG) and 9/10 were transferred to an anti-flag® high sensitivity M2 
coated 96-well plate (Sigma Aldrich) and incubated for 2h at room temperature while shaking. Wells 
were then incubated with anti-FLI1 antibody followed by HRP-linked anti-rabbit antibody, each for 2h. 
To detect protein levels, wells were incubated with ready-to-use peroxidase substrate containing 
3,3’,5,5’-tetramethylbenzidine (Sigma Aldrich). Absorbance was measured by ELISA reader at 640nm. 
Each well was normalized to its corresponding protein concentration. 
 
Transient transfection, virus production and cell transduction with viral supernatant 
For siRNA silencing, RNAiMAX transfection reagent was mixed with siRNAs (both ThermoFisher 
Scientific AG) according to the manufacturer’s protocol and reversely seeded with cells in antibiotics-
free medium. For screening, three different siRNAs per gene were used (Silencer®Select, 
ThermoFisher Scientific AG, Supplementary Table ST2). For transient plasmid transfections, JetPrime 
(Polyplus Transfections, Illkirch, France) reagent was mixed with plasmids according to 
manufacturer’s instruction in antibiotics-free medium and added to cells for 48h. For the production of 
lentiviral particles, HEK293T cells were transiently transfected with pMDL, pREV, pVSV and shRNA 
plasmids using JetPrime according to manufacturer’s instruction in antibiotics-free DMEM medium. 
After 24h, medium was replaced and virus supernatant was harvested after a total of 72h. Viral 
supernatant was cleared by centrifugation, filtered and concentrated (Amicon Ultra 15 mL Centrifugal 
Filters, Millipore). Cells were transduced with the viral supernatant supplemented with 10µg/ml 
polybrene (Sigma Aldrich) by centrifugation for 1h at 32°C. 
 
Cell lysis and western blotting 
Cells were lysed in standard lysis buffer, sonicated and cleared by centrifugation. Protein separation 
was performed with 4-12% BisTris NuPAGE pre-cast gels (ThermoFisher Scientific AG) and 
transferred to nitrocellulose membranes (GE Healthcare, Glattbrugg, Switzerland). After 1h of blocking 
in 5% milk powder in 0.2% PBS-Tween, membranes were incubated with primary antibodies over 
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night at 4°C and 2h of HRP-linked secondary antibody at room temperature. Protein detection was 
carried out by chemiluminescence using Amersham ECL detection reagent (GE Healthcare) or 
SuperSignalTM Western blotting reagent (ThermoFisher Scientific AG). Quantification of blots was 
performed using ImageJ (version 1.46r). 
 
Co-immunoprecipitation and immunoprecipitation of ubiquitinated proteins 
HEK293T cells were lysed in interactor lysis buffer 1 (50mM Tris/HCl, 150mM NaCl, 1mM EDTA, 0.5% 
Triton X-100 with protease inhibitor cocktail) and HEK293 cells in interactor lysis buffer 2 (50mM 
Tris/HCl, 50mM NaCl, 1.5mM MgCl2, 25mM NaF, 10mM β-glycerolphosphate, 5mM Na4P2O7, 2mM 
Na3VO4, 10% glycerol 0.3% NP40 with protease inhibitor cocktail). Lysates were cleared by 
centrifugation and incubated with anti-Flag antibody coupled to Dynabeads ProteinG (ThermoFisher 
Scientific AG) for 30min at 4°C. After three washing steps, the protein was eluted from the beads with 
3xFlag-Peptide (Sigma Aldrich) at room temperature and prepared for western blot analysis.  
To detect ubiquitinated proteins, cells were lysed in ubiquitin lysis buffer (2% SDS, 150mM NaCl, 
10mM Tris/HCl, 2mM Na3VO4, 50mM NaF with protease inhibitor cocktail), boiled for 10min and 
sonicated. Lysates were rotating for 30min at 4°C after dilution in nine volumes of dilution buffer 
(150mM NaCl, 10mM Tris/HCl, 2mM EDTA, 1% Triton X-100) and cleared by centrifugation for 30 min 
at maximum speed. After immunoprecipitation, ubiquitinated proteins were analyzed by western 
blotting.  
 
RNA extraction and quantitative RT-PCR  
Total RNA was extracted from Ewing cells using RNeasy (Qiagen, Hombrechtikon, Switzerland) 
according to manufacturer’s instruction. Complementary DNA synthesis was carried out using a High-
Capacity Reverse Transcription Kit (ThermoFisher Scientific AG). Quantitative RT-PCR was 
performed using TaqMan gene expression master mix (ThermoFisher Scientific AG) and assays on 
demand (Applied Biosystems by ThermoFisher Scientific AG) with the following numbers: USP19 
(Hs00324123_m1, Hs01103464_g1), EWS-FLI1 (Hs03024807_ft), GAPDH (Hs04420697_g1), HMBS 
(Hs00609296_g1), ITGA11 (Hs00201927_m1), LEMD1 (Hs01077215_m1), LOX (Hs00942481_m1), 
MAP2K6 (Hs00992389_m1), NGFR (Hs00609976_m1), NKX2.2 (Hs00159616_m1), NR0B1 
(Hs00230864_m1), PHLDA1 (Hs00378285_g1). Relative expression values were calculated by the 
ΔΔCt method. Replicate values were pooled and represented as the geometric mean with a 95% 
confidence interval as error bars. 
 
Immunofluorescence and immunohistochemistry 
For immunofluorescence, cells were seeded on cover slides and transiently transfected for 48h. Cells 
were fixed with 4% PFA (Carl Roth, Arlesheim, Switzerland) and permeabilized. After overnight 
staining with anti-Flag antibody (1:300) in 4% horse serum (Sigma Aldrich) 0.1% PBS Triton X-100, 
secondary antibody Alexa-488 (anti-mouse, Sigma Aldrich) in 4% horse serum PBS was applied for 
1h. Slides were fixed on objective glass with DAPI Vectashield® mounting medium (Vector 
laboratories Inc., Burlingame, CA, USA). Cells were analyzed by an Axioskop 2 MOT Plus 
fluorescence microscope (Carl Zeiss Microscopy LLC, Thornwood, NY, USA). For 
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immunohistochemistry, tumors were fixed, embedded in paraffin and stained by Sophistolab AG 
(Muttenz, Switzerland). 
 
Functional assays 
A673 and SKNMC cells were seeded in 96 well plates. After indicated times, the following assays 
were carried out: For cell viability assays, cells were incubated with WST1 reagent (1:10 in medium, 
Sigma Aldrich) at 37°C and absorbance was measured at 440nm and 640nm. For BrdU incorporation, 
the Cell Proliferation ELISA Brdu chemiluminescent kit (Sigma Aldrich) was used according to the 
manufacturer’s instructions. For cell number assay, cells were fixed with 4% PFA (Carl Roth) for 10min 
and stained with 0.05% crystal violet solution (Sigma Aldrich) for 20min. After a washing step in water, 
the dried staining was dissolved in methanol and absorbance was measured at 540nm. For colony 
formation, 100 (SKNMC) or 500 (A673) cells were seeded in a 6-well plate and stained with 0.05% 
crystal violet solution after 12-14 days. Colonies were manually counted. 
 
Xenograft studies 
SKNMC cells (4x106 cells) were engrafted subcutaneously in the left flank of NOD/Scid il2rg-/- mice 
(all female). Mice with a tumor volume of 50-100mm3 were intraperitoneally injected with 53.3mg/kg 
doxycycline or corresponding PBS for the first two days. Mice were fed with doxycycline (625mg/kg) or 
PBS supplemented food (Provimi Kliba SA, Kaiseraugust, Switzerland). Tumor sizes were measured 
by caliper for two diameters at right angles. Tumor volume was calculated by V=4/3*pi*((d1+d2)/4)3. 
Termination point was reached by a tumor volume of 1000mm3. 
 
 
Results 
SiRNA-based screening to identify regulators of EWS-FLI1 stability. We have previously 
demonstrated that EWS-FLI1 protein has a high turnover mediated via the ubiquitin-proteasome 
system (30). As EWS-FLI1 protein expression is crucial for tumor cell survival (10,12), we aimed to 
destabilize the fusion protein by depleting EWS-FLI1 partner protein(s) of the ubiquitin system. Most 
relevantly, DUBs can rescue substrates from degradation and thereby directly modulate protein 
expression. To identify relevant candidates, we selected 21 DUBs of the ubiquitin-specific protease 
family in silico based on high gene expression in publicly available gene expression profiles of Ewing 
sarcoma cell lines and tumors (Fig. 1A, Supplementary Table ST1). Next, we established a screening 
strategy to directly measure EWS-FLI1 protein levels as a read-out by monitoring the amount of flag-
tagged EWS-FLI1 protein in an ELISA-type assay upon transient transfection with individual siRNAs 
(Fig. 1B, Supplementary Table ST2). As positive control, a siRNA directed against the fusion protein 
was used which is capable to downregulate both exogenous and endogenous EWS-FLI1 protein 
levels with similar efficiency as shown by western blotting (Fig. S1A). Using three different siRNAs for 
each of the 21 candidates, we identified USP19 as the most potent modulator of EWS-FLI1 protein 
levels 48h after transfection. At least two siRNAs against USP19 decreased EWS-FLI1 protein levels 
by more than 25% in each of three screening rounds (Fig. 1C), values which were compensated by 
total protein levels for each individual well to ensure that diminished EWS-FLI1 protein levels are not 
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simply a result of decreased cell numbers (Fig. S1B). To validate that USP19 depletion could be 
relevant in Ewing sarcoma cells, we analyzed protein and mRNA expression of USP19 across six 
different Ewing sarcoma cell lines and three primary cell samples (Fig. 1D-E). USP19 protein presents 
with various isoforms of different sizes in Ewing sarcoma cell lines and primary cells whereby the 
highest band matches the size of overexpressed USP19. The amount of mRNA correlated well with 
protein expression in all the cell lines, with SKNMC and TC71 displaying highest levels. 
Overexpression of 3xflag-USP19 showed that the protein is predominantly localized in the cytoplasm 
of Ewing cell lines (Fig S1C). Hence, out of a pre-selected subset of candidates we identified USP19 
as a potential modulator of EWS/FLI1 stability.  
 
USP19 specifically modulates EWS-FLI1 protein level. To validate USP19 as modulator of EWS-
FLI1 stability, we first investigated the effect of USP19 depletion on endogenous EWS-FLI1 protein 
across two different cell lines with two different siRNAs. Similar to the observations made in the initial 
screening, USP19 knockdown resulted in an efficient reduction of USP19 protein levels and a 
subsequent decrease of EWS-FLI1 protein of around 40% after 72h in both A673 and SKNMC cells 
(Fig. 2A-B). P27 protein levels slightly increased after depletion as already described before, and 
possibly mediated by inhibition of the E3 ligase KPC1 (28,29). As expected, transient USP19 
knockdown also affected a subset of both activated and repressed EWS-FLI1 target genes in SKNMC 
cells. NKX2.2, NGFR, LEMD1, LOX and ITAG11 displayed modulated expression levels, while NR0B1 
or PHLDA1 were not affected (Fig. S2A). Next, we transiently co-expressed flag-tagged EWS-FLI1 
with two increasing concentrations of 3xmyc-tagged USP19 in HEK293T cells. EWS-FLI1 levels were 
stabilized more than 2-fold in a dose-dependent manner by active USP19, but to a much lesser extend 
with the catalytically inactive C506A mutant (22), indicating that indeed the deubiquitinating activity of 
USP19 is responsible for modulation of fusion protein levels (Fig. 2C-D). Interestingly, the stabilization 
of EWS-FLI1 by USP19 might be specific for the fusion protein as the protein levels of full length wild 
type EWSR1 or FLI1 remained constant upon co-expression with 3xmyc-USP19 (Fig. 2E). Therefore, 
we next assessed if EWS-FLI1 and USP19 could interact directly. For this, tagged versions of USP19 
and EWS-FLI1 were co-expressed and immunoprecipitated from HEK293T cells. We observed a 
consistent pull-down of UPS19 with tagged EWS-FLI1 and vice versa (Fig. 2E, S2B), suggesting that 
the two proteins interact directly. Strikingly, when USP19 was co-expressed with the full length 
proteins EWS and FLI1, only full length EWS, but not wild type FLI1 could be immunoprecipitated 
indicating that USP19 binds to the N-terminal domain of both proteins (Fig. 2F). Taken together, our 
results indicate that USP19 is indeed a specific regulator of EWS-FLI1 protein stability and activity. 
 
USP19 destabilizes EWS-FLI1 by direct deubiquitination. It was previously shown that USP19 
directly deubiquitinates and rescues a variety of substrates from proteasomal degradation (32-34). We 
therefore aimed next to investigate whether USP19 could also deubiquitinate and subsequently 
stabilize the fusion protein. First, we depleted USP19 with three different siRNAs prior to 
immunoprecipitation of tagged ubiquitinated EWS-FLI1 in A673 cells. This resulted in increased EWS-
FLI1 ubiquitination compared to control treated cells (Fig 3A). To further underscore this notion, we co-
expressed 3xflag-EWS-FLI1 and HA-ubiquitin together with either active or mutant 3xmyc-USP19 in 
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A673 cells. Immunoprecipitation of ubiquitinated EWS-FLI1 revealed a reduction of the ubiquitination 
pattern and higher fusion protein levels when co-expressed with active USP19 compared to its 
catalytically inactive form (Fig. 3B).  
Taken together, our findings identify EWS-FLI1 as a novel substrate of USP19 which directly reduces 
ubiquitination levels of the fusion protein by its enzymatic activity.  
 
Depletion of USP19 affects Ewing sarcoma cell growth. To validate USP19 as a possible 
therapeutic target for Ewing sarcoma, we next assessed if USP19 knockdown affects the physiology 
of Ewing cells. To this end, we established SKNMC and A673 cells using two inducible shUSP19 
constructs which allows to deplete USP19 by addition of doxycycline. Indeed, treatment of this cell 
populations resulted in reduction of both mRNA and protein levels with the specific, but not with the 
control shRNA sequence (Fig. 4A-B, S3A-B). To investigate the effect on tumor cell growth, we plated 
cells with and without doxycycline induction and determined cell numbers after four and eight days. 
Upon specific depletion of USP19, cell numbers are greatly reduced by 50% after four days and 
between 70-85% after eight days compared to non-induced and control cells for both Ewing cell lines 
(Fig. 4C, S3C). Analysis of the corresponding protein levels in SKNMC cells after eight days by 
western blotting revealed that depletion of USP19 is accompanied by a decrease in EWS-FLI1 protein 
levels by 40%, but no significant changes in EWS-FLI1 mRNA levels (Fig. 4D-F). USP19 depletion 
further decreased metabolic viability as shown by WST1 assay and proliferation by reduced BrdU 
incorporation (Fig. 4G-H, S3D). To assess long-term consequences, we analyzed the ability of Ewing 
cells to form colonies after 14 (SKNMC) and 12 days (A673), respectively. Upon USP19 depletion, 
colony forming capacity was reduced to less than 20% compared to non-induced and control cells 
which showed similar numbers of total colonies (Fig. 4I-J, S3E-F). In contrast, transient 
overexpression of ectopic myc-USP19 for only 48h already increased cell growth, viability and 
proliferation in both A673 and SKNMC cells which was not observed when a catalytically inactive 
mutant was expressed (Fig. S4A-G). Interestingly, USP19 depletion in non-tumorigenic cells such as 
MRC5 fibroblasts or HEK293T cells did not or only slightly affect cell viability as shown by WST1 
measurements (Fig S3G-J). Similar growth rates of USP19-/- HEK293T cells have been described 
previously (24), suggesting that the oncogenic effect of USP19 is specific for Ewing sarcoma cells, 
despite a slight off-target effect observed for shUSP19#2. Hence, our data suggest that USP19 
depletion is a relevant mechanism for Ewing cell growth inhibition in vitro which is mediated, at least in 
part, by EWS-FLI1 protein destabilization. 
 
Loss of USP19 delays tumor growth in xenografts. Finally, we investigated whether USP19 
depletion would affect tumor growth in mouse xenografts. To this end, we subcutaneously injected 
inducible shControl or shUSP19#1 SKNMC cells and allowed tumors to grow up to a volume of at 
least 50mm3 (Fig. 5A). Then, we fed the animals with either control or doxycycline supplemented food 
to induce USP19 knockdown. Efficient reduction of USP19 protein levels could already be seen after 
five days of doxycycline administration compared to control cells, as shown by both western blotting 
and immunohistochemistry (Fig. 5B, S3A). While all tumors from control mice reached the final volume 
of 1000mm3 after around ten days, tumors from doxycycline treated shUSP19 xenograft mice showed 
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a clear delay in tumor growth. While two mice reached the maximum tumor volume only after more 
than double of the time period, tumors of three other mice were stable at a volume of around 200mm3 
over the entire observation period (Fig.5C-D). Analysis of USP19 mRNA and protein from all tumors 
confirmed an efficient and selective downregulation of USP19 only upon doxycycline administration, 
even after a longer time period (Fig. 5E, S3B-C). Taken together, we could show that USP19 depletion 
significantly delays tumor cell growth also in vivo which corroborates our in vitro findings. Selective 
inhibition of DUBs, as shown here for USP19, therefore represents a novel strategy to inhibit Ewing 
sarcoma tumor growth. 
 
 
Discussion 
In this study, we investigated EWS-FLI1 protein destabilization by deubiquitinating enzymes as a 
novel therapeutic strategy in Ewing sarcoma. In particular, we identified USP19 as a specific 
modulator of EWS-FLI1 protein stability mediated by increased fusion protein deubiquitination. The 
enhanced turnover of EWS-FLI1 protein abrogated long term cell growth and delayed tumor growth in 
mouse xenograft experiments.  
 
The majority of screening efforts in Ewing sarcoma utilized either single or subgroups of target genes 
as well as cell viability as read-outs for specificity and efficacy (35-38). As we have recently identified 
EWS-FLI1 turnover as an important regulatory pathway in Ewing sarcoma (30), we aimed at 
identifying potential stabilizers of the fusion protein, and utilize their inhibition which consequently 
would result in EWS-FLI1 degradation and tumor depletion. Therefore, we chose to screen for DUBs 
as they display a limited number of family members, harbor enzymatic activity and are currently an 
emerging field in drug development (39,40). Focusing on the 21 USP family members highly 
expressed in Ewing sarcoma cell lines and tumor samples allowed us to perform an unbiased screen 
for their ability to modulate EWS-FLI1 protein levels as a read-out in two different Ewing cell lines. We 
chose a short 48h incubation time to minimize secondary events due to general inhibition of cell 
growth. This led to the identification of USP19 as a novel regulator of EWS-FLI1 protein levels. 
However, it is very likely that other DUBs potentially regulate EWS-FLI1 turnover in a proteolytic or 
non-proteolytic manner as we could not observe more than 40% reduction in fusion protein levels. 
 
Nevertheless, we clearly confirmed USP19 as a stabilizer of endogenous EWS-FLI1 by analyzing 
fusion protein levels upon USP19 knockdown. We also observed an increase of p27 protein which has 
been reported previously for USP19 and therefore further confirms specificity of our knockdown 
(28,29). On the other hand, co-expression of active USP19 with EWS-FLI1 stabilized the fusion 
protein whereas full length EWS and FLI1 protein levels remained unchanged. This suggests that 
inhibition of USP19 might be particularly attractive for Ewing sarcoma therapy since it would not affect 
ubiquitously expressed EWS or FLI1 wild type proteins thereby potentially decreasing therapy related 
side-effects. Indeed, our data suggest the following mechanistic model (Fig. 6): USP 19 can bind to 
the EWS domain of the fusion protein, as demonstrated here by co-immunoprecipitation experiments, 
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and reduces ubiquitination which occurs at a single acceptor lysine site (K380) in the FLI1 domain 
(30), thereby explaining its specificity for the fusion protein.  
 
Other fusion proteins were shown to be targets of a variety of DUBs. For example, USP37 modulates 
PLZF-RARA fusion protein levels in acute promyelocytic leukemia (41). It was found to regulate only 
stability of PLZF-RARA, but not the closely related PML-RARA suggesting that the N-terminal domain 
may be relevant for DUB binding. Therefore, the mechanisms identified here might apply to additional 
products of chromosomal translocations.  
 
Interestingly, USP9X was identified as a DUB for ERG, an ETS family member closely related to FLI1 
(42,43). Similar to our results, it could be demonstrated that depletion of USP9X increased ERG 
ubiquitination and subsequently suppressed prostate tumor growth. As about 10% of Ewing sarcoma 
tumors carry an alternative EWS-ERG fusion, inhibition of this DUB as a therapeutic strategy might 
also be effective in this subgroup of tumors. Further, USP9X regulation was also suggested to 
modulate wild type FLI1 stability even though only binding was shown (42). In our screening approach, 
USP9X knockdown resulted in a decrease of EWS-FLI1 stability of around 12% which did not reach 
our defined threshold to be considered as candidate. Whether USP9X might further affect EWS-FLI1 
levels in combination with USP19, remains to be investigated. 
 
To better understand if the decrease in EWS-FLI1 level is due to enhanced ubiquitination and 
degradation, we performed in vivo DUB assays by depleting endogenous USP19 or overexpressing 
an ectopic version. Both assays revealed a modulation of EWS-FLI1 ubiquitination pattern suggesting 
that this is indeed the main regulatory mechanism. USP19 was initially identified as an ER-resident 
DUB able to rescue degradation of ERAD substrates (22), but has now predominantly been localized 
to the cytosol in association with heat shock protein 90 (Hsp90) and other chaperones as a main 
substrate (23). It is therefore likely that EWS-FLI1 interacts with USP19 in the cytosol as the fusion 
protein displays a high turnover and is constantly shuffling in and out of the nucleus (30).  
 
Finally, we investigated the physiological consequences of USP19 depletion on Ewing sarcoma cell 
growth. For this, we used a doxycycline inducible model to deplete endogenous USP19 to ensure that 
no cell subpopulations were selected over time. In these studies, we observed selective diminished 
cell growth, proliferation and colony formation in Ewing sarcoma cell lines upon specific USP19 
depletion. However, it cannot be excluded that also secondary effects may contribute to the phenotype 
as USP19 likely has other substrates such as the cell cycle regulator p27, regulators of apoptosis 
cIAPs or the E3 ligase MARCH6 (28,29,32,34). Even though only few USP19 substrates have been 
identified so far, without a common ontology, USP19 expression clearly seems to be oncogenic in the 
context of Ewing sarcoma as USP19 depletion did not influence cell viability of control cell lines of 
non-tumorigenic origin. 
 
Most importantly, we also observed a significant growth delay upon USP19 knockdown in an in vivo 
xenograft model. Combining USP19 inhibition with other treatment strategies such as classical 
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chemotherapeutics, PARP inhibitors (5,44), DNA-damaging agents (45), inhibition of signaling 
pathways such as the PI3K pathway (46), or antagonists of the Wnt pathway (47) might further 
enhance its growth inhibitory properties. A recent study suggested that inhibition of EWS-FLI1 function 
results in de-repression of metastasis-associated gene programs, as a minority of ES tumors showed 
increased β-catenin pathway activation (47). Whether this might also be the case here, remains to be 
further investigated. Nevertheless, in macroscopic examinations, we did not observe any obvious 
formation of metastasis in mice carrying USP19 depleted tumors. 
 
In summary, our study identifies a novel therapeutic approach, namely selective targeting of EWS-
FLI1 turnover. Even though USP19 may not be the only DUB regulating fusion protein degradation, it 
seems to have a major impact and represents a novel potential target for Ewing sarcoma therapy. 
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Figures and Figure Legends 
 
 
Fig. 1: SiRNA screen identifies USP19 as a modulator of EWS-FLI1 stability. (A) In-silico selection 
of candidates. 21 deubiquitinating enzymes were selected based on their expression levels from 
publicly available microarray data sets of Ewing cell lines and tumors. (B) Screening setup. A673 and 
RDES cells stably expressing flag-tagged EWS-FLI1 were reverse transfected with an siRNA library. 
After 48h, lysates were incubated in anti-flag coated plates to determine EWS-FLI1 protein normalized 
to total protein. (C) EWS-FLI1 protein levels upon candidate knockdown. Each dot represents 3xflag-
EWS-FLI1 protein and is normalized to its total protein for each single well. 3xflag-EWS-FLI1 levels 
upon USP19 knockdown are indicated with larger red dots and for EWS-FLI1 knockdown in orange. 
(D) Expression levels of USP19 in indicated cell lines and primary samples were analyzed by western 
blot. The arrows indicate specific USP19 isoforms, asterix marks unspecific band. (E) mRNA 
expression of USP19 was determined by quantitative RT-PCR from same cells and normalized to 
GAPDH.  
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Fig. 2: USP19 specifically modulates EWS-FLI1 protein levels and activity. (A,B) Immunoblot 
analysis (IB) of USP19 depleted cells. (A,B) A673 and SKNMC cells were transiently transfected with 
20nM siRNAs for 72h as indicated. Lysates were subjected to western blot analysis and analyzed by 
anti-FLI1 and anti-USP19 antibodies. Arrows indicate specific USP19 isoforms, asterix marks an 
unspecific band. Besides, quantification of EWS-FLI1 proteins levels (n=5-6, error bars as SD). (C) 
Active USP19 stabilizes EWS-FLI1 protein. 3xflag-EWS-FLI1 was transiently co-expressed with a 
control vector or increasing levels (ratios 3xflag-EWS-FLI1 to 3xmyc-USP19 1:2 and 1:4) of wild-type 
or catalytically inactive 3xmyc-USP19 for 48h in HEK293T cells. Lysates were analyzed by western 
blotting using anti-flag and anti-myc antibodies. (D) Quantification of 3xflag-EWS-FLI1 protein levels of 
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(C) with n=8 for control and n=4 for others, error bars as SD. (E) USP19 overexpression stabilizes 
specifically EWS-FLI1. 3xflag-EWS-FLI1, 3xflag-EWSR1 and 3xflag-FLI1 were transiently co-
expressed with increasing concentrations (ratios 3xflag-protein to 3xmyc-USP19 1:2 and 1:4) of active 
3xmyc-USP19 for 48h in HEK293T cells. Lysates were analyzed by western blotting using anti-flag 
and anti-myc antibodies. Numbers below represent densitometrically quantified flag tagged protein 
over loading control GAPDH of a representative experiment. (F) EWS-FLI1 interacts with USP19. 
3xflag-EWS-FLI1 and 3xmyc-USP19 were co-expressed in HEK293T cells for 48h. After co-
immunoprecipitation, lysates were analyzed by western blotting as indicated. (G) EWSR1 also 
interacts with USP19. 3xflag-EWS-FLI1, 3xflag-EWSR1 or 3xflag-FLI1 were co-expressed with 3xmyc-
USP19 in HEK293 cells for 48h. After co-immunoprecipitation, lysates were analyzed by western 
blotting as indicated. 
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Fig. 3: EWS-FLI1 ubiquitination is modulated by USP19. (A) USP19 depletion increases EWS-FLI1 
ubiquitination. A673 cells were transiently incubated with three different siRNAs against USP19 or a 
control siRNA for 24h followed by co-expression of 3xflag-EWS-FLI1 and HA-ubiquitin for 48h. 
Ubiquitination of EWS-FLI1 was analyzed by western blot analysis using anti-HA antibody. (B) EWS-
FLI1 ubiquitination is decreased upon active USP19 expression. 3xflag-EWS-FLI1 and HA-ubiquitin 
were co-expressed with either wild type or a catalytically inactive USP19 for 48h in A673 cells. After 
immunoprecipitation of 3xflag-EWS-FLI1, ubiquitination was determined by anti-HA antibody. 
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Fig. 4: Depletion of USP19 affects Ewing sarcoma cell growth in vitro. (A) Schematic illustrating 
shRNA vector for stable transduction. The constitutively active part includes selection marker and a 
tetracycline repressive element. The doxycycline dependent part includes a tetracycline dependent 
promoter and the shRNA sequence. (B) SKNMC cells were stably transduced with two different 
shRNA sequences targeting USP19 and a control sequence. After incubation with 0.1ng/µl 
doxycycline for 72h, USP19 protein levels were analyzed by western blotting using anti-USP19 
antibody. Arrows indicate specific bands, asterix marks unspecific band. (C) USP19 depletion affects 
cell growth. Knockdown of USP19 was induced in 2x104 SKNMC cells as indicated and cells were 
counted after 4 (smaller graph) and 8 days (larger graph). Total cell numbers were plotted from three 
independent experiments, error bars as SD. (D) USP19 depletion reduces EWS-FLI1 protein levels. 8 
day lysates from one independent experiment of (C) were subjected to western blotting and analyzed 
by anti-FLI1 and anti-USP19 antibodies. Numbers represent densitometrically quantified bands of 
EWS-FLI1 over loading control tubulin. (E-F) USP19 depletion reduces USP19 mRNA, but only 
marginally affect EWS-FLI1 mRNA. All three samples of (C) at 8 days were analyzed by quantitative 
RT-PCR for USP19 and EWS-FLI1 mRNA expression. Numbers were normalized to GAPDH and 
related to shControl without doxycycline treatment. (G-J) Depletion of USP19 affects Ewing cell 
metabolic activity, proliferation and long-term cell survival. Doxycyline induced and non-induced 
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SKNMC cells were incubated with WST1 reagent after 96h (G), assessed for incorporation of BrdU 
after 96h (H), and colony formation after 14 days (I). Values are shown relative to untreated shControl 
cells (n=3, error bars as SD). (J) Quantification of colonies from (I).  
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Fig. 5: Depletion of USP19 delays tumor growth in vivo. (A) Scheme of xenograft experiments 
using SKNMC inducible cell lines. (B) Doxycyline induces USP19 knockdown in vivo. Two mice with 
engrafted tumors of ~200mm3 (shCtr and shUSP19#1) were treated for five days with doxycyline. 
Tumor lysates were analyzed by western blotting with anit-USP19. (C) Tumor growth rate of indicated 
cell lines and treatment of subcutaneously injected SKNMC cells, error bars as SD. (D) Tumors of two 
representative mice transplanted with SKNMC shUSP19#1 cells and treated with doxycyline or PBS. 
(E) Immunohistochemistry analysis of sections from tumor with SKNMC shUSP19#1 cells and treated 
with doxycyline or PBS using an USP19 antibody. 
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Fig. 6: USP19 selectively stabilizes EWS-FLI1. (A) USP19 binds to the EWS-FLI1 fusion protein 
which is further deubiquitinated most possibly at the K380 lysine residue in the C-terminal part. (B) 
USP19 also binds to the stable EWSR1 full length protein at an unknown site resulting in 
deubiquitination of non-proteolytic ubiquitin(s) rather than in destabilization. As USP19 does not bind 
to full length FLI1, its polyubiquitination remains.  
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Supplementary figures  
 
Supplementary Fig. 1: (A) Western blot analysis of lysates from A673 and RDES cell lines stably 
expressing 3xflag-EWS-FLI1 with anti-FLI1 and anti-Flag antibodies. Both clonal cell lines were 
transiently transfected with control siRNA or siRNA targeting the FLI1 part in the fusion protein. (B) 
Total protein levels upon candidate knockdown. Each dot represents total protein level for 
normalization of Fig. 1C. Protein levels upon USP19 knockdown are indicated with red dots and for 
EWS-FLI1 knockdown in orange. (C) USP19 is localized in the cytosol. 3xflag-USP19 was transiently 
expressed for 48h in A673 cells. Cells were fixed, stained with anti-Flag antibody and analyzed by 
fluorescence microscopy (63x magnification).   
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Supplementary Fig. 2: (A) USP19 knockdown modulates a subset of EWS-FLI1 target genes. 
SKNMC cells were transiently transfected with 20nM siRNAs for 72h as indicated and expression of 
indicated target genes was analyzed by quantitative RT-PCR and related to control siRNA for each 
gene (n=6, geometric mean, error bars as 95% confidence interval). (B) USP19 interacts with EWS-
FLI1. 3xflag-USP19 and HA-EWS-FLI1 were co-expressed in HEK293T cells for 48h. After co-
immunoprecipitation, lysates were analyzed by western blotting as indicated. 
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Supplementary Fig. 3: (A,B) A673 cells were stably transduced with two different shRNA sequences 
targeting USP19 and a control sequence. After incubation with 0.1ng/µl doxycycline for 72h, (A) 
USP19 protein levels were analyzed by western blotting using anti-USP19 antibody, arrows indicate 
specific bands, asterix marks unspecific band. (B) mRNA levels were analyzed by quantitative RT-
PCR and represented as induced over not-induced ratios for individual each cell line. (C) USP19 
depletion affects cell growth. Knockdown of USP19 was induced in 1x104 A673 cells as indicated and 
cells were counted after 4 (smaller graph) and 7 days (larger graph). Total cell numbers were plotted 
from three independent experiments, error bars as SD. (D-F) Depletion of USP19 affects Ewing cell 
proliferation and long-term cell survival. Doxycyline induced and non-induced A673 cells were 
assessed for incorporation of BrdU after 96h (D) and colony formation after 12 days (E-F). Values are 
represented as induced over not-induced ratios for each cell line (n=3, error bars as SD). (G-J) USP19 
depletion has limited to no effect in unrelated non-tumorigenic cell lines. (G) MRC5 or (I) HEK293T 
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cells were transduced with two different shRNA sequences targeting USP19 and a control sequence 
and incubated with 0.1ng/µl doxycycline for 72h. USP19 protein levels were assessed by western 
blotting using anti-USP19 antibody, arrows indicate specific bands, asterix marks unspecific band. 
Doxycyline induced and non-induced (H) MRC5 or (J) HEK293T cells were assessed for cell viability 
by WST1 after 96h (MCR5 cells n=3 with 6 biological replicates each and for HEK293T cells two 
independent experiments with n=6 biological replicates each). 
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Supplementary Fig. 4: (A) A673 and SKNMC were transiently transfected with control, 3xflag-USP19 
or 3xflag-USP19 C506A mutant. Protein expression was analyzed by western blotting using anti-Flag 
antibody. Cells were analyzed for cell proliferation by BrdU incorporation (B-C), for cell number by 
crystal violet staining (D-E) and for cell viability by WST1 incubation (F-G) with n=3 or 4 independent 
experiments, error bars as SD. 
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Supplementary Fig. 5: Depletion of USP19 delays tumor growth in vivo. (A) 
Immunohistochemistry analysis of section from tumor in Fig. 5B using an USP19 antibody. (B-C) 
Tumors lysates were analyzed by (B) western blotting with anti-USP19, anti-FLI1, and anti-p27 
antibodies, arrows indicate specific bands, asterix marks unspecific band. (C) mRNA expression was 
determined by quantitative RT-PCR normalized to HMBS.  
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Supplementary tables  
 
Supplementary table 1: Publicly available gene expression data sets 
Sample 
# of 
files 
Affymetrix 
chip 
GEO accession Authors 
     
Cell lines: 
    
SKNMC cells 1 Hg-U133A GSE1824 Staege et al. 2004 
A673 cells (siRNA control) 2 Hg-U133A GSE7007 Prieur et al. 2004 
A673 cells (luciferase knockdown 
controls) 
4 Hg-U133A GSE4565 Smith et al. 2006 
A673 cells (DMSO controls) 17 Hg-U133A GSE6930 Stegmaier et al. 2007 
EW24, SKNMC cells (shRNA 
control) 
4 Hg-U133A GSE7007 Tirode et al. 2007 
A673, RD ES cells 6 Hg-U133p2 
https://cabig.nci.nih.gov/ 
caArray_GSKdata/ 
Greshock et al. 2010 
Different Ewing cell lines 10 Hg-U133p2 GSE17679 Savola et al. 2011 
Different Ewing cell lines 5 Hg-U133p2 GSE36139 Barretina et al. 2012 
     
Tumor samples: 
    
Tumor samples 5 Hg-U133A GSE1825 Staege et al. 2004 
Tumor samples 27 Hg-U133A GSE7007 Tirode et al. 2007 
Tumor samples 35 Hg-U133p2 GSE12102 Scotlandi et al. 2009 
Tumor samples 90 Hg-U133p2 GSE17679 Savola et al. 2011 
 
Manuscript III 
126 
Supplementary table 2: SiRNA library for screening 
  
Silencer® Select siRNA: 
No. Gene name #1 #2 #3 
1 USP1: ubiquitin specific peptidase 1 s14724 s14725 s14723 
2 USP10: ubiquitin specific peptidase 10 s17367 s17368 s17369 
3 USP11: ubiquitin specific peptidase 11 s15741 s15739 s15740 
4 USP12: ubiquitin specific peptidase 12 s47597 s47595 s47596 
5 USP13: ubiquitin specific peptidase 13 s17130 s17131 s17129 
6 USP14: ubiquitin specific peptidase 14 s17358 s17359 s17360 
7 USP15: ubiquitin specific peptidase 15 s19338 s19339 s19340 
8 USP16: ubiquitin specific peptidase 16 s20808 s20810 s20809 
9 USP19: ubiquitin specific peptidase 19 s21339 s21340 s21341 
10 USP20: ubiquitin specific peptidase 20 s21336 s21337 s21338 
11 USP21: ubiquitin specific peptidase 21 s25689 s25690 s223719 
12 USP22: ubiquitin specific peptidase 22 s23566 s23568 s230744 
13 USP3: ubiquitin specific peptidase 3 s19343 s19341 s19342 
14 USP33: ubiquitin specific peptidase 33 s22873 s22874 s22872 
15 USP4: ubiquitin specific peptidase 4 s14681 s14683 s14682 
16 USP46: ubiquitin specific peptidase 46 s35034 s35035 s35036 
17 USP5: ubiquitin specific peptidase 5 s15595 s15596 s15597 
18 USP6: ubiquitin specific peptidase 6 s17363 s17361 s17362 
19 USP7: ubiquitin specific peptidase 7 s15439 s15440 s15441 
20 USP8: Ubiquitin specific peptidase 8 s17372 s17370 s17371 
21 USP9X: ubiquitin specific peptidase 9, X-linked s15743 s15742 s15744 
     
     
pos. control EWS (siRNAs only for region exons 1-7) s4887 s4888 
 
pos. control EWS/Fli1 s5266 s5268 
 
pos. control 
EWS/FLI1 breakpoint specific siRNA 
(Prieur et al. 2004) 
5′ GGC AGC AGA ACC CUU CUU A-dCdG 3' 
  
neg. control Silencer® Select Negative Control No. 1 siRNA 
neg. control Silencer® Select Negative Control No. 2 siRNA 
neg. control Silencer® Negative Control No. 3 siRNA 
neg. control Silencer® Negative Control No. 4 siRNA 
  
transf. Control 
Silencer® KIF11 (Eg5) siRNA (Human, Mouse, 
Rat) 
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7.1. Targeting the ubiquitin system – current state and future 
opportunities 
 
Targeting the ubiquitin system for cancer therapy has a variety of advantages over other regulatory 
pathways: It is a highly conserved system which is present in every cell of the human body including 
cancer cells whether they are proliferative or in a quiescent state. Further, drugs specifically targeting 
components of the ubiquitin system have the potential to not only inhibit the activity of certain 
oncogenic regulatory proteins, but they can also activate protein function by manipulating their 
turnover as shown for lenalidomide and derivatives (499, 500). Currently, our understanding of the 
UPS’s critical regulation in human diseases including cancer has generated high interest for the 
development of small molecules targeting critical steps of the pathway including ubiquitin attachment 
and removal. As drug developing is at the start of its future potential, tumor resistances have barely 
been observed in contrast to kinase inhibitors providing a whole new branch of possible targeting 
points (reviewed in (461)).  
 
After the success of Bortezomib in multiple myeloma, next generation proteasome inhibitors are in the 
pipeline promising higher efficacy and less toxicity (437, 470, 501). The ubiquitin activation inhibitor 
MLN4924 demonstrated that also E3 subclasses can be inhibited efficiently and entered clinical trials 
promising even more specificity upon targeting yet smaller subclasses (440, 441, 502). Besides these 
two examples, which other strategies have the potential as first line cancer treatment, in which tumor 
types would they be most relevant for treatment and which approach could be of significance for 
Ewing sarcoma? 
 
 
7.1.1. The developing field of ubiquitin drug targets 
Inhibition of the activity of oncogenic proteins has long been in the center of cancer research. Kinase 
inhibitors are one of the most clinically relevant classes of compounds which target protein 
phosphorylation. Consequently, their effect is mediated by blockage of protein activity and subsequent 
disruption of signaling cascades. Kinase inhibitors most commonly target the ATP binding or small 
hydrophobic pocket of proteins or induce conformational changes due to allosteric inhibition (reviewed 
in (503)). The most prominent example is again the tyrosine kinase inhibitor imatinib mesylate 
(Gleevec) used in BCR/ABL fusion positive chronic myelogenous leukemia (474). Around 16 kinase 
inhibitors are approved for treatment while more than 150 compounds are in the pipeline in clinical 
trials of various phases (503). Like phosphorylation, the process of ubiquitination is implicated in 
nearly all cellular aspects. Currently, clinically relevant compounds are limited to the use of 
Bortezomib and MLN4924 and only few additional inhibitors which specifically target ubiquitin based 
pathways entered clinical trials. The process of ubiquitination is more complex than phosphorylation 
as it involves different ubiquitin linked chains and a high complexity of components as well as similarly 
structured ubiquitin-like modifiers. Attempts to identify relevant compounds from chemical libraries 
mostly focus on modulating E3 ligase or DUB activity as they are the most specific target points (464, 
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503). Inhibition of E3 ligase activity or disruption of their ubiquitin transfer capacity is rather 
challenging and no general chemical screening approach has yet been established. Therefore, most 
E3 ligase modulators are ligase antagonists which disrupt substrate binding and induce 
conformational changes (464). The most relevant example presents the disruption of MDM2 and p53 
by the small molecule Nutlin-3 (450). 
 
The selective degradation of especially TFs represents the most specific way to eliminate oncogenic 
proteins which are themselves considered “undruggable”. A posteriori identified, this strategy is 
adopted by thalidomide and its derivatives. This well known compound displays high efficacy in 
multiple myeloma and other B cell neoplasms. Thalidomide is binding to CRBN which is a substrate 
receptor of CUL4A-DDB1 complexes (504). In multiple myeloma, thalidomide occupies the substrate 
binding site of CRBN leading to recruitment of IKZF1 and IKZF3. Both essential IKAROS TFs are 
ubiquitinated and subsequently degraded explaining the response pathway in multiple myeloma 
patients (500, 505). However, it was also suggested that thalidomide has dual activity as it blocks 
MEIS2 binding to CRL4-CRBN complexes and instead promotes IKZF1 and IKZF3 recruitment (505). 
Most interestingly, the drug showed high efficiency in other diseases such as the myelodysplastic 
syndrome where it operates through recruitment of CK1α to CRL4-CRBN to induce TF degradation 
(499). 
 
Both DUB inhibitors and antagonists are currently in the research focus. Few compounds have been 
developed and tested for efficiency in vitro and in vivo as the USP1 inhibitor SJB2-043 in acute 
myelogenous leukemia (506), the USP7 inhibitor HBX 19,818 in multiple myeloma (455) or the USP14 
inhibitor b-AP15 in various solid tumors and leukemia (459). As DUBs harbor enzymatic activity and 
provide therefore a direct targeting point, the number of inhibitory compounds most probably will 
increase considerably. Unlike most E3 ligases, DUBs do not build protein complexes and provide with 
about 100 family members are rather overseeable group of targets. 
 
 
7.1.2. Chemical inducers of protein degradation 
A variety of other chemical approaches have been developed over the years to investigate and dissect 
protein turnover. Targeting protein levels instead of protein activity is a very recent approach for all 
proteins which are considered “undruggable” due to their lack of enzymatic activity (507). 
 
The hydrophobic tagging technology for Halo-tag constructs was developed to precisely study effects 
of protein stabilization and destabilization. For this assay, the Halo-tag with an additional hydrophobic 
linker was fused to the protein of interest and expressed in target cells. Ligand mediated degradation 
was achieved using the small molecule HyT13 which was directly binding to the hydrophobic area of 
the Halo-tag and induced degradation. Destabilization was shown for a variety of proteins both in vitro 
and in vivo. Halo-tagged HRAS with an activating mutation highly induced tumor growth in mouse 
xenografts, whereas treatment with HyT13 significantly reduced the tumor volume (508). In contrast, 
Halo tagged proteins could also be stabilized by the small molecule HALTS1. It inhibits the interaction 
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of the Halo-tag to Hsp70 and thereby hinders ubiquitination and degradation (509). This technique 
provides a great platform to investigate specific protein turnover without affecting other proteins or 
using unspecific compounds (Fig. 13A). Therefore, Halo-tag fusions would allow depleting EWS/FLI1 
and other oncogenic TFs faster than applying RNAi. Using the CRISPR technology to introduce the 
Halo-tag at the endogenous EWS/FLI1 levels enables selective manipulation of fusion protein levels. 
This approach would allow more accurate investigation of stabilized EWS/FLI1 protein levels than the 
fusion protein exchange system we have used in this work. 
 
Another very interesting approach of small chemical inducers represents proteolysis targeting 
chimeras (Protacs). Mechanistically, one domain contains a peptide which is recognized by substrate 
receptors of SCF complexes or other E3 ligases due to being abundant, constitutively active and 
harboring a characterized binding site. The initial strategy used the SCF-βTRCP E3 ligases for 
targeted degradation (Fig. 13B).The other domain contains a sequence to which the target protein is 
known to bind. To this end, non-SCF substrates can now be ubiquitinated and degraded via this 
pathway (510). An important challenge to modify Protacs was based on the fact that they were not cell 
penetrating in vivo. To prove that the principle is working, Protacs have been introduced to cells via 
microinjection. Visualization by GFP tagged estrogen receptors revealed that more than 70% of cells 
had a minimal, partial, or complete disappearance of the protein by target specific Protacs after 1h, an 
effect which was abrogated upon proteasome inhibition (511). Later, soluble Protacs with the degron 
motif of the hypoxia inducible factor-1α (HIF1α) were used to degrade androgen and estrogen 
receptors. This subsequently resulted in reduced proliferation by G1 arrest in vitro indicating that it 
might be a possible application in vivo to eliminate disease promoting proteins such as EWS/FLI1 
(512, 513). Successful targeting of the fusion BCR/ABL has been reported. The small molecule 
Protacs were consisting of the E3 ligases cereblon (CRBN) or Van-Hippel-Lindau factor (VHL) and 
were linked to different target tyrosine kinase inhibitor ligands. Combinations induced BCR/ABL 
degradation to different extents (514). The best Protac molecule induced a selective decrease in 
viability in the BCR-ABL driven cell line K562. This strategy should also be applicable to EWS/FLI1. 
However, it may be more challenging to identify appropriate binding ligands as EWS/FLI1 displays no 
enzymatic activity. Nevertheless, the Protac technology is fast developing in terms of specificity, cell 
permeability and efficacy towards clinical approaches (515). 
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Fig. 13: Strategies to chemically induce protein degradation. (A) Turnover can be studied by fusions between 
substrates and a Halo-tag. Incubation with HyT or HALTS small molecule compounds results in binding and either 
degradation or stabilization of the tag and subsequently the protein of interest (modified after (508, 509)). (B) 
Protacs are small linker molecules to mediate interaction between a known E3 ligase complex and the target 
substrate. Upon binding, ubiquitins are transferred to the target and degradation is induced (modified after (510)). 
 
 
7.1.3. Therapy induced targeting – PML/RARα as a model for EWS/FLI1 
Most cancer subtypes are driven by a deregulated cancer genome with various genetic backgrounds 
which can be altered within tumor growth and relapse due to the existence and outgrowth of multiple 
subclones (14, 19). Instead, self-renewal and survival capacities of tumors with fusion proteins most 
commonly show continuous dependency on the chromosomal rearrangements (516). As an example, 
the combination treatment of retinoic acid and arsenic trioxide in fusion positive APL has an 
astonishing cure rate of 90% (497). PML/RARα degradation is mediated by two independent 
mechanisms: arsenic trioxide targets the PML moiety in nuclear bodies for sumoylation which leads to 
RNF4 dependent ubiquitination and degradation by the proteasome (Fig. 14A). Moreover, retinoic acid 
triggers a conformational change, phosphorylation of the RARα part and recruitment of the 
proteasome (Fig. 14A). Both events allow therapy induced degradation of the fusion protein (reviewed 
by (516)). 
 
In comparison, kinase inhibition is used in the treatment of chronic myelogenous leukemia. Imatinib 
mesylate blocks the ATP binding site of the ABL kinase and therefore inhibits its activity but retains the 
fusion protein (474). Induced blockage of fusion protein activity instead of protein degradation requires 
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continuous drug administration and can only be discontinued if minimal residual disease detection is 
negative for a longer time period (517). The treatments in APL and CML pursue two different 
strategies: inhibition of protein activity and selected protein degradation. 
However, both leukemia display treatment related resistances and relapse. Resistance to arsenic 
trioxide and/or retinoic acid of APL patients is most commonly associated with mutations in the 
PML/RARα fusion protein. Two mutation hotspots have been identified in the B2 domain of the PML 
part and in the LBD domain of RARα (518-520). If the fusion protein is mutated in the PML B2 domain, 
protein sumoylation is abrogated and subsequently arsenic acid induced degradation fails (519, 520). 
At least in vitro, higher doses of arsenic trioxide have been shown to partly overcome this resistance 
(519). Mutations in the RARα domain resulted in APL relapse, but a secondary remission using the 
standard combination can be achieved. In contrast, this is not possible for patients harboring 
mutations in each of the hotspots simultaneously (520). To overcome resistance, various compound 
screens are ongoing. It has been recently shown that the small molecule LG362B inhibited 
proliferation and induced apoptosis in vitro and in vivo which effect was driven by PML/RARα 
degradation (521). 
 
It is to be hoped that a similar degradation can be developed to treat Ewing sarcoma in the future. 
According to our studies, EWS/FLI1 protein depletion should be favored. As a first step, we 
characterized in this thesis the mechanism regulating EWS/FLI1 turnover. 
 
 
 
 
 
Fig. 14: Therapy induced degradation of PML/RARα fusion protein (516). (A) Arsenic trioxide targets the PML 
moiety of PML/RARα which is subsequently sumoylated by the Ubc9 conjugation enzyme and then 
polyubiquitinated by the SUMO-dependent E3 ligase RNF4 resulting in PML/RARα degradation. (B) Retinoic acid 
docks to the ligand-binding domain of the RARα moiety and triggers a conformational change. This allows 
recruitment of the proteasome and degradation. 
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7.2. EWS/FLI1 stability and turnover 
Attachment of ubiquitin(s) to a substrate protein triggers a variety of outcomes including degradation 
which are dependent on the attachment site, ubiquitin chain length and linkage to each other. Over the 
years, several different technologies have been developed to decipher and understand ubiquitin 
mediated processes (reviewed by (522)). Research has focused on identifying ubiquitination enzymes 
of substrates and on discovering novel substrates regulated by the proteolytic machinery. This was 
mainly achieved by affinity purification combined with mass spectrometry or protein stability profiling. 
Several of these methods have been adapted here to study the process of EWS/FLI1 ubiquitination 
and turnover. 
In order to better understand EWS/FLI1 fusion protein turnover, we first analyzed the half life and 
proteasomal regulation. In contrast to previous suggestions (235), we observed that proteasomal 
degradation of EWS/FLI1 is clearly favored over the lysosomal pathway under steady state conditions. 
As most potent transcriptions factors, EWS/FLI1 has a fast turnover which is mediated by one single 
lysine residue in the DNA-binding domain. 
 
 
7.2.1. Global Protein Stability profiling to dissect proteolytic turnover 
The Global Protein Stability approach (GPS) was initially established to identify novel proteasomal 
substrates (523, 524). In brief, a vector encoding for one transcript of a DsRed-IRES-EGFP is 
transiently expressed in target cells and allows analyzing protein turnover by flow cytometry. 
Integration of open reading frame (ORF) libraries C-terminal of the EGFP tag enables high throughput 
screenings for stability. In the first screening, cells with a stable integrated ORF library were incubated 
with or without the proteasomal inhibitor MG-132 and fractionated by flow cytometry according to their 
EGFP/DsRed ratio. Sequencing of all separate fractions allowed the identification of proteins with a 
shift in their turnover. This most elegant approach was later used to identify substrates of the different 
cullins by treating GPS cells with the NEDD8-activating enzyme inhibitor MLN4924 (325). In terms of 
high throughput screenings, GPS alone or in combination with drug treatments represents a strong 
method to evaluate substrate regulation. 
 
As shown here, this method could also be used to investigate the turnover of a single protein and 
identify substrate modulators. We cloned the EWS/FLI1 cDNA C-terminal of the DsRed-IRES-EGFP 
tag and were able to identify EWS/FLI1 as a substrate of proteasomal regulation both in HEK293T and 
Ewing sarcoma cells. As fluorescence measurements by flow cytometry are determined in intact cells, 
incomplete protein lysis and detections with unspecific antibodies are not interfering with the results. 
By using standard reporter constructs with known half lives (EGFP fusions to degron motifs of wild 
type and mutants of the ornithine decarboxylase), the EWS/FLI1 turnover could be determined in 
between 1-4h indicating that the TF is constantly targeted for degradation. 
 
It would now be interesting to identify regulators or regulatory complexes of EWS/FLI1 stability. 
Therefore, the established GPS assay could be combined with an siRNA, shRNA or CRISPR 
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knockout screen. After knockdown or knockout of candidate sub-libraries, cell pools would be sorted 
for fractions which display shifts in their EGFP/DsRed ratio indicating either stabilization or 
destabilization of the fusion protein. This effort would allow discovering a variety of novel co-regulators 
and cellular pathways associated with EWS/FLI1 turnover. 
 
 
7.2.2. Proteasomal degradation of EWS/FLI1 – common for other ETS members? 
To better understand the degradation process, we identified the main site responsible for EWS/FLI1 
turnover and were able to show that mutation of this residue posttranslationally stabilizes the protein 
and abolishes ubiquitination. EWS/FLI1 ubiquitination is dependent on its C-terminus as full length 
FLI1 displays a similar ubiquitination pattern with distinct localized polyubiquitin bands and harbors the 
same ubiquitin acceptor site. 
 
To identify EWS/FLI1 ubiquitin sites, we applied mass spectrometry of purified 3xflag-EWS/FLI1 under 
denaturing conditions. The protein was digested into peptides using the proteolytic enzyme trypsin 
(bottom-up approach) followed by identification using a tandem mass spectrometry approach. In 
addition, stable isotopic labeling of amino acids in cell culture (SILAC) would have allowed quantifying 
the relative abundance of protein ubiquitination, but has not been done yet. Further, so called K-GG 
specific antibodies would improve sensitivity and provide the basis of whole ubiquitome profiling in e.g. 
Ewing sarcoma cells (reviewed in (464)). 
Several other members of the ETS family including their truncated versions or fusions have been 
shown to be substrates of the proteasome system indicating that this is a common feature (482, 483, 
485). We observed in the first study that not only EWS/FLI1, but also FLI1 can be stabilized by 
proteasomal inhibition. Mutation of the K380/K334 residue in the ETS domain posttranslationally 
stabilizes both proteins in the GPS approach. As the K380/K334 site is highly conserved in most of the 
ETS members, it may, at least partly, contribute to proteasomal degradation of other ETS proteins as 
well. 
 
At this point, we are not excluding that ubiquitination of the K380 residue triggers signaling events 
besides degradation. Mutation of this side may also cause disturbances in other pathways which we 
have not dissected. Further, we have also not yet investigated if the K380 lysine residue serves as a 
potential sumoylation site. However, a yeast two-hybrid screen identified the SUMO E3 ligase PIASxα 
as an interactor of full length FLI1. A binding somewhere near the DNA-binding domain resulted in 
sumoylation of the K67 residue (160). Sumoylation itself has not been investigated in our laboratory as 
identification by mass spectrometry is challenging. The covalently attached peptide sequence displays 
high absence of a basic residue and therefore results in an at least 27 amino acid long peptide 
sequence (525). Moreover, lysines can be acetylated to modulate gene expression and protein-protein 
interaction (526). An in vitro mass spectrometry approach characterized acetylation of the C-terminal 
FLI1 domain which was also present in the fusion protein. Most interestingly, the K380 residue was 
not found acetylated, whereas the K298 site displayed acetylation (234). Mutation of the latter site did 
not abolish ubiquitination and was not used for further investigation as the ubiquitin mark may have 
Discussion 
135 
“jumped” to another lysine. However, our own mass spectrometry analysis did not detect any 
acetylation mark (our own data, unpublished). Even though other modifications may play a role in 
Ewing sarcoma pathogenesis, we focused our effort on the regulation of proteasomal degradation by 
ubiquitination of the K380 residue in the ETS domain of EWS/FLI1. 
 
 
7.2.3. Control of TFs by the proteasome system  
Around ~1’700-1’900 protein coding TFs with distinct DNA binding domains are present in the human 
genome necessary for a variety of processes such as transcriptional control, co-factor regulation as 
well as histone and chromatin remodeling. They can be tissue specific and differ in their expression 
level (527).  
Strikingly, EWS/FLI1 displays a higher turnover rate than full length FLI1. In contrast, it is known for a 
variety of oncogenes that stabilized protein versions are driving oncogenicity and confer a 
physiological advantage to cancer cells. In prostate cancer, a truncated ERG protein (Δ39) displays 
increased stability due to the loss of the N-terminal E3 ligase binding site for SPOP. Higher truncated 
versions as ERGΔ99 are even more resistant to proteasomal degradation and continuously drive 
tumorigenesis (482, 483). A similar regulation was observed for truncated ETV1 proteins where COP1 
binding deficiency resulted in a stabilization of the tumor driving ETV1 (485). In Burkitt’s lymphoma, c-
MYC mediates cell proliferation and tumor growth. At a genomic level MYC can be elevated due to 
gene amplifications or rearrangements, but also to mutations primarily in the n-terminal transactivation 
domain that intrinsically stabilize protein levels (528-530). For both proteins, the N-terminal domain is 
crucial to drive turnover of the protein and its depletion results in protein stabilization. 
 
However, EWS/FLI1 is not a truncated version of full length FLI1 and a large fraction of the N-terminal 
domain is exchanged by EWSR1 harboring a stronger transactivation domain. If turnover and 
subsequent E3 ligase binding of ETS members is conserved, EWS/FLI1 may possibly complex with 
E3 ligases via its EWSR1 part which therefore directs degradation properties. Most interestingly, we 
identified EWSR1 as a very stable protein being only mono- and diubiquitinated. Speculatively, the 
transactivation domain of EWSR1 might be responsible for a variety of E3 ligase interactions which 
would normally mediate specific processes like the DNA damage response in terms of the full length 
monoubiquitinated EWSR1 (186). The generalized idea that truncated oncogenic TFs are always 
more stable than their wild type domains (485) might not be correct for fusion proteins consisting of 
two independent protein parts. We suggest that fusion TFs are more unstable when harboring an 
exchange for a stronger activation domain. Hypothetically, due to their stronger capacity of 
transcriptional modulation, they might need less time to initiate and stimulate transcription in order to 
regulate the same set of target genes as their wild type proteins and therefore only need to be present 
at a low level. If this is indeed a general paradigm or rather specific for the EWSR1 related fusion 
protein needs to be further elucidated.  
 
Generally, the ubiquitin system influences transcription at three major levels by controlling protein 
localizations, co-factors levels and TF abundance at promoters (reviewed by (531)). TFs display an 
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especially diverse dynamic behavior upon binding to promoter regions. Some TFs such as estrogen 
receptor α (ERα) require continuous turnover for high level activation and periodically cycle at 
promoters (532). For c-MYC, it was recently shown that proteasomal turnover is required for full 
activity. Turnover deficient MYC fails to induce tumorigenesis as inhibitory MYC/PAF1C complexes 
cannot be removed during transcriptional target gene activation (533). Disassembly of transcriptional 
complexes for ERα and MYC at promoters seems to be a prerequisite for target gene activation, 
whereas the activity of the heat-shock factor (HSF) is triggered upon proteasomal inhibition and does 
not require ongoing degradation (534). Further, several models reveal monoubiquitination as a 
licensing event for initiation of transcription. After elongation to a polyubiquitin chain, the TFs are 
removed from the promoter to either provide space for other TFs or to reinduce activity by another 
round of active monoubiquitinated TFs (reviewed by (535)).  
 
In Ewing sarcoma, around 80% of both activated and repressed target genes are in a saturated state 
whereas 10% increase with higher protein levels and another 10% are less expressed upon turnover 
deficiency. Hence, EWS/FLI1 target genes reflect not only one type of promoter behavior, but instead 
are divided into these subgroups. Surprisingly, the majority of target genes are in a saturated state 
and they cannot be higher expressed with increasing EWS/FLI1 protein levels as shown for the Ewing 
sarcoma exchange cell lines with EWS/FLI1 K380R. Speculatively, the other two subgroups of 
EWS/FLI1 protein sensitive and turnover sensitive target genes might be of greater importance and 
their dynamics may trigger two different response pathways in Ewing sarcoma oncogenicity. Even 
though it is not yet clear what defines the subgroups, characterization of target genes from the 
saturated group might be of less therapeutic relevance.  
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7.3. Identification of relevant Ewing sarcoma targets for ubiquitin-
based drug treatments 
To better understand the physiological relevance of EWS/FLI1 turnover, we investigated which E3 
ligase and DUBs are capable to interact and destabilize the fusion protein on a molecular level. 
Indirect targeting of these regulators may affect the degradation rate of EWS/FLI1 and subsequently 
tumor growth. We focused our attempts on understanding ubiquitin related degradation most possibly 
over K11- and K48-linked chains even though there is a general relevance in ubiquitin mediated 
signaling and DNA damage response by mainly K27- and K63-linked polyubiquitin chains.  
 
 
7.3.1. EWS/FLI1 regulation by E3 ligases and their potential for therapy 
The identification of E3 ligases for distinct substrates is challenging. Two approaches are most 
commonly applied which include identification of the proteome by mass spectrometry or degron motif 
profiling of substrates. To characterize the ubiquitination process of EWS/FLI1, we aimed to identify 
which E3 ligase(s) might be a potential interaction partner. For that, we purified flag tagged EWS/FLI1 
from Ewing cell lines and subjected them to mass spectrometry. Here, we decided to not co-express 
tagged ubiquitin as this might lead to artifacts as shown for neddylated proteins (536). Instead, we 
stabilized the transient E3 ligase- substrate interactions by short term incubation with the proteasome 
inhibitor MG-132. However, we found very few E3 ligases and none of them seemed to induce 
EWS/FLI1 degradation by overexpression (our own data, unpublished). It is possible that we have not 
co-purified the turnover mediating E3 ligases due to the transient nature of the interaction with 
substrates (522).  
We then identified an N-terminal PPxY motif to bind HECT E3 ligases (333). This directed us to the 
identification of WWP1 as a possible E3 ligase responsible for fusion protein degradation. As the 
observed degradation is only limited, it may not be the only E3 ligase to regulate EWS/FLI1 turnover. 
Interestingly, the binding motif of the E3 ligase is in the EWSR1 part which we have characterized as a 
very stable protein. Speculatively, this motif allows binding of a variety of HECT E3 ligases from the 
NEDD4 family and favors the ones mediating turnover in case of EWS/FLI1 while others might induce 
signaling events in case of EWSR1. This demonstrates again that EWS/FLI1 protein is more than just 
truncated versions of two proteins.  
 
 
7.3.2. Destabilization of proteins – DUB inhibition as a promising approach? 
We also hypothesized that the turnover of EWS/FLI1 is critically regulated by a continuous interplay 
between ubiquitination and deubiquitination. Inhibition of DUBs which are involved in EWS/FLI1 
stabilization may serve as a potential therapeutic target. In an siRNA based screening, we identified 
USP19 as a stabilizer of EWS/FLI1 protein levels. Inhibition of USP19 increased the ubiquitination of 
the fusion protein and posttranslationally stabilized the protein. Phenotypically, USP19 depletion 
resulted in a clear delay of tumor cell growth and proliferation in vitro and in vivo. Our data clearly 
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suggest that DUB inhibition might be a valid novel therapeutic strategy for Ewing sarcoma therapy. 
However, no specific USP19 inhibitor is yet available.  
 
EWS/FLI1 regulation by USP19 presented a quite unexpected top candidate in the screening. Later, 
we were able to show that neither full length EWSR1 nor FLI1 protein levels were influenced by 
USP19. This could be explained by the fact that USP19 might possibly bind to the EWSR1 part and is 
originally a regulator of the full length EWSR1. As EWSR1 is only a mono- and diubiquitinated protein 
with a half life of around 24h, cleavage of these chains may cause changes in other pathways. When 
USP19 modifies EWS/FLI1 protein, total polyubiquitin chains are removed subsequently leading to a 
rescue from degradation. This would support again the idea that the N-terminal domain is necessary 
for binding of stability regulators and the C-terminal part carries the polyubiquitin signal as shown for 
the K380 site.  
 
Deubiquitination studies of ETS family proteins have only been conducted for full length ERG. Here, a 
mass spectrometry based interactome was used to identify USP9X as a regulator of ERG protein 
levels. Depletion of ERG resulted in growth arrest of prostate tumor growth in genetic assays as well 
as upon treatment with WP1130, an USP9X inhibitor with lower specificity to a few other DUBs. Most 
interestingly, the binding of ERG and USP9X was mapped to the ETS domain and was also 
demonstrated for full length FLI1 (484). Whether this might also be true for EWS/FLI1 needs to be 
further elucidated. In this case, EWS/FLI1 turnover might be co-regulated through both the EWSR1 
and the FLI1 part.  
 
Even though the regulation may be different, depletion of interacting DUBs represents an attractive 
strategy to target tumor growth for both EWS/FLI1 and ERG dependent cancers. This has been also 
shown for USP37 which was independently identified as a regulator of c-MYC in lung cancer and 
PLZF/RARα positive APL (415, 537). The latter confirms again that these interactions are specific and 
depend on one part of fusion proteins. USP37 modulates stability over the PLZF part and has 
therefore no impact on PML/RARα. Depletion of USP37 is inducing proteasomal degradation of the 
fusion protein in this subtype of leukemia which is characterized by resistance to arsenic trioxide and 
retinoic acid treatments (537). 
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7.4. A novel therapeutic strategy: degradation of EWS/FLI1 protein 
To this end, we have identified EWS/FLI1 protein turnover as a critical mechanism in Ewing sarcoma 
pathogenesis. In the proposed model, our work identified members of the HECT E3 ligase family, 
most possibly WWP1, as regulators of ubiquitin attachment which is mediated over a conserved motif 
in the N-terminal EWSR1 part. Ubiquitin attachment at the K380 residue in the conserved ETS domain 
results in proteasomal degradation of the fusion protein. Due to the continuous transcriptional activity, 
EWS/FLI1 protein displays a high turnover. Even though target gene activation is controlled by 
EWS/FLI1 protein, the majority seems to be in a saturated state. The ubiquitin signal can be removed 
by USP19, rescuing EWS/FLI1 from degradation. USP19 depletion was identified as the strongest 
target for therapeutic interventions as inhibition decreased tumor growth in vitro and prolonged 
survival in vivo (Fig. 15). Our data provide a strong understanding of the proteolytic regulation of the 
EWS/FLI1 protein and led us to the identification of novel target strategies. 
 
 
Fig. 15: Regulation of EWS/FLI1 turnover and its consequences. EWS/FLI1 was found to be ubiquitinated at 
two sites by mass spectrometry analysis. Ubiquitin is attached by E3 ligases including WWP1 and removed by the 
deubiquitinating enzyme USP19. Attachment of polyubiquitin at the K380 residue mediates proteasomal 
degradation. Unmodified EWS/FLI1 acts as a strong modulator of target genes from which only a subset is protein 
level dependent. The fast turnover of EWS/FLI1 protein ensures constant protein levels in the cell and continuous 
exchange at relevant promoter regions.  
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“Analysis of ChIP data to elucidate transcriptional regulation of clock-
controlled genes” 
 
Oct 09 - Feb 10 1st laboratory rotation at group of PD Dr. Strowski 
Clinic for Hepatology and Gastroenterology, Charité, Germany 
“Orexin A stimulation of lipogenesis and adiponectin expression in adipocytes” 
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Oct 2006 - Sep 2009 Biology, Bachelor of Science 
Humboldt University Berlin, Germany 
 
Feb - Aug 09 Bachelor Thesis 
Group of PD Dr. A. Lukowsky 
Department of Dermatology, Charité, Germany 
Title: “Clonality Analysis of Patients with Cutaneous T-Cell Lymphomas“ 
 
Aug 2000 - Jul 2006 Linus-Pauling-Gymnasium Berlin, Germany 
Abitur  
 
 
Teaching experience          
Jul 14 - Aug 15  Supervisor Master Thesis, Biology student, University of Zürich 
Nov 12 + Nov 13  Course assistance “Cancer Cell Motility”, University of Zurich 
Oct 08 - Mar 11 Seminars “Mathematics in Biology”, assistance with exam supervision 
and corrections, Institute for Theoretical Biology, Humboldt University, 
Germany 
 
 
Competences            
Languages   German (mother tongue), English (fluent), French (basic) 
Computer competences Good commands in Microsoft Office (Word, Excel, Powerpoint). 
Adobe Creative Suite (Photoshop, Illustrator), Clone Manger, 
PrismGraphpad, dChip, ImageJ 
 Basic knowledge in GnuR, Latex 
FELASA, category B  Course for Animal Experimentation, University of Zurich 
 
Grants             
Oct 15    Travel Grant Cancer PhD program, UZH, Zurich, Switzerland 
    EMBO Conference “Ubiquitin and ubiquitin-like modifiers” Sep 2015 
Aug 15    Travel Grant Hartmann-Müller-Stiftung, Zurich, Switzerland 
    AACR Apr 2015 
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Conferences and talks 
 
International conferences 
 
Apr 2016 7th Proteasome and Autophagy Workshop, Clermont-Ferrand, France 
Talk (selected short communication) + Poster: “Proteasomal turnover controls 
oncogenic activity of the EWS/FLI1 fusion protein: Implications as a novel therapeutic 
strategy” 
 
Sep 2015 EMBO conference “Ubiquitin and ubiquitin-like modifiers: From molecular mechanisms 
to human diseases”, Cavtat, Croatia 
Poster: “Identification of deubiquitinating enzyme USP19 as a regulator of EWS/FLI1 
protein turnover in Ewing sarcoma” 
 
Apr 2015 AACR Annual Meeting, Philadelphia, USA 
Poster: “Identification of deubiquitinating enzyme USP19 as a regulator of EWS/FLI1 
protein turnover in Ewing sarcoma” 
 
Aug 2014 Benzon Symposium “Nuclear Regulation by Ubiquitin”, Copenhagen, Denmark 
Poster: “Targeting the turnover: Diminish EWS/FLI1 protein level by ubiquitin-
proteasome-system (UPS) dependent degradation in Ewing sarcoma” 
 
 
Public communications: 
 
March 2016 Joint Cancer Meeting, Cancer Network Zurich 
Talk: “Proteasomal turnover of the EWS/FLI1 fusion protein: Implications for novel 
therapeutic strategies in Ewing sarcoma” 
 
March 2016 Colloquium of Applied Cancer Research, University Hospital Zurich 
Talk: “Proteasomal turnover of the EWS/FLI1 fusion protein: Implications for novel 
therapeutic strategies in Ewing sarcoma” 
 
May 2015 Colloquium of Applied Cancer Research, University Hospital Zurich 
Talk: “Understanding EWS/FLI1 fusion protein turnover and its impact in Ewing 
sarcoma pathogenesis” 
 
Nov 2013 Colloquium of Applied Cancer Research, University Hospital Zurich 
Talk: “Deregulated Turnover of EWS/FLI1 fusion protein in Ewing Sarcoma 
Pathogenesis” 
 
 
Cancer Biology PhD program and Cancer Network retreats: 
 
Feb 2014 Cancer Biology PhD retreat 
Linh, Switzerland 
Poster: “Involvement of components of the ubiquitin-proteasome-system in Ewing 
sarcoma pathogenesis” 
 
Apr 2013 Cancer Network Zurich retreat 
Grindelwald, Switzerland 
  Poster: “Deregulated Turnover of EWS/FLI1 fusion protein in Ewing Sarcoma” 
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Publication list: 
1. Gierisch ME, Pedot G, Pfistner F, Lopez-Garcia LA, Jaaks P, Schäfer BW, Niggli FK 
“EWS-FLI1 protein destabilization by the deubiquitinating enzyme USP19 as a novel treatment 
strategy in Ewing sarcoma“ 
Cancer Res. submitted 2016 
 
2. Gierisch ME, Pfistner F, Lopez-Garcia LA, Harder L, Schäfer BW, Niggli FK 
“Proteasomal degradation of the EWS-FLI1 fusion protein is regulated by a single lysine residue” 
J Biol Chem. 2016 Nov 8. pii: jbc.M116.752063 
 
3. Giorgi C, Boro A, Rechfeld F, Lopez-Garcia LA, Gierisch ME, Schäfer BW, Niggli FK 
“PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1” 
Oncotarget 2015 Oct 6;6(30):28895-910 
 
4. Thalhammer V, Lopez-Garcia LA, Herrero-Martin D, Hecker R, Laubscher D, Gierisch ME, Wachtel M, 
Bode P, Nanni P, Blank B, Koscielniak E, Schäfer BW 
"PLK1 Phosphorylates PAX3-FOXO1, the Inhibition of Which Triggers Regression of Alveolar 
Rhabdomyosarcoma” 
Cancer Res. 2015 Jan 1;75(1):98-110 
 
5. Humme D, Lukowsky A, Gierisch M, Haider A, Vandersee S, Assaf C, Sterry W, Möbs M, Beyer M 
“T-cell receptor gene rearrangement analysis of sequential biopsies in cutaneous T-cell lymphomas 
with the Biomed-2 PCR reveals transient T-cell clones in addition to the tumor clone” 
Exp Dermatol. 2014 Jul;23(7):504-8 
 
6. Dubiel D, Gierisch ME, Huang X, Dubiel W, Naumann M 
“CAND1-dependent control of cullin 1-RING Ub ligases is essential for adipogenesis” 
Biochim Biophys Acta 2013 May;1833(5):1078-84 
 
